var title_f40_31_41456="Chylothorax CT";
var content_f40_31_41456=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F64375&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F64375&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chylothorax after esophagectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 321px; height: 319px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT shows large low attenuation right pleural effusion with inversion of the right hemidiaphragm and cardiomediastinal shift to the left.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_31_41456=[""].join("\n");
var outline_f40_31_41456=null;
var title_f40_31_41457="Patient information: Allergic bronchopulmonary aspergillosis (The Basics)";
var content_f40_31_41457=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?4/11/4275\">",
"         Patient information: Asthma in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?21/43/22195\">",
"         Patient information: Coughing up blood (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?19/57/20371\">",
"         Patient information: Cystic fibrosis (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?27/50/28450\">",
"         Patient information: Shortness of breath (dyspnea) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?30/25/31124\">",
"         Patient information: Trigger avoidance in asthma (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Allergic bronchopulmonary aspergillosis (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/allergic-bronchopulmonary-aspergillosis-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H93365600\">",
"      <span class=\"h1\">",
"       What is allergic bronchopulmonary aspergillosis (ABPA)?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Allergic bronchopulmonary aspergillosis (called &ldquo;ABPA&rdquo; here) is an allergic reaction that can cause coughing, wheezing, and other symptoms. It usually happens in people who have asthma or cystic fibrosis. These lung conditions make it hard to breathe.",
"     </p>",
"     <p>",
"      People who get ABPA are allergic to a fungus called &ldquo;aspergillus.&rdquo; This allergy is more serious than an allergy to pollen or pets. ABPA can cause scars to form inside the lungs. This can make asthma or other conditions worse.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H93365615\">",
"      <span class=\"h1\">",
"       What are the symptoms of ABPA?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Coughing up mucus with brown specks in it",
"       </li>",
"       <li>",
"        Wheezing or noisy breathing",
"       </li>",
"       <li>",
"        Fever",
"       </li>",
"       <li>",
"        Feeling sick",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      A few people who get ABPA cough up blood, but not everyone does.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H93365630\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you are coughing up blood, call your doctor or nurse. Call 9-1-1 for an ambulance&nbsp;if you have a severe asthma attack and your symptoms:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Get worse",
"       </li>",
"       <li>",
"        Do not get better after using a quick-relief medicine",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H93365645\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor or nurse will do an exam and learn about your symptoms. He or she can also order the following tests:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Chest X-ray &ndash; This might show changes in the lungs caused by ABPA.",
"       </li>",
"       <li>",
"        CT scan of the chest &ndash; This is an imaging test that uses a special X-ray to create pictures of the inside of the body. It can show more details than a regular X-ray.",
"       </li>",
"       <li>",
"        Breathing tests &ndash; For these tests, you breathe hard into a tube. The tests show how well your lungs are working.",
"       </li>",
"       <li>",
"        Skin test&nbsp;&ndash; In this test, the doctor or nurse will put a tiny bit of aspergillus on your skin. Then he or she will make a tiny prick in the skin. The aspergillus has been treated so it cannot make you sick. After 15 or 20 minutes, you might get a red, itchy bump like a mosquito bite. If you do, it means you are allergic to the fungus and ABPA might be causing your symptoms. If you do not get a bump, you probably do not have ABPA.",
"       </li>",
"       <li>",
"        Blood test &ndash; This can show if your body&rsquo;s infection-fighting system, called the &ldquo;immune system,&rdquo; shows signs of an allergy to aspergillus.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H93365662\">",
"      <span class=\"h1\">",
"       How is ABPA treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;ABPA is treated with medicines. These include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Steroid medicines, such as",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?27/36/28230?source=see_link\">",
"         prednisone",
"        </a>",
"        (brand name: PredniSONE&trade;) &ndash; To help the lungs get better. Steroids help with inflammation in the lungs. These are not the same steroids that athletes take to build up muscle.",
"       </li>",
"       <li>",
"        Medicines to kill the fungus that causes aspergillosis. These include",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?33/17/34069?source=see_link\">",
"         itraconazole",
"        </a>",
"        (brand name: Sporanox&reg;) or",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?32/39/33397?source=see_link\">",
"         voriconazole",
"        </a>",
"        (brand name: VFEND&reg;). &nbsp;",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Your doctor or nurse will do blood tests every month or two to see if the ABPA is getting better. You might also have X-rays to check your lungs.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H93365677\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?4/11/4275?source=see_link\">",
"       Patient information: Asthma in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/57/20371?source=see_link\">",
"       Patient information: Cystic fibrosis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/43/22195?source=see_link\">",
"       Patient information: Coughing up blood (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/50/28450?source=see_link\">",
"       Patient information: Shortness of breath (dyspnea) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/25/31124?source=see_link\">",
"       Patient information: Trigger avoidance in asthma (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?40/31/41457?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83427 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-189.2.19.178-DF24B1B659-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_31_41457=[""].join("\n");
var outline_f40_31_41457=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H93365600\">",
"      What is allergic bronchopulmonary aspergillosis (ABPA)?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H93365615\">",
"      What are the symptoms of ABPA?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H93365630\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H93365645\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H93365662\">",
"      How is ABPA treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H93365677\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?4/11/4275?source=related_link\">",
"      Patient information: Asthma in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/43/22195?source=related_link\">",
"      Patient information: Coughing up blood (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/57/20371?source=related_link\">",
"      Patient information: Cystic fibrosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/50/28450?source=related_link\">",
"      Patient information: Shortness of breath (dyspnea) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/25/31124?source=related_link\">",
"      Patient information: Trigger avoidance in asthma (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_31_41458="Dorsal slit procedure";
var content_f40_31_41458=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F61427&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F61427&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 543px\">",
"   <div class=\"ttl\">",
"    Dorsal slit procedures for reduction of paraphimosis and balanoposthitis with urinary obstruction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 523px; height: 554px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A: 1) Incision of constricting band along longitudinal axis of penis, 2) Reduction of paraphimosis and suture placement along transverse axis of penis, 3) Reduced paraphimosis with closed incision.",
"    <br>",
"     B: 1) Incision of constricting band of paraphimosis (also appropriate for balanoposthitis with urinary obstruction), 2) Reduction of foreskin followed by suturing of incision, 3) Reduced paraphimosis with closed incision.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_31_41458=[""].join("\n");
var outline_f40_31_41458=null;
var title_f40_31_41459="Papules in Cowden syndrome";
var content_f40_31_41459=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F60952&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F60952&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Trichilemmomas and verrucous papules, as well as oral papillomas on the mucosa are characteristic of Cowden syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 392px; height: 262px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEGAYgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDsJImjYJA8UgUA7uAOhyORyOvb39RTLaGTz2/dHbgksRwBjjnn+vOO+CI9Oma6EMkQD4GxgUHyqR298Ac+3tWsLV5YhKrRqsQAUAhct1xgd8k/n2yQMLX1R9HzOOjKsV1LHJHKoHmD5MxrtPbJ45//AFetXmmEQLQNGy7uMOOQemeOeO/9KptIsglcKcMPnAHDHnP0/wDrenR6wxzbliTzHU5bJzn8Tznv+vUYLWw79y7BcRzmR5BFleGLfdbnHGfw/wA8mvOqI7qJXDs24oCOuexx/h39DmGNRYzJxH57A/vFbBXrjrx3z6fj1f8AafsyMrSKwk+Vk/hHA6fQfyH1o6BbXQlgghS6R5Y32sAwDNngnnPbp/nHFOW6WO7nMJaRRwFUnBGc5Y5Pt17++MVlYzyIoIAZuFY4b88cnv25HrT2vLuwtvKuJNiMuF3DO1T0ORz6/n7mkml5Dd2WpDco6xTkxsRv5bKruGc9P6f4U26+1PdRBljXAOEjUoF4POSSB3/PvVCe+c2c2/8Ad7gHHzkhuB1556dK0LGKOK3S4uH826fBdADjaPT8SPy+gqLp7MTvFXY5NTvLWHy/LADsoLA5Ctnrzzwf198k6dnFOLJy0qOi4UZ4OSccD/D8PWq8r/aS6PAo3qOgHJ9uf84x0pzpH5j7UkLnMalZM5wMn8xn8ueK0WmrZk3fpYSaWQyS+VKC694xkOO+SOuRj8PwNQxXunvZ3MDL+/SQBVCngZ689+e36cVPpt2luGEiyr8+QcE/KM/eOM+p6frxWNbSW914nuAoyssZfLR5O7OOPr+n8x2ST7lRV736G/LbLJBLPFDF+8YDavQn+L26Z9uvbIMbW8kCzJHGvnbtvzPhcdQQfx5rThtTPDtsmlRYj94gYXvgfT/D0FY8U3/E6+x38kphl5Wcn+IDjB/u9OKqWljOM27+RUu3v7mfzVa23wbQDnOCOyjvz2/D6WbF5UhmkJRp9wMjy4bjB7ehquktzp7ILm0t4Xt3fdNFGdj4Py8nBJP+e+LcGpFs3N5vdZ2JAJwWPTpUxaNJN20Whdt2LyxyNKig5ZQT6dTjt7f41JNcl5XWF0KowOcFR/8AX57/AM8VSjgKIHXOCQRjrjdgYHY57f8A1hUc3nCXyJEbDbpHwQrZx09O3+etXcz3ZaiijkYxhTh843NjGeh/z/iTbtBJNFviYGOP92XL4BHbgf59O2IVljKRGT5snJA+Ugemf8/lUXlXUAmELExucoMbiq5PU9uc/r60aIltsvRnZ88WMqNpIXcpHp2/T9BTZJSLfdMnlRO2GXByAc9z16dfr05zAjSiGMTSMHQgEscKQBmm62JLxLSNpgnm446Nz6cdRx9Mj2y+gLWVhzT2syzXEMUQiGI4jMu4se+O2Pr0+nFRxxXGIWCARo2VUsCAfXn6/r681b1CSKSJQzRgxgY2jyyh7YA/l/WuYtbie5u5V8xhbxjGR2PPAx3P+eM7VO0XqaU05K6NyznWVmALHzSRluWA9R68j/PSmZRoZFtNgZsnLsAevf0/X8eMEgh2MLolZwpUDgDHt/Ks+3mUxTiS5cRk5UDkk9jnr1zQ3YEr6ofqcc0QRoLtjs+RsKQM9wPXnPPr75J5zTZhPqBillEaySE+YTwB1wB3z7fh3zJq+oeVDGmVMZBAUYJPsPQf56Vj2ZTybd2jeI+Zl3dcjn6n/P8APKUk2dNODUdTuNQ8lrC4hh2mRckr3ccdD37fhj2Ij8PXaxXcts87mAAPErZyM8np7n/PWrdm1st4sPnsbYRGRynVmKkgZ9eSf19QM6ZEbUbSKFDudSi8jKHjGT9B+v56ta3OeLunFnRw2MV1dbpHby1QMGxjcx7Y9h+nsK0IPkkRAnlIq4c9ckHqc/5+lU7VBDkzXGGjAX52zlhj8+36e2YpI3ZN5cDcTyG6j19u36VolynM7ye+gpmlaeUW7IsLMUDvjlfUj8f196qx6hZ298k9vZyQeRjA+8pxwST6Y9PT0rShnjhtVXZ5sX3QqruI471mCR1aRp3Cxx/8s5Aenfn8R+lDViou97oqeI7OK5votZtbpIWYhEiR9rRNjk5x069v0ytYWp6aZXKXF9Jd3ayHhvmXZ3YNn9P/ANddFqEEUkriOJlOAw2Ll3z0I4OOeP8A6+AazAWReSW2SUbMFZ2Jb/CspRWpvCckkkZo0iWK3WVBEzAkqHBz06beM9/x/EHhJHlh1A26yeXl/mUHjn19R/n0A7S81S23K4SS4l24Vk+SKMY54ONx5A9Pf04/7E1zqxe6DRRM20SbW4PbPGcf565FTPlduU2p8yu5BcPN5zR3OzLsoVgeQAeR/M/5xWbKVe8kQskqk87lwckn/wCv/nNbPiPSlsXtZ4G823+5JcW8pkXd3BI5Dc5xWbcxJbQkq7bHxkynI44wMfhQ7p6hFp6oryXPl2MioGaNj8pdvmzxkY+uD3/oYrG9eGACF1iZm4Odpbj5h/L/AD0ntttxcR+eSqsxxtHzYHUVq21oj2szsIQrg5XHIUHAbjocd/8A6+BO70KcrGC85VPIG4mJW5yCAxPY+mf89i28YpGtwkapGi7CqrncSOv0yD/kUy2kEVxOJdwZ2JDnnkc/nRema4McsiuJJOOBjI9/85/SktC76jbd1WWZ1JKqAEkjUrk5zk/Q1oabfWTz+XcLGQpAjO8gqfTA6nr/APrNZUDtA7JKSxwQMHnHbHr3/wA5xbsFjuY0WRCm0EtnqSDzR6A9jS0q5Rr+7W2h2r8xU7FyegIyRjGeenbjHFFRzRCOZnbasrDlVHAPGCc/ifc0UGTV3c7W2jtbGKRZWZ3MQYYXG0FgDyePU45AGCeCMTWTRSiZvMKRR5bLhmAPpn1z6/zBymmTC3vbd5Wd4mjbLsuPnzwfU+ox/jiATvZzTIkhIY/NG4IPQHPp0x04/DFPQzSeqL8khkCNL5RVV2jOfmUcg5/z06HkVYjuBaGF4483CsZDM454yAqjPuDznn14Ip2zC9tIpIhHg5O0sdygfwkY6n2/DPezYPHCu1ovN3bsFeSmMkZB7c/lnHGaEDtYmnklupFmnWMK/wA4CjlieMHGMEHgDv0ovhI7KPKgYlizMHBBzgj8Oe3HXt0ULH5sMlxvFqxHnxDqcckZ7g5GPbiqMgHlSyNFmNSFMmOAevLdc/Xnv60mwihrBXMm6KFFkOwSM5UKR3H+f8aVroqyxQGNjHHjZGTsPI5OeT0P69MEGSFm1OQzTFY0cMd6nknryOw/z9bcdpbwMskfJcgkOMZJAJwOwGRz9P8AZpWvsW2luU1tY9rS6hErTlgcDOD/AD6Dv7+mBWraucKLiXaowyqqklQBgZPqTgY9/XFRTbJbeSdjta3GeVJ8zHIyR9314z+HNKkax2xlCxLhtxIc9xwFAHbP0+gzgtbVEN8y1JbpmWa4khKJA2WIxk5xjjP/ANf8elVY0UbDK8iueCxfPUj8AMf5PGLF3E3mIdqbowCVBBC8dz0ye/8AjVgqqFPNjljV/nMuBtLDJwPrnv8A40/UlOyRm3kLwMLeFW2+YwGHB46DjOc54+oI6gmpLaE6XahsbbkvtMu7kew9h14/xw66mi/tCJV2RPGS0jKAoZiMLtA46cc9h6YyzUWaVSN6K8RL8nO7nlf8/wD650d2aatJM6DTo47OPJWYxTcMgJIyQMZGepHf3+hGPqXlvqMJZilsH/do6kgSBTycc7Tz+Xbms258QXKCJcOQCQFC/fJGPxP5/qcaegQKljMdSiQ3iv0Y4KjsP5fXH0rRzjP3Ymfs5U/fkRyy2u+3iklkMkKk/vXLqjEEkr26YOTn8hy/V7pIZo5ba3cIsYMrTKAUPcj/AD/TJra2RjRSrLM7Al0bvjkHuOef/r8VSvbq6i01fmie2kfJdv48cdOn5H/GpfupocVzWZoQJIkkDwzo74EgIGMDp/n/ACK1Lt4LpoyN0RZCCFcHB9M/kfy9qz7VreDYbQoIWQB0/u5J/wA/l061O7f8s1J2OcuD68jj68/r7itI7Gcld3AR+UHQmRmzlNoIUjuCOuf61eWLywEgSRmc/dd+M9s/l/8Ar5qCKd45re5lLOY9zIODyeBxU0rsmJpDGjS8R7Dhs98n8ufb2GaWupDuV9z4l89EZArN5atjJzzn2/z71ThsJdRaJTN5apnb8hPPsRz/AJ/LSs7Z4Ihvj3gvknORn0/Hj/PBvARWtiYmiZirYO0bt564Hofb/wDXUuN9WP2nL8Jz2oeHL35BE7JZyEB7iVt7D+Rx/Oq8EdtpEDQKwMwBPmgAZOc5I/z+A69G9wjM+8gFQPLDEn3IA6VlahGJ5hlxEzsAypkMPx6Dn/OeKUopaouFST92WxkTyvc3Ci6m8pTwjLzj2wePX+XtVSSzWR18ye88ksYzsUDdk9Aev1/Lrgnd1Wwg0+SJLy33SmM7OOg/xH+fWqtywmihjgQCfGFYjABPH0rNx11NYzuk47HN6doyjUkNn8wQsA0x4wAemfrn/IFSyRLLdFpHCTKc+WR8jY459D+Y6deMdHqiyPZ29tciKNbfLEA7S5Py5xnnv+f1xiXKLFcww28XmKZBu3kYYHp/X/OcD9zQuM3PVnQaNHG9pGqDa53GVHXDAcAYOen5/nyY9XX7EYrt9rbBmNQSCSO/H+f1xX+1WttLCEiDQ7cSKSSF57Z9P89BmlqeoJcwzG3DtHCS4kLZLDIOPU9v07gZv2i5bGUYScr9DrpLFAEadRvYb8YycnqP8+vrgiKG1t/LZTKQpO0B+cfQfn/nJpsN4dUtFmhnQIEDdegx0/EfpnsSaSKaBUmD25dZE8tznBUgdvxx+VaKSuYWklZ7j47gWhIikkaFmxuYAY9T6dvy56ZqyYg6s7RxuqEAs3IH4+vP+eSajb49LSMxo6Mp5J+Ynrn+v69eKg0uMWaG3kuWVXIIRCOB25/z/KnfWzBx0bRdtYpVnRrONY1HzZUnnHr7e3/6xmeILMKrTtEpLSB9zuW4PP8An/Od3Ylsm79+JNpDM/Q5rL1OA3mxvKeO0UYIL559RRKGlhQn71zDv7bdZBgym08obHwM8YP4fX09q5aW9SexMCXEwZmIwgyFC59eQf8A9XByToy3EsNnNEJGVUkwVz0XPB+ufT+fTDWKSBQI/N8yWQgKF/1gxzz26j9O2CcJTT2O6MLJ3M+7u5kia1h3pbSyCZounzjoT68Dn6Z9jn3MtwHVZmEccnDKc4OO4/z3+mNF1F9rMS2akHO0+Y2NzDJyT26fmKjuwrhpZ3AlgJVAy7hjJyp7c5Jz7+5wD2MmGR7cCWMDzVO7ap6fU/5/oZor83N20yxFJCpKRrkIW65Ptx/nu26t5xbpNKsKxsBtCEZ/D3GeapFjbPGixCNkOQS3OfTp/nFFuhW5dlsLj7UHuT5bShpME9COp9h/nHanXwElsEtvJd48s/lKTgAjqRWbb3s9/eSzzTPGx5LngFs5P0rRN3Hb214JPtHm4CwIrDac8sX9Rjj8adkFmjNuLlbtYzcTOphI2DqMMec45z3z/wDqLkzbyrE67pGGV2nGc85P55/zgV9SvZbqU3HkW9u0SiPES7B8vfb6+9P1K4+0yRTRxIrAbmVBwPU+3rSauizpreJmu8tFh2iTcQ2clsYP149c9fxKq2V287R+SG8rrJ83C4Ax7+3Wiqi11MJJpnbw+ZcLJCSCA23uQnPJGeg4/Q+jZkks4heQurtJH5gXc2BvHHbtxT9N8i4tWmeZ/thYAI2RgZxuB78f09AKsx2o/fhGZFjAZMDkEnAzjr64/wAifi3J5rMgubdrO5ljSEW7eadpjwu7nvjp17Hp+BqKOQIVMzMVAAyOdue2Py/+t0Nx7xre3lWB9zEKzmRwx6dTnucnj3+pqlNEkcOHhb7VI2FKsuBjB/P6+/HJxDeuhUVpqTazqDmNjbNvikGfL9MDrn/OOM5rHsZzcW0NvExJYhZOcBT+P0/T1zVa/hnvZ08iRM9GzlQnbHHfrXRxWMcFpAsAyiqNzAHIYkZJHGeB/n5d0tuUmae7CKRfsYUilYnLLGwBLcgkdenUk8f5xVia6a4mlnn2IQ2zYvQDnHHP+T9CGwWySwRyxygA4XlTgAnHJ9enapYod98UuCyBBn/af0J/PmrXZHM7XuyFmZ0RZJgYCcsYzjzB7+o+vpVi+upXEEflyeYpMShMABiccnuOD298YyCt1bZuJIBKqzRHzd0mc5xk/Me3Tj3/AAGebqETQ+cm9trM2T/ECBuz3PX/AAyOE3JXTBJS1RoyRXUUUjzvbs6syeUTgZHv7Y/z1pZbtpkCrjzIQquxG7jtjpnk4/Dn0NSG5a8iuyWUQIfMDEAuoGOnfBPOPx9zpWs9tFYsjJNkKTu75OME9sirTUtES01utStqNql1HHbmOZ1+ecKBsJcdTk/VTnHfp0ApTMoitlmlV3C/vHR/mwex7A5x+Y7kYvNN5kV7NcW4kuZWHlyBx8qbccgHHUE49+3JFK9S3WG3Xy45NuCFUZ3oRjkjp3GP8mZrcuHZlS8igExkhP8ApKkMgEhOxjx09cj/ADgio4YBMqSx3JW8j+Z2l7nOQRnPI5/+v2nsfNWOLB3JvymE2BTwfxA4/L6Ua7cfZtOkjQRg7/L5kUsBySeOQORUxinqa3d1FDIGk1C4kvQHSRz8zIgCgnjkHPUg/wAhz81Z/il59Pt4j5uEU5KY6e+MYA/z7Vd8O67aLplvDMWBn/dyAcBSo6n6jHT19MVU8T6xYS2d3DcRTvIxaGIRsBg/3myOee3B4/JNrlvcqEZKpbl0Rq6S63EB2gusIDcfxAgcfQDn8fQg1oxxR29uXjllljyEAkA4Jzjpz2P5e3NTTGt7aaOG3eQP5IEkcgwoC9D7fT6+pxdTbFcIybkwdwI4yff/AD/TOkbWuc89xWtdjjzZ2DxkHkZGOvGOp/w9OKdEZZHMjNI2WIYOgwFz6dj078Z9xi0h8uUsdyz5HKHr+H+fzqmAfKlCbsEncueOPb/PX3NXZIhO+5oic+UZJX+bfnyw2flHr+P6+/Sy87pbL5aRx4HJJABxz/L/ACelYMUkcdwjKN3BLrkcj0H+f05q9dytJEXk4zglATlfqe54HT+dXchw1Rbt52jkk3oDLI4XAXnH17c/5PWkncRByyYOcYBPzew/+t6HuDVBLsrO/lSkoTg4A/Dg/wCfwqrdXZaANMyvHg45GMcdOe/H+OADScrFKndliZU1GWOW7ZyxQkjO4nBO0fljp/Lmq5KXMCovm/NgDgAA/wCPT8+3FXdCt4jaSXFwWcz5bHII9PzOev8APIFe/SO1WBVkbyt3KMeU7f5H+JxC25mNNc3Kile200quQyGXdnjJx/kc/h9cs0Sygu9RmtwF81ETd5pwBnPIz9P/ANXfStmiFwSEffgHYflBHcnn/OPbNRLZ+Qbi7jgWJrgjAxjgcD6c5/z1LXd2VzuziZd1LMuqQ6dNEsiTSGNWx83P9P8APoBc8VWJttOisrWBeEYxuqBVzxuy3AHbj/61M8UafILT7dbEM9qyyIqHG4L94fln/PNWrjVtIvtNtdtwZI1y5jfkKcZyf8/1rOatdMpNvllH5nPaVrAtJ3lu0CRoBG6xj/Z4bHv1z/8Aqrp7RvMRWAlCuxfBG0H0J/z/AIDiY4W1GeW4sxI4ZsgA4GzOCW//AFZ/Hg+iQWMlvbxyBSFIB4PHHeqoqTKxPLG3cl+z2z3fmsWdegAB2njBwPXPH/1+TWnaEHHkqytlQrDp7jH1/wA9BrzoAgEhQBjv4H+fT/IrmdfuAl0scZw0g2vu/PP6V0T0Vzkp++7GnE00EYglyW3FVLN8rD3rK1GGSVEXBCBsNsbHBPY/n/8AXIJJqU9zEkdwJFJ4YKPugc//AF/85xWa+kM29XCyMm7IxjbgDj36f/qxmZSvoaRi17xQvLMrcRh1O2Ug7QvJyO5/z0rG1SOKObc0jxqRtwpJI5+8B2/D1461qzlppBLL/qlLMxJ44GeK5zWbzcgcHnH1POf056e31xi9Ezpim3YuaRpz3GnLcArDDyycZLEcA5/Pj/6xGc13DBeSwPbE28sRgmXqckdV9MkfX0750vDuo+Z4Zmt40aO4yzOV4Az3z+fH5965O/uoH2N5UwnXh5AQdxzwc/57VTaSVg5XKTuIyMbdkWMDeCQQ2QuDz+mOf6VklozLHJKJGkQ7vkGCx7D27f55rZlvzFYzIkG+5b5GLAZXnOQRWALqaJxKVjZFPCFchiOeR3FTc0SZa0+/tkSa2S3VmZw6qxB+vIHT6cenFF5HFNqSlsrEdo2gk4Ht7dDWHeytcXb3CPtlDA4UY9cn25q/DcTDNzHlZRxlQcDPqffn9TQ2PltqTu5CtGu1kz0AGcc9Pz/T2qPSLofbVMMBQoeOQce2Px/WnLFJKtzOZ3VFwzkHG7JxjH+f61JpVrCJfNnmyA28KoxyO2T/AJ4q7sWmpoRIxvYzCcNI3IXrnPoB9P8A9XFFaktzb2ask0VvLGRh3hUkoeeP97jr0+vNFJpGbu9jobe/js3XzIgJOqh/utwCOnPf9fU8dFNqizJGySRxqIzuUL1OBj8D+X4VStoNOuI919EruxJQ7yCEA6EdPp/+smrZMpkUwSFLxCrRq3JJBxgZ4PX0/LoYTaJtGXTVFqaWMxrDHbLKpARy5JXdn3yOmD/9brHe20yl5EtpoZTJ5YyAFH4Y7+n1rNhUXV4Vh3xSSksoU7VXnoBjj+npngdFYSi01CG8lElzM2UJkxkjGAMn8Dj9T1pc1ypLk2K1pYeU0ZOHYtgeoHPP0z+nPStC2iD3ZQYaFAGynUt2B/P26+4AZd3DyiV0I+YArEpAVWJxye5zk8/40xJpVVYYGiV3bZkrgjnhuO/X8/rhr3djN3ktToPKSAhNhWJFHJ6EkduevUe1US6w3D3McJkjlG5CJA2COzHt7/8A6xV+wu44raUSS+Yypg7ySWxx/P8AmPqa00ZSZpLaRkYru8tQCvr39R/T2FaS7owju0zMuWkaPeh2Akb0RSdhHB5Pvx0/M1Lpmlg2qTSFZlhLHEvPB+n+fT1qHT7kzWqifbMH3uEOADyQRx0wOPp7dLNle28qm2kcxHnfhMeYOMjB7n+VYpKUrs3lzJWRl6laXEDxtYOjR3GVWNOo4zgY4PT/ADxWrFtbyyGC3CkMC2SI8dQRnHXn/PFLUXa/vLmK0dkO3eG3OQnByBj1wR09e+QGQxyLBE0E52K21YHXluMZ44A746/Xsl7s3Yp6xVy5cT+U5cPG8yNklRgMx5IPYn6dvYZqtqFrKu+Y3DCOd8ocBecdMdQM/l/O7FaNHaljGw43buRv9SB65/r1wMxNAro6o6bhjahGGyf5f5/C2n1JjJJ6FO9eRttuVyqjDAeh+p9P8Ppnx+H7fUUmMCyEKpfaeCF/+v8A57VbkcQXLhFPnFSknGQ27rt7Dj+f1NWdOLxN5c80iEqVkx3Xtgeg/rWWjdpGl3BXiytp1la6TE4e2huFPzKxXPvg/wCf8Kgn025uZYmis4bdgwkVlGQwzkZGTj8f/r1ZmeV7dbltzRxNtGeh5x09eO3/ANatIWpbTftsMha7Qg7ZDhRz/F+nH9OsQTldIbk4vmb1KenPcmXY7pFIrH5VPTsAp/z/ADzrxSROsajJJyW2jc34+3Xp/wDqpSyyrNGBHF5w/wBZhckk4PzH+Xt+VS3JURo8qeaFUOGjOQvXg/1+n5dELxVjKS5nctW5SeNgWZssejYH/AR19O/cexqnsuVka4UQvCGztcjew79sev5du9e2lEsZSFYnYZPH3+nJ9+p/zmsy/vI4AyyKSQCDIpw30598f5xVOdlccabbsjU8PTWd+LmO5Yw7GPlt3APT8ver10E8l41ZiYxglycE+3NcXoV3CkjFGOWGHPb2/wAj/wDXf1DVkWzZ4HRjHkEZHtjAHt6f4mpjO0dTSdF8+hrw3kCTtL8keIsbSc8nr1+n+elQqzT/AGnZICoTDHgY+gwfX9fcY4O11nzLkOWA8uYsB29cfTp/9bt2dndm7jadyA055Vcgex/n+frkURfNoVOlyanWaUjQWCsqkKFCKjA8e3HI6d/pyeTQuraOS6mmuiVhVclA2Sx7fh/h7GorTxDFFp+HyrHBzxwf5Y/z0qlLepLcqSS0JG6QkfeIGefbp+megrRyi7I5Y05KTbH6Wq3d7cyWzu0akKFD8H1Gfp0+vuCOkvminlQW6hXUgey/5/zjrWJ4bQnQ4WVkiaRmdnPO4ljxz6c/r6kVfLxo/mPIFGTx0yB16/5+vaqa93XqKprPToU7+1S6mMDbgrIcbMdevX/Pr0zWT4d0a1a4aK6jlkeFiAoYYkX1OeP/ANX57mtlY443Zi5JxtT5Tnsfz/znGS8xA1rcWu0BGUEc5x3GAP8APvUci5rlRnLl5V1NGLT4rO3lFpD5cRGFV+WI9Dippm2oT5LbCP72e3H60kupx/ZTI74j2kqwUcYHAP8An/4oVNW1PdakruK4woGPmPf+f863dktDmSlJ6heXoNujs0obbhh0/H0/z+FczJKt5NhU4R85zx75z/n8aqah4jWCzC71Qc5wxyvp06f579OVsdYe1t975Erhju69en6f571hOdzupUGkzqNVuYIpJTAcxgk/MxI5H19v89GgubmDyIGfCo7bSYzjIx6n6/r+A4bVvEHm6a0MYBl3Y3Edegqhc68zxRhkX90P4eMn1/P/AD6S32NvZaK7O3vdQhtY5UkZRIi4AGcnjGPX2/xOK5J5mu7gRw7lBXjcMYyOT+n+eRWLcXrzSIrD5nB288Af5/z6aWk3i7pXdg4IwOc5wR/n/IzPqWo8q0OgSe+sbUWsDtEGjYMwAA2nj/63496xbqNFPlIy+Zg7hnqfb+mP8Klm1UTT7gP3WcAZyPXr/n+lQ3pZ034Vj91QDx9P8/40XuyFpuWIo7YWc583ahzsC8vkd/TkZ4z6fWsJbVJ3kG47CMKxPTPr/n/CtK4QeUdjb92SeOnPf+dJaIZLcgn5YxuYEZJyRgZ/D/PSqv0FfS5Sazt42naEeZGowgB+8Ofyx1/zmlQjAVCvoQD3x3A5P+cd6tFSUAiZA4IIOO/b+tWhdpDDPGgjnMm4MzoN4G3rk9P8+1F7ivYyILiITPDJGZYQciNcbXPbOO30p0DkKFI2sT8qKeQpH9KijwS7hiH65IJJ5/mf8+laX2xdh2syqyNEQow2z0OOx49apMTbRXeVhtjgdghYM5DcHHQ9/X/PNFKmS+F3PvJDMVzk/Trjp/kCio2G5rqemxv5cbDY8gDKVI4IGeef89Prltu5S93RTbCE3AgA4Ye+D64+p9cVDFJDNEUMoRgeHxzgfTnt/nAqeJ47ibYIlQqfl5wCoHQLjnuM+57ZqFqTaxIyW5lhaE/aGQfvGjJ4Y84z35I571ZhZncOxQ7WXA6HjnHp1I59+w4FZ7h55UlZSquvzIi/dUdOBx+Z6eg5q7bTI09vb3crLLJG7JtB+6uMnp1yR789O1V6ESdlqJcXD7SYolaeQZAAOMdyB7evb8jV+NY2t1lYBBnIY4Jz04/U/h7GrVvBEsMVw+YSGO/cg+8RkAdjjBHGf6U+5mUXbwkTMsXVmHAPB7+rEfkM/wANLke7Znzp6JDFilikjeSIAtgBl6nnqRnj/JqjfR3EF0IW8uJJs7QBuPPJ9xz7+3XFbLvHdImAUlypPH3P9kdskn/JrH1KRbW/jEiKwVSq8lsHH3fy/TPbJGVW0dnoOnJtkVlIkWrNB8qFYwcFt2PxH4HNa1/DYm3klldPMQAhgQAD0H8/85rnZ4ZIZVnilbyW9GwxyRzz0wf855rZhijks5pJW/fbGjkIbcD7Z/D9D05FFKpvEupHaVzmrWWWbVhHbuI4CMSsBxg8Ejv1x/8Ar69HDp9vEqpaymQrk7VIIXnH6/49s1Q05rRYhNEpF6zBGUsAgUdSB06fX8uaupezpKLL7RGLOPOG2BTj04GD7n6ewLpNJXkVVbbtHoatukyCUQKrbsGNGYZxnsPct0/+tisxguSIYH/eOzPynKheMe/TP+eI790ikiaKS3VvKXE2Ad3HPTn15x0z15AbY20czSrHIryb8gqeWX6k8DJ6Hmuq/QwUdOZlFbiA2jef+8kMZ2hVA+Ycjn9f/rZFX9AtVkH71DI7cPubGD369O3+eufqNv5cszlfmyAShI5OOD+WeO49cCsyK6nsZjhl8uUYIHb8v/r/AOGHNyyXMjfk54vlZoayyxwuIQTJuZkiEvygjlsL3/P/ABqs2ozXNnHBD8hYiVucAgDj0z1/zwKoTao8cH7tSckqMAYGRj/P+HzVkLLPHHCzjDc4ycgjPbv/AJ+tQpXk2jeNLTU7OG/t5U865YeZnBCoV6AYHr6fn7iqM9xHHI3kgxEHghu2O5P4/wCQa5+W/bO+TAZwATnAH+ef19zWZdaidjnbuO7k9OeOn+R29s25scaCOiOtva3ySZwwIxnqQOn+f/1Vna/rsEhaSbCtyQVGee/+f/1jj9RuvtBjSMs0pOfoM5/z/kVIliryQrLuYlssh/uj3zUq7NlThF36l3T9VjWMAM8UjNnd14Pt/n+orSzzXt28nm7oh98jAB9P8/8A6q6LTNO0y4vXgeLy4IlDPyWZ+OASTxWpcQiOxFn5CpHtJA28sPwHuf8APTRQ0uyHWSeiOW07Ti0Ucm0EElxzjP5+3+e9bOmarLYxQ28ikxxylSdhJzngH/Pt1q7pN+l1D5J2iW3GwKfbpj049P8A69V3slMV0kjEM5yqgY5x168dP8jmnbsQ53dpC3+oq7+U8Qy+SAn5/wCf/wBQrSsNXjbTBFGpTEZ3ZUdOnXt19f5jGAk32zTXvHUm4t5PLbBxgjvz6j+vviwk8Q0ne0sQbGGXzMuG5xkfT09frU630YNJq1jvPDrNJosYDu6bMKAucc9vft+nWk1GaW0sFLrH14Y4z+f+f51yvhzxLbrZhLwyYibbmNgAAB0PB7cf/Wxmlr3iVJoZltpdz4+VeTj29+g//XjOjqLlsjBUW5u60Omlu5bW7QyZwsZz/ssRgHH+ev0IzZNVu7iNYiXDBTlm5IOeKxLHxf8A6IRcIT5i4K/eOR6Z/wA/hmof7bJh4iPmMTyUzxj/AA/D+mb1ejNY07bo7aHWVbQjDckNJnIwOT3HPuMn6c9K5zXvEqQWStEoDEYbjnIGMDP+fyNc42oXclxMVLCLjkk5z/Prj3/HArD1K6d5zHcOuWBOFHH+en+cVbk2EaUYu5oalftc2082QCyg4HQc/wCf85Jil1Ay6cEZEjVFwT3I9vc0/wCz27eHXBVvNUc9+n+f88GuTfeJmg3MVJ4B6KDQo2Q3K5YiLELu3YYlgM5JParZtUdRCHIYYaQ9h7f5/wD10Li9S0CiDY82MDP8FaumLDHZbpZUTccszsBz/kf57uxNyi8amKeUOQVO1cj/AD/n8qg8uaG2cROVI5PPGMf5/P3pbzVbc20tvBFlSMbjx+P9aZplzvtzE+C2NuW6/wCf/r+9PlHdpDY55UWJlJO77uc5rTS7jmEKMGTGc478f55//VWHv2wTQs3IYbV96WdyqBiFWRSBkHt61LiO9zrDeRKNkYyrIBnrgirWm3jWj7mjUg5zkHHTA/mT/wDX6crb3Ty4DtxnG7+77VvAByp3bochmyeDj/P+epl6CcVsW9TkeeT7QIlSN+0YwMj6VUmCKcCUMp2lsjGWx0/X/PazdSSXcrMz7VJ5JPt/h/nrUzWtvDo8MxkQzs5ZlH8AHTJz/wDXpkbaGMgLuEJyw65B456VOQY7sGSRs85CAHPXGP8AGktlBc+ZwjggkH19v8/4yhFuZf33mFwME569qaEyKJY5iBIzKONuwYC+p9e+fx+mCtJVVhm0KrKrA5h6qO/vx/nuCUibnbvFA0SzxTeZKHClQmE57D154xxn+S26xRyhnSQxkjAU9T1wD0Hr+FEUyyywxZWEfM0eRwWPTOeo/wAcdMU2eGf7WpnO91fbGp7YOMn16A5PX69IS6oE+jLvlSC5doXK7WLOFGCE6Yz05Pf2HrWxYQQyLbGaACCLcpckbtxHAGeV9Kr2pdLd1JL5GWHOGGM/hzwPx960jAVjjMe6RHIYfOAWwOTjsOvc8D0qnda2MZy6GtpVvLdSSvJsVVJeMkhmQ98Z46Zzn8PbKuQtgt2sWJYHVoyEjyzc8ZP19PUU2Z1tJY2G15RypA5XAzgdvT9PbNa51+XzUsokheS5zIjMdojI6jHcdR1H4U5zvGyM4wle62Mu3FzGGFoDOTgqnLl85BA9+DVvT7yKeJ3df9IRvLZThihGcgn9c+3pkU2bUTaWhQCOOeSQvIOqquPlx0Oc9j+nSqlleNePcSALcBiXZXKou7u2R15x3z+NcMvd0Ouzkm2g1pbSC2RFl+1T7g21X2rnuo9Mf596El1+8ENiCySPuZZtxWP8R1zg/wD6xmo3nivFMNkiSCInbgHBGeRjqRwaLSRpJBYR7o5EkyvmAAHB6N26n1/PihvXRG8Y2VmdHfabp6aerWwlidJMqijd26Bu+CRz+PoBSt5Ba2ji+hdmzlNw+bGcAHHTn19fcVcsvEDSW72lxHIt5HJtY42fQ8dB/n1NOa1jikeUu7pL95h8w3f/AKs/hntmujlTXNE505L3ZkEOzAWUR7pCoXoMcdf931+nsaspM9sP3bE3KIMDsoz7f559MiorOExKUeUsZMZ83JIGfX8Qf88zXURiELQlo5kwrAAc+3XH4j/9dx2uJtXsJ9oacSBoCFYgFxn5SRjGfU46euR1qrZy+W0kM8ccjKANz4OO/BHPvx+lUrq9bbMkysImG4gLgHvk/oPy7YrMubuXY0kcisU4O7nP1Pf/AD7Zq5pGndWHeIRbtKEhDKrEMZDgn3H+f5cVy2o3cvmJHE275sHqdw6cf5/xM+o3Ut2uWKkdORgDr/8AX/M++Mq4uFt0WOMq8pPLAZ/D/P8AhUWTdzriuVWLUksruSSxji65OOcZx/WqU92yL5cLFnb5unH+f8+lRQ3SlTBdSbctkknG7OPb/P16yzvbRoCu1T7j8sf5/rVcoNjYgtrEZWKvIcHnvnt/n+dQ6bqmZ2muQWYnhM8ge3+f04rMuNTjErl9oX0xWNf6oHb9wDuJ3b2PNWoXMp1oU/iZ3b6g8UhuLThsfMGP8xUt5r872pAlQOwwCQQ38+K80gv7mBt6TMPYjI/KpZdWurgLvdQfZcHp/wDqqvZsw+tQfQ9A0G7aw1ZLhpiN/BzyG/p/n0rs7m7gnUy27Fmxnbg59j/n+orwq0vri3lDRuT/ALLHIP4V0MXi2WKPiIh2GDiTjj2Pbn+f4Nwa0QvbQnq9Gb099Np2oSyTI32acjzCv16jnnvVudoraFnjKPFNjB3DH1J7f5988Re69JdrteP5hnq2eaTSdcnt8JKvmw5BCqdpX6VHs2autC+534sI7G0bzGLR4I3Kff8An/j9MZumzx3jXUECIWU4jLcEHn86x7zxJFPDs8iRgB0JxnjA/wA//rrEi1K4gmNxDGFjbjBHGfTPr/jVct3sJzilqzsLlorG5gkmQFIiM9wf8/59K7KWyWW0jKSohfAXGOPX6V5FLrbXDgvESoOWHmE57/zrsLDxZbfZFRrvyiq4w4549P8APr07iTW6BtS2ZsX9la20EjvcvsQ8LgDcfr+H6HuDXO3FxYagC0YVQjAYxjPasfXNfN7lI23FThGA4H4f56fSsBtQuChAbBz2HNOzexLqRjo3c7xNShtrcwPIDFgbc4GB7n/P5dPOtT1SW5upZIyEVj8o9BTZ5pp1AlckDgZPFVHjIIz93virjG25y1qrlpEWO+nTOCjAc/MM0q6lcKQZQHX06YqB16Hace3rTWjwp/Gq0OdTqLZmn/asJwDlSP8AZ/z61YXU4mO2J8f73FYG35+o+lOYnacYxjpik4o0ji6iOhgdA/myPvcnJzUt3MswCjO0dMADmuatbp7eXcoDqD909D/hXSW99pc0W/a0LdNjPnB/LkVLR0U8RGasSBl8lfL4bdnHXNaUGpSeTGhZSAe3ArJSaM5MaKemOelO2ljl9qnPYcYrNq50pnUxXQkWNMjgDIXqf/r05pBMxidgORwD8vvn0rmoriSNm2Nj2FWre+ZVaNieTkYH+T/n1qLWHbsbIG1jL5jhg21lxgYHb/63rWnawCHygZMq43yDjgAZGD+PT3+lZdhIZVR3GBwQMYXp27f544q5LLGMs2C55AK8fl/n+tNIzkuhpWh+0ZREB6kgoCV55ORyfpn+tFVv3SRby7ruOzCjJI6g+o/n6UUJ2M7M6Zz5UXViioZMj+Fux46Adef5VZ0q+hu51htw0piAEjyAkA/ic8emf5HPKvqd7a6ut0JP3DgRthflA9wOo/znvXR6FJbDTvMWREbO0MDjPPUfX+n0qU03oazjZXZ2EtnM9mkcxMMchwNvG7nPJ/yOPatC1ukhs1ijQ/JkyFl+9joBnp/n2xi2l1Iwt1ZpJN2CsgxjHfg9jk8/p2qo906RAsyNuk2ndkFTuxg9h+Z6nkjmrlNWOb2bloy3dpcmWWeC3CLtClWJOO9YV/pD2dyt8WnuFmYbyq4UqTkr0P1B/p03L64k3faIIbg2ySbHO7OHOeuSA3TPrx61JduyTADYUyJlbyzlT1wT2z7fl1xzNW6msW1YwNY3i2iVc28LybVWZuMZGd3dR/8Aq65NUluY4IJbWYCNWBIkVMknpke3Xj689c2vEN8t+ktqJN0MScfLgO3PPbjp/wDqwTf8N6PDdaZZS6gqzFsxxI53BOckfXj88dOAc2uaWh0cyhBORymnq0d4ZhKQgOA8bcAnOPzxjH/1q0fEWrRQLbXES+VPEQ4JwQx3Ag8dfSuj13wjZR+X5fyRvw2zjGRngfz/AMiuCnjvdJ1Ly7vcy2+4gSLk88EYPsT/AI1bg4qzKhONZ80TpLnxdpk8xuLeZYI58Bl8lRs6ZGem36D26Vs6XqBe1tSlzGB5nmKQgYjOM7vX1x2/KuEn8P240xrqzZjEsgYwNuAyOMnsMZI9fbOVHSaZqNtJpTi3cW1sp2MjDBBxn6c9uv41cVeV9rmcoJRsjq4rvzo2eaKOC4VjtVEwxz689P8APqapavdnCmFCIxyxPfPrxjPHoP8ADIh1BVjsmExkRxllQHch9P5cj1HXjOVqOon7Q4hC+WQOoxn/AD/T8tnLQiFL3i3NeK6HfMc5J5Q7h7ZB/wA59xjn9Ru42BSJi+AcZOP8/wCfeq17qEmxthATGMjn9f8APU+5rBlvS52Sb8dcZ6/X1qb3R1JKJbubtdgjEnHTJPH+f8/WhLcRRDcZA7k5xjpUFzqUaIylo0X0zlqxb6/VgEtVAVuC56/hVxi2Y1MRGCJb3VhIgEYBPqR/Ss2S7nlODKwB4wOKQrnoDj69qVQRnPb16VskkedKtUqbsjwxOev1pdh6VME3AACpo7dmwFXrz/hVXJjTbKqoVyeMVKsBGPlxnmrq2zcALxwOvJq1a2u1wzAckYxyRUtnRGiZi2xx05/pTlt2bkDofpWs1sGZyFwMn6D/ACP84p8NuI3wx3N06dKnmNFRuZK24wQRg5xj+KlFqyjKHrwQAa1/swYscnseB2/z/nFT/ZgYsqqljk7jkEj09P8APPajmL9kupz5iZV3sSM+vQj/ADip3sXEIbL7TznoDW3FaRSgiR1jCocfKxJIPQjsef8AJzTYrJiwWBzgpuIXnr2H+f8A6xzB7NHPCEhwvPufallgbaAo5xXQNp7BnSRCHU42498Yx65/znFMhtQJQCzbWXnAyQR0/X/OadxchhPbhVAPLY+n8qhMBG7PXOT+ddHJZRo8bE7s4yoIycjntj/P40uo2CNLClvFIu4DIY5+bHOCAOM0X7idNHLmMjqBikmRQi7Q2/kN9fateS0I+dgAvc9R+lV2tdwOwg9smmmS6RktCMYC4J6iozBxya2pbIJI2CjMT1U5B/Gm+WqW80ToC52hGJOQP88UJmbpGAyDOMdKYwxnAGa0J4xvOcj6n/CoJEG4noP896Zg4GfsO5ueAeoqNgSMda0NgJIIyDwBVaWEB+4IPTrVGEoW2GWl5LAwI+ZP7p/zxXR2N1BdL8pZWHVSeRXPx2+5xjn3NaCWgTDYx3BzUyR0UJ1IeaN1olHIzjJ+lRRssZ7Zz3GazYXuU4DtkHnPNX4ZnB/fdAMlqzasd8Zpl+3vXjkBBUhfXoati9V3QyuDuB/D/PvWSjoTgSqV64HetmG1thbuzyAjtggH/P0/WlYtluEmR1EqsRuK9eMn1opunXMZhIjXc/3SGHHTr/n/AOuCotcl3PQo20kQeRIJrabiJpniK7GC4KsMksAepOOn1FY+nrAj31mz7ikg2yRv905z6dRkjp+fBqCBLWa0uJbu7nFwzAbUgDDpwWyecn0H64qtcW91YSjy7d4pNgeOJfmym0kNkd8BifYntnEXuloUo2vqdtcXDHy4ra8aB4YirRvHvDDnA/n0P9DXN6lq8kxikDtjKk7mJ59QMfy/QcVknXpJmjNtuMgB3bRnPrx06fyqTR7EzasiXDACIg7WOeSccg96ylJtNGkIKCuzvNP1XybaOONvM3KdokY7AO+e3THH/wBarTXP2lknJlZUwrI4IBbPI2+2GH4eoNczLmxLQNKoGSQ+MdDg9Onf8q6e31BrGMw3UccpfYQyYXK47H+90Gc9cf7OXTfQ56kLaxK3iCAweH9QvpZEiAlQRxxKC0nHzbuMoAOQCOSe+cVF4e1y0+x25SXdIw5ixnvwenXn39M9CEutPn1fUbmaacna3lRRcswAAwqgZGPT6HvXA6zaXGj38ghjdEVxuyuCjEE449s456Z98NXs3YcYKSs2eka34hNlNA4TBTg5k3An09Mf59TWFY3SalqphuAhiZXIbAX3/wA/4HFcRd6nc3i+ZLIxI+XJ5AqfQpp4Lsyx585zgFU3DPXH44xx/jTu7m8aKjHTc76wsbSUTWLOg52lXQtkH8c4x7+3GNx5K50i8tLt432njiOIEEHrnaeOnp6fWpLi/li1G3a5zb72AlYEbscZ6cDjt/Tr0urX+n21n5zJHGQoBfJZ369+pz/ntnXkTVtiNYyT3ucvDcNaoRcRsZD04xj/ADkfn7gCCe8Vy7NtBxzk4zWRqGrG4nMsuAvRR6f5/wAfesG41OdTtQge+KIwvoipzjDVmtqOrJGCGzt9uv8An/PTiufvNU8zIt8qD/F/gKoXTySy5dizdcmoAORgdq3jTSWp51XFyk7R0RIoLHJORnrUiKScN+dNTlR656Vcih3soHU96pmMI3IwhJAUcU8Q4HJ4IzVyG3O8ggZBxxitCK0T5cxkE8df8/5/DMt2OqFIo21qWbGBjrzV+3s2zgBh74961LSyVsbVIZeTt9f8/wCe1atnpxXeGTzCF6Zx17def/1++IubqCRz0enlznGeOxq0unFpFQcMemDwP8+tdNHp7WxTzYQpD/NFJn8mAwfwra0TS7csrXaTyRbGMvlIcpjpnHJzk9OmPXOBJt2KclFXOWstDle0nkjZNsI3ySMwXr04PPPTA7/mYY9EmaJ7hoBsUhSSQME9B9a7vTNPgMssl1p05hWTMbp8qqBgFWHJwcjkHI96gTTVuvtdw8MUFpCD8uSeX+VQMcnHXn0646vl0EqtmzkG0VYYITJLAPOAYES7uOnOOn4/4UsdoYYIgwt41IZo3U7mbnGCR0xzjOMfiMdsujx2lrKbu2ZpGh86CRJCVVB1J3cnrnHHU+5Db3SoY7WyeaO1t8swkZmZ3wf7wz16cDHX60cjsCqp6HCmxY25Zoz127FOGPv9Pr9PWl+zNBIBDGfKYcSkjnBPOf611L2tt9hVdjPLv24OFOFHt1yO/bA7dbOkrYw3u+VSjJnEKje28bThmb7oPsM+vOMq3Qtz02OYgiZYWOyNZ3CqSQeRnOfqTgHt/MRS2UF0qsY3VimZCQB82eox26Cuq1ZILi5jN3cF5FgChoFAVH5IUZA+X171oaP/AGXallaSZvNhKSbuFGeCN2chfUkHp7UJXdjJysr2PPpLWQyJeyAybX3EsuVz1we2MDp3/OrVx5bxwSNDsiTAkbAJOR0A4HbOOvHJNd1YLp9tBdxSTWd7AT5UcMQMTuu4Pl2254Jxnr9ThTQn0/SILS6FnPPd30wBt4PJIHORjg/MRjr046ej5WT7RPdHG6lpS31sraXavMkI2XDxW7gZ55bLNzwfT+pyYNNMqOCqjahYYXJ4PT24P+e3daleGwtpLTTZri2sWGZUjlYrM+0KzEZx1444wPpXElt8/wArBELHAxwP88//AK8im9xwba1Luh28Lx3MVxEyyOW8uRCiqMjpIWBGOMjHI59a5fUYEDfuiSoO0lhnp/Q/599yKWKOTBbcpXg4x7A+45/n7kU9RVcmMlfOHHoAfahXJejMB7XfE7AgENjGfXnp1rKdNoPP1zWlI535Cktk8deKqfYJZW3SgIv0ye9VdIyabKHO7A5//XUy2mTkA9Og4rUexh8smJvr8v40R2kgICN1pcwlRfUzI4HVjjIOa07WJ8DeuQavJakBSQCPUCtO0sUkUKVIb3H+f8+1F7o1VPlMyKzLtkICOtStZfKwdCBj0/Wuq0zTkJCy44/z/n/9YrYm0SNFWR1ba3O4Dr3/AK/56VG+qKi1E8lvopVUJJuCqeP9n1rR0qyv7iENFkoCBuI7+ldRr+h5ttyoQTwTj/P+fwzU0O7u9G3rEu+Jn3leDg+vP+f6F+5tFdUadvoOtW9r5gskWPp5r5Cg47UVdXXNQ1y9jgjjcXEwIG44BIzgc9P/AK9FOy+yiHPl+NpClp/MRJFLWgC+YsbKSqbucZzg8fT17VAt2bS3udQjjkEcP7pGZwSWbO0YOMjPXjsfTFa01sJJmSRAJScu+3JHqdx9z2qGztIb7T7/AE6a7iSYKZLV5iFUPkZVjjPIUY5xzXLqpK5o5e62ijoeIibuQI0jElyq7Tz1Ht6/5IO94f8AIu0nkuRAvm5C4Y5HyFuPYdP0964q31VraW4tpYmjmfIcMAMMD0Ht9Kfa3Nwg8yCUk+w44/Tp/nFS29ilDnV0zbmuEt/7PmupIZhEzA25UgrjqWPoSf8A646C1q2sx3ckTqxUKwAG7O0A464/z9DisW2uGXUrS/lj85mkDFRjawzgjP1x/WpWeKK8uPtFqI5Gl3pIxKbF/ubfTt0z+OaFC+xo4WaubNtrl0kbLaQsQT5gLAA4BPQ9zgnj8Kv3er2OrXoN0wUOOd67dpB6EAcDGfy/A4tyskYX7PIrx7jgMMmPPPBrMmuSdSH2wCUABV+X5Qw7n8f85xW0Lw0ZHs1J3Rd8QQWdpqLfZbdjau/mKwPBXuASMZzxjmqU33GMcx3ZwsYXgAnj2z/nrgipqGoXEttHBPOWSDiJd3AHTAH+f51VW6LxLFGGy3G49BnihKz0NF7qXMyWeaM48wgDJy2PvVl3135v/Hv8qggKGPIq7HYSPOjF/MYHOzblSPf/AA/+vVsaSEdQASvHOO9UlZkSbkc9Dau+7fjjt6VBeWflLkAg5rsDY7WyUxj68/54/wD1YzQ1OGFIcYB2nOQPT/P8quMtTnqQujjLmNoirYBx2PQ1VQYOcjFbs1pFc3EcDTLCjsmXcYCgnBP4VV1Y6dZ6yq6GXlt7bYFml5891OS+3spPAHoPetop2PLqrlkVIlwOevWtvRLS4u2It4jI0YMh2DkKOp/CtDxX4rbxRA8lxptsl/KyyT3aqAzlRtwMAY4Azyegqt4XYNcukkkMStEwLuxAXAyMY5zkcUNGlJvqWhCoc4HB5JBrpNNs1aON5U2r6kbs9CcD2/qPUYwI5kSZlEqsoJ5GcNz1rVtr/EiKHUoWByRyBn1/z/OsrWO6Oux1VgliIbm0Vnkj3YjmHygehI9Mke4x64I1dAsLe3uhdXYEsELq24SrtHzHkActjHt3PAyDgx3UTxSSORCVXC7EAyOp3euQev8ATmrjX4bDOYlXbtGzg9vx7D9O4WmrJ6hytqyNtriI6hc/ZIYJ1a5MjTsmXKE+pB2j36d/rPFdxQXjyeddyGCMxoIsj2A355HQnFY1vPKtvLLAdkTtsJD7Q2ADtIHUf568VXS+jM5UzAFOPLGMHPrzgf8A1/Sq5rC9knob1vqF0umvbtP5cMjlyOu4nk898n/OPlqjfXQeM5uZNkfy5VuDk/y7/j34xi3V+qyea0jRunAjZOPf+v8AXngZGo67HHCRuJLc5yfzP+f61DqX0NY0VujrpbmF0BtTcEoNv71txLevt9B6VltcxEOWlI3HDdsfn/nj655jTbma+YbJfIU/xlsYHTgetddZaHo0cCvcXck1427cr9fbjn07j+lEYymD5aZUtdTit4HNxIk0j4EZjG4qM9gO/T8/cEVxfqigMDGUbAVhhhxjPrn/AD9Nm/hme2iW1lEUAw4C7SdwySzY5Byc4P8AjVMwNGGkmMcl0DuB2qRzk9D755/pTcWtGxqSethovYI4nubmXDJgIiY3E9mJPA/I59hnOY+uJHeSTpHGGU7l+bgfhVOwl0uHWopdatJrq0PzG3jlKFm7YxyR04yOPyNnxdeaTcacING8Pw2k5fcbkSEsF5woGcZ5AJ74z1NT8S3FK8ZW5WyxbeLbreFcK6c5DRKRn8Rnpx+lWNV1q6ZLdLYqkcqhT5a+UjE87SRtzxzyf8Tz1xLDd21ljTILFreIRuYGO6ZgMF3J4zx0Hr+UE8XnSB5pTIVOcHnr25/CjmsCpc2trHQ6Zbafq9/GuoavFp8KQsZA7hd7Z4C54GRjnHTt2qC3l8P6f4yUfZbrWNEXMeyUgM7EffG3GRnGB3/njLFLw0S4deQeu0+v+f58VILeRQhwWI4wCOPejnXYl0XJ6vQg1eKVbvUVjtorW2mnYCILlo1DEhcnJGOBx6fnnrZtdktIjOQOWHPT+fH+emN77I7YEkbbR6nIz/n/ADnGdCygMP3gfLJzhhjPt+ef175ATkx8iSsc1baYjOu0Yyef/r/5/pVu40uFXEe9SMZJHP5fl/P0rpmhjMjBNglkIPAxjP8AP/PvUVxAIpGjmiMe5SMf7XQn9P8APFJuwI5NdOV5CqqCpx6jNS29h5cmSowCRn0H0/H/ADmtsxJEgCybmJ+7+ox/9aghXRTncpbnGeDzx/n/ABoKZDBp9sI3ZlJwv8Xr0Gf89vxDrSz2P6DBOcduv+f/ANYNuEDdu+YqRgMecmpjCAyyRvuXggY9/b+nP48GtSLA8QhRDG2CASAO/wDn/PqNHTrt54TC5BI5G3k/TH+fzzV7T7NG0Y34ZGAfYELDOPp9O/T045rItLg2eqrPGCEWUHbjjr0/L+ntQ+hG6aXQ6TSLKPXRY2QicNHKfNbd+7CMeo9+3HHQ4qI+GIYpLuAQOZbcgqjDl1OeT6Y4/OrFut3pGu6ha2UrRuIT8yjOUBLcZ65H+etaEEsi+Jd91cCVp1MZZOc5TKn+X+ea0VtFI5nKSbcXpucxZaCfJW7tk+eCUycZBUKQf6/z9DkrptAYRSSwyCMoQQTKTxwVOPz4/wAMUVUYaaBOrZ2krnlFxeXM5d42PmYbKgkHjkjr/nn0NS3LCaJcD943BGCCD6fn/nkVkzwShfPQO8S4ZzkgAHqDx7dv8KhuL4ytCGLKpG3cDnI7cV5/KeovI6zSbmFttpcQkMmTyMk57e3YfT9HaroduZHltbeSFN5KuBjPPfsOT/L1punSyWapO8olll/dsZOWAbAwT/n/AB7HxCjH7IgnjZDErmNQAR15OOOef87quK0szJztJW6nDPolxDMhNwpVfmUKTgZ5+gOR/k1HLa73IkySCAN3Ix/n+R9DXW3sK2sUWASNgZvlO30+mfr9Kybqyuo7cztBtjI6nHfkcdfT/wDXWjjYuM77nO3NjMgKq7c8k56fTn/P61m3EIijG6R29SSf0FTvPdPdsvlgbGwH5449uO9dBb6fpkdpbSzRzSXiO32gSMPLdf4duOR6Een1FK2pq5cu5yNvai4WBo3Mk8jFGiKYCrxg56Hufy+ldZp3hsRgB42Z+AM9fpz+H9ewroNJ8Mm21GB3jEe1S5XfkZOTj8M4/Pvmuoj09ZZkQH5R2x0x/n/PONVA5KlaK2OStNAKbWCbVxhx/n6f5INXZdHKqjtgRdwB0/znrXfwaen2fgdSe2PbH6fp61l6tbFI2O/uMLzn61bhZGEcQ5Ox55qluFcxopAzjkHPX/P4+545fVohEjZPJ9s+3+f/ANeO8vYmMhAAK8ZCgHHb/P8AhXIa+FCMq/MMfe9axejOpO6OIvi7Tb1Y+YpyCMYGOBijTdPkkkAgtRMTgYbOOenQj3rorLT45ypPJJz2z/n/AD616FoHh+SaFktYIsoAwJIBb6Y5PT9PTFWpNuyMZ04pXkeUXdrPFm2NpBEeMlATz9WJqS00eRhuYY4x1xn/AD/ntXoeuaPJbktcQgMCc5JHf3HP+faoba1GFOF2noc9Pb68/r71Mpu9ioUopXRxSaN+9KuGBzwAevtVo6N5agsWGRnlq7OS0RWDMqnGQfl6cVHPA0q/OGIJ5Y5z9Of89e+anmb1ZrGCOatRNazF4Lh4yRt4IOceuR/n86tWxvhbmBbmQIvqozz74z+v/wBba+wRovIJOcjJ/wA/T+VSR6aOABtAyMkf5/z7Ypc7L5YmZHLdBZV87O9ixY4JJP8AtYz69D/jVKeC9lLmORthIfnHpwenX/Pc1t+SQreShK56mmvBNIijAAPLANwO/wDj/nOHdspRSOfuoryS1eFTDuxy5Bz9OvSucm026S5Uz/MCeCHz+v8An/H0SztVVneaHegU/Lis+/sv3jFk2LnKjBGP8/n+OKaYnBPQq6PoOo20McrCBS5Hlq0uGOTx2xjOP/1cV2DavFYj7PLbSz3MWQ+0BWRiRxnkEHJ/T1XHO2cV3aW5e2mljVcZAOT7kE/d69qn0y/e1vkk25Rjh16HIHB564z+pHfnVTXQylSb3OrW8gne3uJLV7hSFRl3+Wv3TgDOSTn5ieM4PvXJ67qvm2S2sEYVh94YAKnjPOOR1xnpnv0Grr8FpdvFJbXEjlky7dO+c+/JPXn8axI9PhjmcgHC/dOcnH4f0/xwptt2HRglqZ9jpzrI88255ByMrx/n/wDV15q4Ld2lLhVKIMgf5z6f55xrRwKyFYnDMRjk/Qdv88Y9M2U04iTHksqOeoGc+/5j/JxWa8jZyS3Oduo0MhXG0E8HP4/16+49RTbewDSFg3A46/h/j/nJPXy6fsQSKcMRwT1/z7/03EJb6cI8bVaRs4GBnPt1GelHKS6kbGdbaXELVgqkcDocZ/H/AD+hJry2BOdq9e39f8+v0z0vkxKG/d/OByASAwOD/TP/ANcCoY7OIuQcxhuQMnn/ADz+vamkYc9inpWmsdpuACucPg9M8f5//VixJpm0gHITcdrMmRnsPy/z3bWtYT5SADP1IwffJ9sn+dJfMXjB3KVRj8yEYOOp9/8AP4XbQyc25HNXkMkK+awUNGQ2VGMY6j+v/wBbircx+2xgSliVUghjn2z6+2P/AK2NW6jk+zRyRMpEhI4OWXHcj0//AF+tc/Z221pHLssoJ45/ID8vzHYjMtWdi1JSVzKu4JFnErrjBGF7gY5I9j/n0oMfkI8r+WGbByM46en0x/8Aqq9qV1NLMsczAkKEwVAJUdPr/wDr75qpPI86+QAVDOGBHByBn+v+cmpejL1aLFk+LRH8tePuknPPpz/n+VNleGKdEyEhk5JYng96btWOA7CX+TeQ4xgjpj24/wA4rNvrxngDOBlWyB/n/P6VXMJK7Oh1rSLnQ7vynnhk4yGjPBVh7/5/lWTqJKxs5ICNjABHPrxUY1SWaDDyF5CvTH3MVCrK6IBnBBBJ6ADv/n/GlJroEYyS942odTm1DUreeWZmlMO3cQcHjpx+P9e9X71zDdQvC7cYOCMHpyPp1/zkVzGnZN3tZ+FGBzjnj/P/ANetCS42yBWbO0nHsM8Uc3cThrodDDcbXRWHDdWJz/nnH/68UVlWjnb8vAPf/P8A+qirUjJxRwyo3mot3KQoGNoPGBz+PasxLbzrp9rExq3JPOOe1dPc6f58D+Yp4JGP6jNc20U1lKURwVDZy2Op4x/P/Oa5IT6Pc6dTf09Sm0oCI2YxhmbI3Dn+vT+XWuj0mUhSxPybtpY8+4H5fy7cg8db3j3O21YDKMdoQD7x/wA/5FdzbaXJb2CSjcOdrYHfrk9/X349c1ai3LQG0lZna6f4bkvAq3N5IED71aLgdOnPQdK1dRtLe9gFugLR242CNcKTgjdgnvnPXv16UzS9RaS2Q2kWXVArgNtDN0x7d+lTQOjOzxbRuG1xghVwp/A87efb6V6EUrHlTlPmu+hwUGhWtvqF0zzCKWObYASc4yckYH+fTtU+maXphu1eNGEqZyGOVGNvT6knufxOCGXl6JLidyq7nc5wOK0vDkAeCZmZj5jjap5UDHUfXJ//AFZrDS9kdsuZR5mzatt7zJIIjsjK528nk8fy/wA9TqaabSNjHcqwuGJMeDwRjOPwHPTp7U/SdOhYQXTFy6khEOfwJrVsdOikPnOJI2JO5T3PrW1m9TzqlSKuhzxiHT3dY8l8KCe2e/8An8+9c9rKQLPCzuQjRqZQo3MBzk47Z/zjpXTa8CtnCkQfap6j9MmuQ1Aqp2KoyTgn3/z/AJ6UpvQWG11OU1fCSN5Zbyzzlh/P8x+foQB514imleYIDgKcHA9a9Q1FInlWJnCKvWQ+2f8AE/53GvP9WtornVZNhUIDtG3oTgD+o/OuWaPYpNNDNDWOHy2Od3qcHHH0x2P+civRo9Ta2isntojHdQxld+doyM+nXg45z+Ncfo+kSPfRxQrmRm+XqR064/yfTnFbF7Y3EEhjO5toBUrjABz6f56+9ON0rimozdmLqd3JqcqwyBzM2TM5OQDnoB259/Yc/NUXkKE2qx45Hy9v8/hT7K0cSSymVVwvO48NwMD9fp+FW7a3eaMhE3AD5sZGf8/55zUvV6laRVkZ4gdo1b7qseWYcY/z/wDr5BqWKFiVTPG7lgPbp/P8u2Dm1JBNuMW4NnoAM/57/r709oDbybMFVOAefYf5/Af7OW43DmGwWnnyybRkrl84HTv7f/W9uKh+xStl5GIQE47Z557/AOePUY0IJIEDbxtI6Y5z9D6/561MIhdzKWyE4wAMZ/D8T+fpmm4ojnaMy3sRM7KhJ9S/r/n/ADnikbTv3+GdFxwAcccf5/8Ar9K6U2YhgURrtZunGM/h+VNNnJMQ0ELjYcs4Oec88jkc/wCc5xXKT7Y5q7gEWFyy7QQdqnnt1P8A+v6nmqBh+YmRTk8cA/5/z9a6S6gm2kSDDAYycAf4d/8AIrIu4WWNJJBxIPlzjp0Pf6f/AKsVMlZmsJ3MG/TZkRlgp4GDxjrn8j/kYNZ0ULoFfPPXk9Pp+f8AnjHVGwklh3PkfxE44P1z7/j+OcVZ9PRrcFMvcHJZdvCjoOf89frSZtGotjFjJW32bcnJIAOF3euPTH8vTOdODdKi+ZFyg4Gcfn/n/wCvctdCufsa3Rjk8joW6ZI4H6gc/wD1q1rTQpcLJ5ZHoOnIPQ+mP0+uKpXJlVgluZosZQBJE288fL0A9fT1x/nA6KysZBJukBZmQBg46en9K17CyENqqSORGOMMSQPoM/5+lSNIxmVEUhT2I6e+fpWiglqzhnXctEVvsf7hjK4BAJJIxkd//wBf4+1UorbZuHlkyDHzfp3z/nrnt0aRx7AwB3k44PP6f5/GnCDM0aj94Bxw2D+lVydjD21tzk7q1SORdzlmBBUOpbJ6c9/br1P94ZMc1sXLOhKN1UBvvHjp6j3/AP1DqLvThMJYmysxQ+UuQpJz1weDxn/9WKj1Tw7JYWcc7zrKEQCcHqCff6n6/rUuDLVeOib1OWspZrdywIdVBTZIAQMjr9cng+uO+DSR20ckdw6ARqv8B4JPbjrnr0/nkm4tpxPKrTHyWHG3OAc87uw9uev1xXnvJDNFbyHcpDMhB78cYPHYD/62KlR0NG7vQhbzYnjR23HHzbeODjj/AOv7fjVptDE95ePZS+ZDCpcKGG7gAg4/Go2n8/eZFVndVAbPQ9/rViDVHi0yWwEkZDCUsyAtuG3G0Dv3PH9DilbZkycl8JwWpwH7OjElnGQckE56YGPb0/TgiOyR5yjQgswAY884H/1v89c29QZrpZUnyZGbJZu4xgY/L9fTrWS4ezQNayeXI8ZQfL94fj7gY+g9qya1Oq+hD5oUkrlQQDjHJ/yP89xTvViWRtpDBsHgev8An/DB5qlf3BWEBsSspxuU9RUInhMCogw+MHPPH+T/AJFJbFJalqK6BZoQBgnO4dv84P8ASnb0jTJLYOcgeh/l/npWYkgUuw6kckHOeev51Is3B+bjoBjvxUWNGtC9aTILoK6ktjoD/n0qxdXSG4yGIKjOMY/z+f5dayYJhDKzHA4x35/z/ntVN7mWadjDGSD3wTRuTotzqbDUhGrbuVHPP+fp/wDq4orEh0+/mXMSDacE8Ginz2M3y33OyggW4s2+XEkfBBPcdv8AP/6uZ1jTxKkxfkAbjg8g/wD6/wDPY9LAVluLonIHm7gPXjPH61V1GN5oR5vySKuSgYnBx0BP04//AFVzN6XHF2djzzS7kWOqK0oxLG+Sewr0268YpfaSYLNVEsg24VR19h+f+QTXmfiOIw3yuv3XHPatPwrdH7VGcr5u5Su7GMjoc9jkD8/pXQpO10O0W7NbHs/hfU5LMW0NyYwpjBk3EFlbuMVq3d8r2L/Zy7RyW0hJ5IyMYx+Gfz/Cuf8AB99aX+sJc3ShXkLt5ZIARgRySfvHJb/PFXdXnibUZIEfEMhK7ewzkdvqf85x2KXu6HDKCdTYrzT6aNItGjXe8kbiTj+Lt/n0q98PpI5LKNNzBSxBY87T6j8f89jxd3ugZoejrkEDP9f8/wA69J8PW0FjZRRW8JUwhSzE53EkZP1zn86zg3KXoaV0oU7dztrVo7No7XyyAsQLSEcZJAwPXqaaiHflBtB6Df1rKvbsSI0iIqeaVLIz5b5lIHP9P5CtjYrLsLMpCDkf59q6UeM48ur6lTWHKwRxqrF8+uRWRNZgXsisVZo42lGeh7CtyZjI9uZsFBkcjknoD/n/ABFUJ9p1W5ALK3kEEADjPc1Mlc0pycVZHmvigraoVZtzNGJGyQeoyB/X/wDUTXEaFGXlaRgdxPQc/wA+n+e2QdzxOZA8ruc5/i9vX+R/yuZPDttZSs6l5LeQ9mUEED0HHP8AXp7cTvJ6HuxfJDUs7Gh/eRGRHxkENznv+n+R1rdsns5ltyXkaTADRnnzDjp0AAyf5e2Y7fQ21ZZjp+B5SNvL8ZAH9eR/9bmrS2wSzht5oo18oLLLN02buCAerDIPPbP1NapNGEpxel9RtzbM0d2kkK+fKyiGNEJIUck5xgcfUn07VXsX+x3kUhTcqsD5ZXgkD0P+fx5qUwQLd7ZblvK2eYhy2MnoOmfb0qWzi26mLa7DwjgoHbn8fYen9Oo1rcE9GifU2RvMuFiij5BUKcAn6e/9Paqdwyb1RlEgxjgZ4Iz278/57bE+nTm3e8hHnW0blQ+clugJA9O1b1hp9jLFsEBkik5DMpVgwPI/PP8AI1pycxg60YLuc/pGgvIEkjgbY3AyOo7+/wDnj+8L0llskaMqA68bTgdf5dM//WyD1it5V5sVW8pVIJxnb06mq89kLnzXUjeGwW7j1Hsf8+mL5FY5PrTk7y2MuLTBcFJGlUAHkcg8dQB9K1rKCKyieJU+ZyWGepI/H/P847ON4ISyZkJ+8p6r2z/n0q+6DcszhQYxnceO1UlYwqVG9HscxqFsIZJWlXEm4sGIz/tZPr34/wD2a5a4tpbmYhBlw2OQAAB/+sfn3yMd7cSJI1uMvv3HBzkEjPB/AnnrUSxrYwMsZOyU7gTyVxnj/Pv75mULnVSrOC21OPttPE8K+cAJFJwvTOOP8/41XGkskzFThSTjnOP8/wCPvXTvp8ok+0SDIZSSRjv9P8/hVJ7KNotx6noScE8j8ug/L6VnyHRGt5kFjo3naeYl3iUZYK/3T6bTn1/z0I0Layk+yj7Qx38bmZssT+PJ71LpUkyLKVJ2BgWbG7d78/X/ADzWhb6eJssHBjAwzN0J9/8AP/1tIxVjCdVpvmZXgggUBZTiPoxB5U+oP+fyzUwFkbiTyoI98gYsSM9ABkg9Og6f/XOdJZSRl5EnbawwNxzyDnPrx1/+vgGHTXkXUEWZCoHcnoD6c/5zV2RDhza3LSmK5tjLbeW0DxhojENyuDxkHvxmr2g2Mbs29shRgKTgk/8A6sf56xqRFIFkUuuG27v4lzjj/PHHpxoC6htIDJGVCKAxLccHvz0//XSt2M6kny8q6mb4mnjt57SFcyPLIrx89wwJ+Y8Dj9B+FRX00smis5Z5Hd+jDOAx4yPXoBWd4kvoJr9F85ftdvKApYHaoKkHp16/5PTK1G4ura0sGRgbo/vS+c54wvPQ4qXK1zanSvGPci19DaOLWBVDmNfNKn5Xcc5/z6fgcvTrO41BmEbphY9jFsDBPQAnsOv09iAq61qaXfkZjSN4V2OA3DAfxcnr6/5NYN5eGEpsYRy54YHjJzz/AJ/nnGLkr36HdCEuW3U21unshA8b4v7Oc7uco6g8DH4d+cn1xWdPqpk1sXUKDeW8wg8jJ5x/P8vY1FbywAXBu5n2iI42nkkjj19Tx/TNZSM08eYsF4xuJyOmQPqTnHv+lZuT6GkYLVsvtagRzPM7LJuwBjOBnr9c/wCe1cxqzyx3G1c/KOF7ce/+fz6X9QvLiK5a2mA2SLnJPJ/L8aoSs11ceXlcA9B2zxg+vH+etEnc0imtWU9RsWS3iuCcB1H3T3PrVN4Skm1MgMOT3Pv/AJ/xFbO0SWkxnMhmU7Y0PIPqT+QqmGkDsdpYFcKPXn/P+cZm9ikyjHb7Q2HJ9jx/n/P1psriEYc5yM/5/wA/rmpLy4ENvk5LHoM1HpdnLez+Y/Jz0wCB+dRKQ5TsJptnJdTOzk7QcjAyK7TQtElmXcIGVTgYHT6/5/xrpvBnh62aMTuMSHhgQR/OvQ7ewhgXCIB7f5/z+lOEHU1OCriOXQ4S18N3IjMeSE6ZP+f849iaK9Bkg65xgjGf8/5/SitlSRze3kzzbS9Iigt23q7nAwo7nnr65z+lZWrbS7hcAHgHtn/P8/cY6y9ZljADRgkYy3QDnkn/AB/lkni9WKxzE5bHPXrn15/r6+pNc1SCirI76MnJ3ZwPi5QYWIXIXkH8ax9DmCyMTu3gArj69/atjxWG+wz7s528jP1xXCWt48ThjjIPFXShzQsOtXVKor9T2PQtTiC20TMkHlIQGAzl8+nbrXdzrEuhxuS5l2hiRk72ycNjt0P4fQk+M6BcwyxwNJMCDxtPy/rXpOlte3EQiV0Uxtygf16dM8cDj6dsY1pya0NKsU7STJ7/AFR7ixlttokR/m246HGeB69Of6V3+hXu2ytlbHmZ3Pnrjb3H1x+f0rzxh9ivTNMeSPnJUD5h2x+J9/XnIrpLW78wwtGBzHyrcZ/+v/n+8RpF2lqYVoKUUkdje7JFhaJSh87fzgBjjnP51rNOpQBnXcOeewxzXJifyXKu3+sUAOOcY5H8v88GrY1ABVy6OTyM4DdDzgfl/nB6OY4JUrpG406/u98hJBGOPT/P+TWLrN+v2ucQso3ptJzyR/Uf5+j4bsuwcxrgDpnoP5f/AFvbmuU1i8Z7iQqFKkkkn/H/AD/Q51JWRpRo3lqc/wCKSGvSrYcb1GOvy5Ax/n19xjahtree3QyQSKyW3mySeXtLFV+Ugeh4+uCfWuS1y4V5vMc4VsZx1HX/AD+fuK0dM1ibUIbeO782SIYU4ONwHQE/57e1csJK7PSlTlyq3Q7Wz1+HRNDtWihSWWZHLqxwRhiNxPTH19M+ubGLiCyiuri2t7iSaR3Kvhimey+3Qc/Ue+RJeaYFl+zWgR5Pl/efNgD+6B6nr/8AqFW9E8mXTSZLnbHDL5oQc7AcFVx6fToD9cbRetrnHKCS5rdSndC6uNQuTPxMSWkcg4jGR0x6DA/zmtqBgcR3jC5afA89mEhQ4zlTjocDt/Sqt7qNrqOtsYrhbciEqTF/y0btz75P4fiayY9QlbUmWJwVjkK5jHDYzz+f9fehNRe5fK5pK1tDqbeG6iD2qAm1kyn3uR6jp/n9B1EO1rWGIExuMs2RtIzzwK5LQNd+zWd1JL5kkhO5UIG0kfr6dP8A69IPEa3dyflW2wAFI5ye3T2x/wDqwTqpJHJUpTm9tjtJtkImLjIO0kluSOmPz/nT1iguFDbm253EA8c9q5kavHc7RKpVSuSFPIYY9O3+faujszC0WYiXKKpYkknpnv1q9Gcc6bgtS7HCmAABkGqV3PgywRFd+zIJ9ew/Q1ahcjyw3DyEtj2FVbq3kWS5KIrGTDo+eVIx2/X8KnqZQ+LUyr2zP2WO4jfzpMCUKeM/rx9aviFSxndh86g7T69On1x6Uv2SElpH5nI+QA4C59B9f896sWCuYyJFG4jrjg89P0/WmbSnoV3ZuFPKHhePlB6Y+v8An2rH1WAIWQk7WYbjgDA9s/5/prqfLmE3zyoGLMO27pkfT/PNEnk6lcKu4ptzgqMEdwaocZcjv0My08tInjdmC+wIz/8AX/rx1zm9FsijPO4SD8xVfUAczEqo8sgFgAAOg/z/AIYqjDcgylJXcAZXJBIOP/1/54yy7c6uSXb43umPmBCgjjOcc/5/PORLrEJS505rbGQ4QnPy8459+fzqpeRn5GgZXQ4k+Y+3/wBf/wDUM46G1jeWdbqWMJHEgSNWOSD3bHQZ/pUsU5KFpAI4migCFmii3Lkrgsemfp7/AI1y/ih1tbRI1AVmyIw5BIHtn/P0rpiywM33vLcAqR2xjp9fz/SvP/E+pQXN2yIqlUyFc8kknkj+X+eFL3UPCxcp+RzVxMDqInyytgEtjOf/AK3T/PNTXWoF8TSTB/LOQcdPfjtj/IrH1GZrd40JwisSMDOfUH8+n17Zp+XuFZI2IIVid3TpknP4d/8A9XHfXQ9pxVkyHU7pPPcIcbjuCqBx/h/n6VkTHe8rtgqh+YH16dPTj/PU2r3e6RNHgyEkbhn1J4/X/wDXVG5Z96rKOD8wx06f/q/+v3TZcbImmk81JHkYlfKBx3Xj2/z9OgXT43V02gDCZYsOR1/z/wDrFZ007OH3gKhOMA4xVlLvywBv2svcHr1/z/8AX3VCepTXYbcg390qSMV25zvJ6Dr/AJ/rWVHL9ndovMOAcggc47/5/wAKs3DncrRtgkZXgcD3/wA/41GIUNupZAzMwPbt/n/PekO1kNV3ljRmyvzbep4/z/n0pR86McYVCcnpgd/8/wCRYa2ZFWWQBY3JAA7H2/Sor/KaVM6MScd+vfp/n+pqZIm6MKU/adQRBznAAH+f8/pXoPg/QXaVXAYEevT9fx/X0Ncx8P8ASGvdS8yRM7TjnnFfQGl6OIbdPlx0xt/OplFzdkclatybkdrDPHbGO0CrcAAgyKSvB5z3z1/HGa6KEZXkj2qssQRMDI9PT/D/AD6VNbzR78F1J9BzXRD3XZnmzfNqh5iGcdB70VIJCZljWNiu3d5nHUdB65oroRjex5XrF35KESY39GJwcYB7duv9a4zU7jc5IPA7Z/z/AJ/HOlqd6rjBYsTyxbqTn8+v4+nNctqFxgcEhcf5/wAj+WK86b5me7RjyowvFMxNlcHj7pGf6V5yMjHJA9xXXeKbkixwGJZ8DJ71xxbI55P6V0UFaJwY+X7xLyNjRp3MnlFgU6jB6fSvefBf9p3GmJd20f2iC7BUsT8wZf4ce4yefT3r50tp2gkVxwR+FeoeCPFyJYQWBcrIrkgA4x/tD14J/wD1E1bVnzFYapzR9nfU7jWL8uqx7FyGCtjt2PHr1/zzW79sHl20iZWMjluo6dP8/wCOcjxLc2t3aQPChSWNACxOSxx/L9MY7YFGnSq+nc8qpyue3r/n8+cUm2m1c7ErxWh0dpeu7Q4YfKflb8gAeent/wDWNb6mJpQzxokrDOBjj8On+e3bgrUHzUELF2CDk9QfqPp/nmt+C8y++Uu20Y65PT/PX1/GrjIzqU+xrXN/HNasUKtG4O0gAfj/AJ+vTiuY1aXA7nI4HT6/j1rTMi+Yeu4nvn/P9f8AgWTWXqjpIB8qk+x6HH+f85rOoyqMbMwLlYLiaGO4IVOmTkc8jJ+np7eoNTafeC3ae2Dna/DcDkjgH2/z+Mc8TPejax4znrz09Pw/TH8JNK9SSJ0dT8+c4J9/8/5zWKdjssmdbp0y2YkRI/NkmXaJeSQD2XuD75/pirNaz2l0sLFcyLuBU5HPX/P/ANesqznkJVVLBl5HPP8Ah/8AW9s1YubyeS7V7lyeDgsePp/n8arn0sQoNMsSo8sMQCgkKeQRnGf59/8A63W1p8jQYG3JC7WH+f8APB+tZRnuJEcxRuecZHGfr/n+oqxYLeqfMIUNyCAQCO30/wA/SoU0gltZnSlvskUcyMjrMpGeuDVC0d4nIf5ozJhmznPfg/j+vuKqpPOIhG4KGMthiOfx/wA/rjOxYxR3MhLHCZzhT1/z/j/tY2jNMxa5VqbehiOQyh9+4DIzzg45H+f59NXRGlm1CNVdkjOQxU/p6f5+ucLSrMxPIv3UO5kx9e5/lz+nJ1NPZoLlEeQrCTuXHUev+ev04zvGVziqq97HZyzobtI+Cx+UAdRUd/cyQwx+WV3vII8sDtBORk1hWl05vYn6rHuZy3U8Y/z/AIVviMXERhZVeORNrjjgjnPvVrVHnSp+zauV/wCz90xN3OZPlJyFCgj2FTaSEVphCGZFxkk5y3f+lVnsnmSOOaeXCcB/4sY/X/PuK1bWKOCILGDt/U0PRCnL3bN3GSRiKKUJ/GxPryaLeAQAgc+p7ipcg7lzx9eaRT90DG3HHPalrYwbdrGPq0cCw3AlZyWIcAHkDv8A5NcxPEyBkYZRzhdxwVHr/Suo1hv3gOwOmO3r/n/PeuWvwg2ny2IB5IwDj07Z/wA9smtL6Hfh9jorC3haxiEiqSkfzLyOh/x/l+et50ZgwDwSV5PQCsbTSW0sXDBnfYPLK8Oq+lO1EiF94LbME+Uo+99Ow/P/AOuWuYTjzSsY2u66IlWDDCSMklSuBjOB+vH6DnFcDc3DNcTSlcKe4HY+3+elbPiC+dryRHEfzpgoMMqjHTn269ucfdrk7iUQ5V3GSdw4yAfXn8ev488Vz1Znr4akox0Rl6rKbqfYisTnfkt29fzx/nirtvK3mIQHBdcMpPUdh/P/APWCTTcLMRIZFLFSOPx7en+fWnxsBvD4ALZyOO2O/wBB/wDqArlbszrkSLHC6rnK4OcYJyPT/wDV/wDXrN1S7Vp4xbrsReTu79v8/wD16W8llaUxxjcxB6/kf8/n2zCukXNxlzGzgfe5Ixn/AD/nnEuWpPNbVmW0pZy28kcEdDn/ACP89wsQ3sWdmw3GQM4/z/npXT2ejWTx7JVAk+7gg9fx/H+tFx4ejiLNFITjIJA49/6f17ZEx+1RzlqjSsCzMY2IBZucD1rfs9PH2Z2RNiRjGW4/T/P4cESQ2UtgcTR7o3/i5I6/r/nvWhctBDHlXZlcYYf0Hb+n4Zq4JNEynfYw7uD5wpYsN3I6j2/z/KqOriO20K6kd8upwEx1z/n/APV32pjD5vmHLcYOST3/AM//AK8GuY8SI10I4Y+DI+3/AD+VJod7o3PhXc5vhjaQwycjJ47j9a+jbAI8CY/ujpXzn4e0K4094JV3KON6k44J7fp/Tsa908N32+3RScMPlIPrVYeVpNHnY2PMlJGteQEqWXkDnr/n/P5VkW9lFBd+fEPKY/exwGreE4kjKDG8+1VpYAzEoMEYz/iK65QT1OKE2lZkigsmVUb+uPf/AD/n1KbENuec85IH+f8AP8ikI+Z766HljdgEry3oPaudv7hWzhioHTn/AD/n8Kt3krNnc5ckAfN1P1/z/SsG+kwTjr6en+f8964Ern0F+VHPeJLkyPHGxyAM8GsYn3x6ZqXUJjLcuc5GcYquc56ZrsgrKx4WIqc9RyJEJyOlWInZXVhkYPBqopBOcEdqsQkA/ezmmTB6nf8AhvWBcmOG5Lrt4+9jP513mlSrGuyMEQRnbtbqDnj9OPx+hrxewkkhljki/wBYjAr9Qa9D0rXFu5yZP3chUhhjgnuf8/8A68nGz0PXo1XNWkd/ZFXkkKjBxnAxg/5/zxgC9HISoA+b0JHbmud0qfKDYGYL95vTn3/z+tbO4EIZAVPOc9/8/h/ShM3lEvSOdyncORx9P8/56k1J3QqFZ8sOSP8AP5/h7Gl+0KqvjquTyOvt0/z78A4mo3yoWy6rnPUcHn/P5DqcVnOQ4RuJJeiDU1ZBu9jxnH+f1qpqN7vui3mDccfd7c1Vmtbq5w0MUhz0Yrj8f1/zzVnw74O1fX9TEat5FqGBklI+6pPQe5rJS5tDWU4Q95svaTbXF5OiWy73LDcw7Z559+//ANY4rvNM8JiJhJLEzyAYy/AGfb9O/wDWuz8OeG7DRrJILVMFRyx5Zj6k9T/n610CQJtAIA9Pat40W9zya+Pu7R2OLj0lYl2C2j2k9NuP5fSobvS4QCfK2H3PQ/5P+e3cC1QD5RgjnnnNQTWSuDkDkEZpuic6xOp5pc6R85aEqnHHJ/lVIWxiA8lzuPAKjhv84P8AkGvQNQ0tsb4xyM5OOvH/AOv/APVxWO6P+9in3Juzljz6df0/TvisnBxdzrhX5kUNIvw0qxXY2ydfY8Z6n/P4ZrotEiguZJGuQWWPAC49Qea5S7sjaKhhZyoOV5zg546f5/GrmlanI8mEIRgpzwMH8P8AP5VrTqa2kKrDmi3EfdypbahPblnkRH++TyR1Ga1p/EEMiRQNHIFH8a8kH/P+eQKx9StTk3RBfnd06/5/zzzUFqIxcLKd3lkgockEN2H8+Pr/ALWN4tp2B04ySb6HeaRdTXECLLtCqMZAIbGeOtaoBDHLYY8CsTTJ3ATcCUIGASeM84+n6fhW3DtCAgkj1NaPY8qsrMUN2brkj61GcI3IOc4BPOfenSncxCthugxjIOOtVL6R1h8uEbpAM9f60RVzOKuxmqoiwBvlBBycn1/z/kVzWo7vLJVSQQTlOCvPv/n+uteljaMzqS5+YqM89+n+fz4rGN6NjE5wR93HA/IH+vTv206WZ2UU0jWsrKL7OVdfmCKZQzcZxkMOf1H86qam/wBnQ4lQcFFwh4+vrS2lzbytAxjCjmPKRHn8c8f59jVbVLy1knKArGnJJYHKnt/Xj/6+BDipc2pxGrzggs5dJiRj5cEDPb15IOffPcCuY1MHaT2Izg+3p9K6LxBdrNd/u4gjDOSG+9znP1Jz+Z75I5a5ZHlVmPAO0DPT6+3H+RzXHVsexR2uQR27NBuC4AbAP4f4/wCeoKO6s+1VJwM4B6n/AA/z6YtTbTHFsXagXGDgD/P+fSjQbfz5tzn5M8jGeB/n/POeWXYuUtLsj0+y8yRnnIXByM9efb/P54x2GnWkjjdatuQcgFevA6H3/wA9609F0aOYmR48hvuLgcj/AAI7entnHbaXoscYVigUAAAKMf5/z+NQpuRwVsSonJ2WiC5KmS3APG7pjOPTtWzDoEcUYGBtznYB/n3rpmtY0U4GM9xwajnlWPPH+f8AP+cV0KklrI4nXlPY5i60KB87ox/j/n/PrXLa54TjnhPkZSQZIbrg/wCf5fUV381wZARuwR7dP8/59DjXUhXcCS2TkD+lTKKN6U5o8huLC4spmjvFwAeo/irIldTqVmNpA83OM5OMf/r/AMg16nqltDdDZMqsG6fX2/z/AIHzfxJoNzZX8N1G/nWyvkNgDafRu3pz/wDWzk9mjvjU5tz0yL7NcWYAC5A4PGf/AK/f/wDV0ksWubWfNs4kDclD3ri9D1tldkn7Y4ORz9cf5+vFd3pzLcIrLnPJwf8AP+fzASSltuYyjyLXY27DXYZQFl3W8oPRuB+B6Hv+X1rdS5EyZDKOeeP1/wA//r58aYJl2yfOp655wM9P5fl9KlTSZoubWV0jB4AbI6eh6d/X+g6ITnFe9qcU403tob4VSoBx60VlxpdsmGnzjkhl5P40VXtL7Iy5PM+TLqcg4IyPfsK57WLvZAwX7zfjV+5mIydxGf5VyupXPm3JAJwox+NY043Z6OJrcsSq4yTxxTeMd80oPvnPSkbrjIrdHlMcrcjJA9quW6g57+2KpxjJ5FaFuhJBwf8ACkzWkrsv2g+ZCCQRXQaKwhu4pXTcg5YDuO+PzrHtAQ+Aev61uaVG23nJ9MHof8is2z06cbI9K8P7VtDJGfldfmHPA7Ef5/XJqxeT7k/d9B6H2/lWF4duHYNCCdiHAA547j/P8sE9NaaJda/emG3PlWyECWXOfwHv/n0zMpaI6eZR96RjWIv9Zuja6ZHlv4nb7qD3P07D/wDV6J4b+H9tbus1/Ibm44ySMqPwrpNE0Wy0axigtYkBUde5Pr9ff+lPvbxoEdImIcj+EdT71moq/vHFVxUqj5aeiKeo21pARb20YeVsfNgHA/l/n04M9optY0RPlUcHAxmorOGTcXfmTOck/T/P/wBfArREZZAWY7UBPPb1/wA//WxvGPUwbsrMntZWzhmOT7/5/wA/rpw3JI5Ix+v+f8+lZMaYCjAx61bVS3VjnqP8/wCf51av0MJxTNQT5x2+tTgE/jwfasaKT5wvOD6/j/n/ACTV2O6AA2lRgDOf8/5/naZjKnbYnnh3dMe+e4rG1PTlb7oOQCQMZrYWYOyrxnHrTpEUjIA571MoqQQk4M4d7aRTNGMtuxzt/PmsWWEabffaMPgfw5HK98/qfwrt9ThCKxXIz7f5/X/61cz4gQT2bMf9YgwdpIyP8/56Vyzhyano0qnN8yw0o+z/AD7fKYgnI7dqq3eYUREVd55yOScdM5/D/PJzNImd7GItywBj9+Mj+n+TxVm+kBg3A9MEKQOfc4+n/wCviumErpM05LSsblnrKQ2ccBQEE87mwR7/AOf/ANWjY6qZYnU/LIh5A5xj/wDX+vuK4c3Db0AQkuMYx1x0I79P855q0uqwJKA48t2AO8HO4c8YP48fXH8dbRkZzw6eyPQI7hpIEZFyAOSsgBJ9MVHc3BCbpJOgyQvAX6/l/nmuVtdSEpiNuRvUYIAPQ9+OPp+fTBJcalKymEu6BGy3JUMP8/5zjOitucv1dpj7/VA8TLtCpuPLg5bPb+mffHNZcsiniOZh8wBPqfz/AM9qp6nevsbzhnAyoByB6cdM9vz7ZFZd1NcEK0UnzA9CemRz1/D+vaolI7qdKy0Oksr1WgkVkJAbH3wCpzjqf8/hxVPVNQYJIYykwkyFBXLf4fj/APrPOC6nicpGxz1Pbdjr+P1/nkVDLczBGjEqjy+xYjd+P5f5xU89tDRUNblTULsqjuxUtjHQ8f5/p9ayopA7b+Dj/PT8v/1YFRzXYhmkEyo+SRtJwv1HOOg/zxVD7aN7bRxjHr1P+f198c0tTtULGjdzs8DMMblUAYHr/wDr/wA8Y6jwbpRu1EUnmqn3yVOMjHTNcHLOdny7iDyeT69/8/zJr1r4ZKpgU8liBgOe3sP8/kBXNZOdmc+JbhBtHoej6WkCK7Kc4HU54rYACjApsI+QHHUZpZcqp5r0YxUdEfNTm5y1IbhhtbaRkDFYlxL8xYkjHU5q1czHkEj8v8/59qybltzlSpyOnPQ54/z/AFwSTOyjCxHJ8+cEg9xnFMIMicqCfTPT/P8AnmlhRiVO0A4HIH+H+fwq5DAXBX7rdOP8/wCfpycrG7fKc9f2Tvkrz+n+f8/hjT2jDcuzcOpU/wCf8/pXePabgRjmoJNMXYHIUH60nTuVHEW3PH7zShFOzIo8tjzk9D/hn/Pc73h67vdNGGiMkIGflOSB9O/Tt6fWt3UNMB3HaAuACCv+f8+1ULdhp8wSZS0J4DEcr9enb6fyNczhyyvsdTqc8bHa6LqUF1EjrJG4IwQOPzrbgkBHA+XrxXEwwgAzWreW/TpjcPcf579ORWhZas0EgiulCN9c59/8/wAq6IVLLU8+pTv8J1rwo+GXg9iKKq213kgBhjPX19aK2snqcr5lofCuqTlYjjPp+dc5gk9c0UVnDY2xMm56jgpI5xijv2x6UUVZhcnjUcHJHetKzjLdTyOKKKhnRQ3NOBdhTPr2rf0/gkg8E5I9siiisZHrU9jrdEhNxqMcELFBJnluoH+P+enA9t0CzFjYxRREAKOSBjPFFFYptyMsU7RSLF7eSQRbgSWOR9P8/wCe5MFjH5j72JJ7A9v880UVS+MwStG5uWtoM8Ebvf8Az7/561adQuRgEAdx6/5/z3KK60cjbb1I0hA/eeoAxn/Pr/kcU9uPmFFFND6lNwTIQDx9ae8jRhs4J6f5/P8AzxgoqLmqRLaSZlzk8Dn/AOtWqr7lUgYGM0UVpE56m5i65K23YmAv8Xrntj/P/wBfhNQckzS7nIK4IJPTjj9f5/UlFcOKbWx3YXYxPBupPcw3H8ISVtvGeCf8/wCemnqF2pi2hCHJZs57DHH6j/PFFFb0naKO6UV7RmVdXLRxtkHCsNuD+Y+n+feoRKzSIc4BbZ0/H+n6Ciiqjq9TWysW7e8ktpI5FLCVWO5t2c469frUJ1Ka6nnkmdvkHr7/AOf84wUVq29iVFXuMmuy5U8liRyeeTxn/P8AiDUvLtomkcZUKN3ynuOn+f8A6+Sipk9BxSuJZ3nl2MsyKPNDbFLDOMjnn05/p7jLNxKsroSpIXoRwf8AP+fcoqZPYtLVmJfIJF84k4bkY4OAP8//AKuKoFPkReOp/LpRRXO27myZLcwmHT3lDsSwHQ9M/wCf89/Q/h3dy26W+92PyjkenH5/59gCiueo3zHNX1i7nuemT+daxtjnHNTynIAxRRXrU9Umz5eStMxb9Op/EiqEUW99hOCQCpHb2oopySO2m/dLVvCCozg56DFXYYcDA/8A1f5/z6UUUrETY7YB0+vSq0sanIIwo9DRRUslGPeRrnAzz0rA1OIKCRz169z/AJNFFYzOyl0MbT9SmjUxn7incpzz1xg/n/nvsyzLdx7JF+9x7g+x/wA/4lFc8He6N6iSd0Jp2pTw3LW7MXC8qx/rRRRWkJO25lOEb7H/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Trichilemmomas (multiple skin-colored warty papules) on the face, as well as the mucosa of the lower lip.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Color Atlas and Synopsis of Clinical Dermatology, 3rd edition, Fitzpatrick, et al (Eds), McGraw-Hill, New York 1997. Copyright &copy; 1997 The McGraw-Hill Companies, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_31_41459=[""].join("\n");
var outline_f40_31_41459=null;
var title_f40_31_41460="Dizziness and vertigo";
var content_f40_31_41460=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"topicTitle\">",
"   Patient information: Dizziness and vertigo (Beyond the Basics)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/31/41460/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/31/41460/contributors\">",
"     Joseph M Furman, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/31/41460/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/31/41460/contributors\">",
"     Michael J Aminoff, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/31/41460/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/31/41460/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/31/41460/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dizziness is a feeling that may be hard to describe, but often includes a feeling that you are spinning or tilting, or that you are about to fall or pass out. Dizziness can also cause you to feel lightheaded or giddy, or have difficulty walking straight.",
"   </p>",
"   <p>",
"    Many people who feel dizzy have vertigo, a specific type of dizziness. Vertigo causes a sense of spinning dizziness, swaying, or tilting. You may feel that you are moving or that the room is moving around you. Vertigo can be caused by a number of different problems involving the inner ear or brain. Some of these problems are not serious while others can be life threatening.",
"   </p>",
"   <p>",
"    This article will describe the symptoms of vertigo and help you to know when to seek help. More detailed information about vertigo is available by subscription. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/19/32057?source=see_link\">",
"     \"Approach to the patient with vertigo\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/15/13559?source=see_link\">",
"     \"Treatment of vertigo\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     VERTIGO SYMPTOMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common symptoms of vertigo include a feeling of:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Spinning (you or the room around you)",
"     </li>",
"     <li>",
"      Tilting or swaying",
"     </li>",
"     <li>",
"      Feeling off balance",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These feelings come and go, and may last seconds, hours, or days. You may feel worse when you move your head, change positions (stand up, roll over), cough, or sneeze. Along with vertigo, you may:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Vomit or feel nauseous",
"     </li>",
"     <li>",
"      Have a headache or be sensitive to light and noise",
"     </li>",
"     <li>",
"      See double, have trouble speaking or swallowing, or feel weak",
"     </li>",
"     <li>",
"      Feel short of breath or sweaty, have a racing heart beat",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If you seek treatment for vertigo, you should mention how long these symptoms last, what triggers the symptoms, and any other associated problems. These clues can help point to the cause of vertigo.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     COMMON CAUSES OF VERTIGO",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common causes of vertigo include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inner ear problems &mdash; Collections of calcium, inflammation, and certain infections can cause problems in the vestibular system. The vestibular system includes parts of the inner ear and nervous system, which controls balance (",
"      <a class=\"graphic graphic_figure graphicRef52509 \" href=\"mobipreview.htm?34/48/35589\">",
"       figure 1",
"      </a>",
"      ). Benign paroxysmal positional vertigo, Meniere disease, and vestibular neuritis are three of the most common types of vertigo caused by inner ear problems.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Benign paroxysmal positional vertigo (BPPV)",
"      </strong>",
"      &mdash; BPPV, sometimes called benign positional vertigo, positional vertigo, postural vertigo, or simply vertigo, is a type of vertigo that develops due to collections of calcium in the inner ear. These collections are called canaliths. Moving the canaliths (called canalith repositioning) is a common treatment for BPPV. Vertigo is typically brief in people with BPPV, lasting seconds to minutes. Vertigo can be triggered by moving the head in certain ways. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/13/19673?source=see_link\">",
"       \"Benign paroxysmal positional vertigo\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Meniere disease",
"      </strong>",
"      &mdash; Meniere disease is condition that causes repeated spells of vertigo, hearing loss, and ringing in the ears. Spells can last several minutes or hours. It is probably caused by a buildup of fluid in the inner ear. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/61/32729?source=see_link\">",
"       \"Meniere disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Vestibular neuritis",
"      </strong>",
"      &mdash; Vestibular neuritis, also known as labyrinthitis, is probably caused by a virus that causes swelling around the balance nerve. People with vestibular neuritis develop sudden, severe vertigo, nausea, vomiting, and difficulty walking or standing up; these problems can last several days. Some people also develop difficulty hearing in one ear. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/15/35062?source=see_link\">",
"       \"Vestibular neuritis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Head injury &mdash; Head injuries can affect the vestibular system in a variety of ways, and lead to vertigo. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/59/29626?source=see_link&amp;anchor=H20#H20\">",
"       \"Concussion and mild traumatic brain injury\", section on 'Post-traumatic vertigo'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Medications &mdash; Rarely, medications can actually damage the inner ear. Other medications can affect the function of the inner ear or brain and lead to vertigo.",
"     </li>",
"     <li>",
"      Migraines &mdash; In a condition called vestibular migraine or migrainous vertigo, vertigo can be caused by a migraine. This type of vertigo usually happens along with a headache, although sometimes there is no headache. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/8/15496?source=see_link\">",
"       \"Migrainous vertigo\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Brain problems, such as a stroke or TIA (transient ischemic attack), bleeding in the brain, or multiple sclerosis can also cause vertigo. There are usually other symptoms, besides vertigo, that happen with these brain problems. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/38/17001?source=see_link\">",
"       \"Pathophysiology, etiology, and differential diagnosis of vertigo\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     WHEN TO SEEK HELP",
"    </span>",
"    &nbsp;&mdash;&nbsp;You should seek help immediately if you have dizziness or vertigo along with any of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      New or severe headache",
"     </li>",
"     <li>",
"      Temperature greater than 100.4&ordm;F (38&ordm;C)",
"     </li>",
"     <li>",
"      Seeing double or having trouble seeing clearly",
"     </li>",
"     <li>",
"      Trouble speaking or hearing",
"     </li>",
"     <li>",
"      Weakness in an arm or leg",
"     </li>",
"     <li>",
"      An inability to walk without assistance",
"     </li>",
"     <li>",
"      Passing out",
"     </li>",
"     <li>",
"      Numbness or tingling",
"     </li>",
"     <li>",
"      Chest pain",
"     </li>",
"     <li>",
"      Vomiting that will not stop",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, you should seek help immediately if you have vertigo that lasts for several minutes or more if you:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Are an older adult",
"     </li>",
"     <li>",
"      Have had a stroke in the past",
"     </li>",
"     <li>",
"      Have risk factors for stroke (high blood pressure, diabetes, smoking)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If you have dizziness or vertigo that comes and goes but you do not have any of the above problems, make an appointment with your doctor or nurse. He or she will perform a physical exam, and may order further testing, depending on your exam and medical history.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     VERTIGO TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most people, vertigo is bothersome but it is not caused by a serious problem. Treatment for vertigo aims to treat the underlying cause (if the cause is known), relieve the bothersome symptoms, and help with recovery. This section will discuss treatment for symptoms and treatments to help with recovery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Treatment for symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;If you have spells of vertigo that are severe or last for hours or days, your doctor or nurse may recommend a medication to relieve severe vertigo symptoms, like vomiting. Treatment with medication is not usually recommended if your vertigo lasts only second or minutes.",
"   </p>",
"   <p>",
"    Possible medication treatments include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An antihistamine, such as the prescription medicine",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?13/33/13844?source=see_link\">",
"       meclizine",
"      </a>",
"      (Antivert&reg;), or non-prescription medicines like",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?33/50/34596?source=see_link\">",
"       dimenhydrinate",
"      </a>",
"      (Dramamine&reg;), or",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?24/60/25537?source=see_link\">",
"       diphenhydramine",
"      </a>",
"      (Benadryl&reg;).",
"     </li>",
"     <li>",
"      Prescription anti-nausea medicines, such as",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?2/47/2806?source=see_link\">",
"       promethazine",
"      </a>",
"      (Phenergan&reg;),",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?33/45/34517?source=see_link\">",
"       metoclopramide",
"      </a>",
"      (Reglan&reg;), or",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?24/24/24965?source=see_link\">",
"       ondansetron",
"      </a>",
"      (Zofran&reg;).",
"     </li>",
"     <li>",
"      Prescription sedative medicines, such as",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?24/58/25509?source=see_link\">",
"       diazepam",
"      </a>",
"      (Valium&reg;),",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?19/13/19669?source=see_link\">",
"       lorazepam",
"      </a>",
"      (Ativan&reg;), or",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?21/43/22197?source=see_link\">",
"       clonazepam",
"      </a>",
"      (Klonopin&reg;)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most of these medicines make you sleepy, and you should not take them before you work or drive. You should only take prescription medicines to treat severe vertigo symptoms, and you should stop the medicine when your symptoms improve.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Canalith repositioning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Canalith repositioning is a treatment that may be recommended for people with benign paroxysmal positional vertigo (BPPV). The treatment will be done by a doctor, nurse, or therapist in the office by moving your head into certain positions, sometimes called the Epley maneuver. You may be given instructions on how to perform similar movements at home, if needed.",
"   </p>",
"   <p>",
"    These movements encourage the calcium collection to move into a part of the ear where it will be reabsorbed. You may begin to feel better immediately after this treatment or within a day or two.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Balance rehabilitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with vertigo prefer to keep their head still. However, staying still and not moving your head can make it harder to cope with vertigo. Rehabilitation can help people with vertigo that is caused by injury to the vestibular system. The vestibular system includes parts of the inner ear and nervous system, which controls balance.",
"   </p>",
"   <p>",
"    The rehabilitation works by helping your brain adjust its response to changes in the vestibular system. The therapy can also help train your eyes and other senses to \"learn\" how to compensate. This therapy is most helpful when it is started as soon as possible after you develop vertigo.",
"   </p>",
"   <p>",
"    During rehabilitation, you will work with a therapist who will teach to you perform exercises at home. For example, you might start by focusing on an object with a blank background and move your head slowly to the right and left and up and down. You would perform this exercise for several minutes two to three times per day.",
"   </p>",
"   <p>",
"    If you have trouble standing or walking because of vertigo, you are at risk for falling. In older adults, falls can lead to serious complications, such as a broken hip. Talk to your doctor, nurse, or therapist about your concerns. To reduce the risk of falls, get rid of hazards in your home, such as loose electrical cords and slippery rugs, and avoid walking in unfamiliar areas that are not lighted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     WHERE TO GET MORE INFORMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"   </p>",
"   <p>",
"    This article will be updated as needed on our web site (",
"    <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"     www.uptodate.com/patients",
"    </a>",
"    ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H263301039\">",
"    <span class=\"h2\">",
"     Patient level information",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H263301048\">",
"    <span class=\"h3\">",
"     The Basics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"   </p>",
"   <p>",
"    <a class=\"medical medical_basics\" href=\"mobipreview.htm?40/59/41905?source=see_link\">",
"     Patient information: Vertigo (a type of dizziness) (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/12/22722?source=see_link\">",
"     Patient information: Concussion (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"mobipreview.htm?8/47/8947?source=see_link\">",
"     Patient information: Closed head injury (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/10/26785?source=see_link\">",
"     Patient information: Labyrinthitis (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/10/40097?source=see_link\">",
"     Patient information: Meniere disease (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"mobipreview.htm?43/20/44353?source=see_link\">",
"     Patient information: Vestibular schwannoma (acoustic neuroma) (The Basics)",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H263301074\">",
"    <span class=\"h3\">",
"     Beyond the Basics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    This topic currently has no corresponding Beyond the Basics content.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Professional level information",
"    </span>",
"    &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"   </p>",
"   <p>",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/43/23223?source=see_link\">",
"     Approach to the patient with dizziness",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/19/32057?source=see_link\">",
"     Approach to the patient with vertigo",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/13/19673?source=see_link\">",
"     Benign paroxysmal positional vertigo",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/59/29626?source=see_link\">",
"     Concussion and mild traumatic brain injury",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/44/32458?source=see_link\">",
"     Epidemiology and clinical features of multiple sclerosis in adults",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/61/32729?source=see_link\">",
"     Meniere disease",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/8/15496?source=see_link\">",
"     Migrainous vertigo",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/38/17001?source=see_link\">",
"     Pathophysiology, etiology, and differential diagnosis of vertigo",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/15/13559?source=see_link\">",
"     Treatment of vertigo",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/15/35062?source=see_link\">",
"     Vestibular neuritis",
"    </a>",
"    <br/>",
"    <br/>",
"    The following organizations also provide reliable health information.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      National Library of Medicine",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;(",
"    <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/dizzinessandvertigo.html\">",
"     www.nlm.nih.gov/medlineplus/dizzinessandvertigo.html",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      National Institute of Deafness and other Communication Disorders",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;(",
"    <a class=\"external\" href=\"file://www.nidcd.nih.gov/health/balance/pages/balance_disorders.aspx\">",
"     www.nidcd.nih.gov/health/balance/pages/balance_disorders.aspx",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41460/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41460/abstract/1\">",
"      Neuhauser HK, Radtke A, von Brevern M, et al. Burden of dizziness and vertigo in the community. Arch Intern Med 2008; 168:2118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41460/abstract/2\">",
"      Hillier SL, Hollohan V. Vestibular rehabilitation for unilateral peripheral vestibular dysfunction. Cochrane Database Syst Rev 2007; :CD005397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41460/abstract/3\">",
"      Sloane PD, Dallara J, Roach C, et al. Management of dizziness in primary care. J Am Board Fam Pract 1994; 7:1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 721 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-210.101.131.232-8FC26C7E2B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_31_41460=[""].join("\n");
var outline_f40_31_41460=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      VERTIGO SYMPTOMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      COMMON CAUSES OF VERTIGO",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      WHEN TO SEEK HELP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      VERTIGO TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Treatment for symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Canalith repositioning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Balance rehabilitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      WHERE TO GET MORE INFORMATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H263301039\">",
"      Patient level information",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H263301048\">",
"      - The Basics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H263301074\">",
"      - Beyond the Basics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Professional level information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/721\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PI/721|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?34/48/35589\" title=\"figure 1\">",
"      Vestibular system PI",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/43/23223?source=related_link\">",
"      Approach to the patient with dizziness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/19/32057?source=related_link\">",
"      Approach to the patient with vertigo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/13/19673?source=related_link\">",
"      Benign paroxysmal positional vertigo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/59/29626?source=related_link\">",
"      Concussion and mild traumatic brain injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/44/32458?source=related_link\">",
"      Epidemiology and clinical features of multiple sclerosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/61/32729?source=related_link\">",
"      Meniere disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/8/15496?source=related_link\">",
"      Migrainous vertigo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/38/17001?source=related_link\">",
"      Pathophysiology, etiology, and differential diagnosis of vertigo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?8/47/8947?source=related_link\">",
"      Patient information: Closed head injury (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/12/22722?source=related_link\">",
"      Patient information: Concussion (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/10/26785?source=related_link\">",
"      Patient information: Labyrinthitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/10/40097?source=related_link\">",
"      Patient information: Meniere disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?40/59/41905?source=related_link\">",
"      Patient information: Vertigo (a type of dizziness) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?43/20/44353?source=related_link\">",
"      Patient information: Vestibular schwannoma (acoustic neuroma) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/15/13559?source=related_link\">",
"      Treatment of vertigo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/15/35062?source=related_link\">",
"      Vestibular neuritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_31_41461="Iron sucrose: Drug information";
var content_f40_31_41461=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Iron sucrose: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?28/41/29331?source=see_link\">",
"    see \"Iron sucrose: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/39/21110?source=see_link\">",
"    see \"Iron sucrose: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F184604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Venofer&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F184605\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Venofer&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F184620\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Iron Salt",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F184607\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Doses expressed in mg of",
"     <b>",
"      elemental",
"     </b>",
"     iron.",
"     <b>",
"      Note:",
"     </b>",
"     Test dose: Product labeling does not indicate need for a test dose in product-naive patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Iron-deficiency anemia in chronic kidney disease (CKD):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Hemodialysis-dependent patient:",
"     </i>",
"     100 mg administered during consecutive dialysis sessions to a cumulative total dose of 1000 mg (10 doses); may repeat treatment if clinically indicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Peritoneal dialysis-dependent patient:",
"     </i>",
"     Two infusions of 300 mg administered 14 days apart, followed by a single 400 mg infusion 14 days later (total cumulative dose of 1000 mg in 3 divided doses); may repeat treatment if clinically indicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Nondialysis-dependent patient:",
"     </i>",
"     200 mg administered on 5 different occasions within a 14-day period (total cumulative dose: 1000 mg in 14-day period); may repeat treatment if clinically indicated.",
"     <b>",
"      Note:",
"     </b>",
"     Dosage has also been administered as 2 infusions of 500 mg on day 1 and day 14 (limited experience).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Cancer-/chemotherapy-associated anemia (unlabeled use):",
"     </b>",
"     I.V.: 200 mg I.V. infusion (maximum: 300 mg/infusion) over 1 hour every 2-3 weeks",
"     <b>",
"      or",
"     </b>",
"     200 mg slow I.V. injection over 2-5 minutes every 1-4 weeks. Total cumulative dose: 1000 mg. Test doses (25 mg slow I.V. push) are recommended in patients with a history of hypersensitivity to any I.V. iron preparation (eg, dextran) or those with other drug allergies (NCCN guidelines, v.1.2013).",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F6010345\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/39/21110?source=see_link\">",
"      see \"Iron sucrose: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Doses expressed in mg of",
"     <b>",
"      elemental",
"     </b>",
"     iron.",
"     <b>",
"      Note:",
"     </b>",
"     Test dose: Product labeling does not indicate need for a test dose in product-naive patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Iron-deficiency anemia in chronic kidney disease (CKD):",
"     </b>",
"     Children &ge;2 years and Adolescents: I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     Not indicated for iron replacement treatment in children and adolescents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Hemodialysis-dependent patient:",
"     </i>",
"     Maintenance therapy: 0.5 mg/kg/dose (maximum: 100 mg) every 2 weeks for 6 doses; may repeat if clinically indicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Nondialysis-dependent patient:",
"     </i>",
"     Maintenance therapy: 0.5 mg/kg/dose (maximum: 100 mg) every 4 weeks for 3 doses; may repeat if clinically indicated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Peritoneal dialysis-dependent patient:",
"     </i>",
"     Maintenance therapy: 0.5 mg/kg/dose (maximum: 100 mg) every 4 weeks for 3 doses; may repeat if clinically indicated",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F184608\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F16160034\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F16160035\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F184587\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Venofer&reg;: Elemental iron 20 mg/mL (2.5 mL, 5 mL, 10 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F184573\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F184590\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer intravenously as a slow I.V. injection (",
"     <b>",
"      not",
"     </b>",
"     for rapid I.V. injection) or as an I.V. infusion. Can be administered through dialysis line.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Slow I.V. injection: Administer undiluted over 5 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infusion: Infuse diluted solution over 5-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Slow I.V. injection: May administer doses &le;200 mg undiluted by slow I.V. injection over 2-5 minutes. When administering to hemodialysis-dependent patients, give iron sucrose early during the dialysis session.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infusion: Infuse diluted doses &le;200 mg over at least 15 minutes; infuse diluted 300 mg dose over 1.5 hours; infuse diluted 400 mg dose over 2.5 hours; infuse diluted 500 mg dose over 3.5-4 hours (limited experience). When administering to hemodialysis-dependent patients, give iron sucrose early during the dialysis session.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F3071704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in NS;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in TPN.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F184589\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of iron-deficiency anemia in chronic kidney disease (CKD), including nondialysis-dependent and dialysis-dependent patients",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F9349644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cancer-/chemotherapy-associated anemia",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7897706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Iron sucrose may be confused with ferumoxytol",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F184618\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Events and incidences are associated with use in adults unless otherwise specified.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypotension (2% to 3%; children 2%; 39% in hemodialysis patients; may be related to total dose or rate of administration)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (3% to 13%; children 6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (5% to 15%; children 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle cramps (1% to 3%; 29% in hemodialysis patients)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Nasopharyngitis (2% to 16%), pharyngitis (2% to 16%), sinusitis (2% to 16%), upper respiratory infection (2% to 16%; children 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypertension (7% to 8%; children 2%), peripheral edema (3% to 7%), chest pain (1% to 6%), arteriovenous fistula thrombosis (children 2%), heart failure (&gt;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (1% to 7%; children 4%), fever (1% to 3%; children 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus (2% to 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypoglycemia (&le;4%), fluid overload (1% to 3%), gout (&le;3%), hyperglycemia (&le;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Vomiting (5% to 9%; children 4%), diarrhea (5% to 8%), taste perversion (&le;8%), peritonitis (children 4%), abdominal pain (1% to 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site reaction (&le;6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Extremity pain (3% to 6%), arthralgia (1% to 4%), myalgia (&le;4%), weakness (1% to 3%), back pain (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Conjunctivitis (&le;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Ear pain (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea (1% to 6%), cough (1% to 3%; children 4%), nasal congestion (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Graft complication (&le;10%), sepsis (&gt;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Anaphylactic shock, anaphylactoid reactions, angioedema, bradycardia, cardiovascular collapse, hypersensitivity (including wheezing), loss of consciousness, necrotizing enterocolitis (reported in premature infants, no causal relationship established), seizure, shock, urine discoloration",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F184593\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to iron sucrose or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F184577\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Cases of hypersensitivity reactions, including rare postmarketing anaphylactic and anaphylactoid reactions (some fatal), have been reported. Monitor patients during and for &ge;30 minutes postadministration; discontinue immediately for signs/symptoms of a hypersensitivity reaction (shock, hypotension, loss of consciousness). Equipment for resuscitation and trained personnel experienced in handling medical emergencies should always be immediately available.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension: Significant hypotension has been reported frequently in hemodialysis-dependent patients. Has also been reported in peritoneal dialysis and nondialysis patients. Hypotension may be related to total dose or rate of administration (avoid rapid I.V. injection), follow recommended guidelines.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Withhold iron in the presence of tissue iron overload; periodic monitoring of hemoglobin, hematocrit, serum ferritin, and transferrin saturation is recommended.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F184581\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dimercaprol: May enhance the nephrotoxic effect of Iron Salts.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F184583\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F184594\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies. There are no adequate and well-controlled studies in pregnant women. Based on limited data, iron sucrose may be effective for the treatment of iron-deficiency anemia in pregnancy. It is recommended that pregnant women meet the dietary requirements of iron with diet and/or supplements in order to prevent adverse events associated with iron deficiency anemia in pregnancy. Treatment of iron deficiency anemia in pregnant women is the same as in nonpregnant women and in most cases, oral iron preparations may be used. Except in severe cases of maternal anemia, the fetus achieves normal iron stores regardless of maternal concentrations.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F184612\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F6789329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Iron is normally found in breast milk. Breast milk or iron fortified formulas generally provide enough iron to meet the recommended dietary requirements of infants. The amount of iron in breast milk is generally not influenced by maternal iron status.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Venofer Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg/mL (5 mL): $60.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F184585\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hematocrit, hemoglobin, serum ferritin, serum iron, transferrin, percent transferrin saturation, TIBC (takes ~4 weeks of treatment to see increased serum iron and ferritin, and decreased TIBC); iron status should be assessed &ge;48 hours after last dose (due to rapid increase in values following administration); signs/symptoms of hypersensitivity reactions (during and &ge;30 minutes following infusion); hypotension (following infusion)",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F184588\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hemoglobin: Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Males: 13.5-16.5 g/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Females: 12.0-15.0 g/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Serum iron: 40-160 mcg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Total iron binding capacity: 230-430 mcg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Transferrin: 204-360 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Percent transferrin saturation: 20% to 50%",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F184595\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Ferrofer (TH);",
"     </li>",
"     <li>",
"      Ferrovin (KP);",
"     </li>",
"     <li>",
"      Maxifer (PH);",
"     </li>",
"     <li>",
"      Rafofer (CN);",
"     </li>",
"     <li>",
"      Rinofer (ID);",
"     </li>",
"     <li>",
"      Sucrox (AR);",
"     </li>",
"     <li>",
"      Venofer (AR, AU, BE, BG, CH, CL, CN, CO, CR, CZ, DE, DK, DO, FI, FR, GB, GR, GT, HK, HN, ID, IL, MY, NI, NL, NO, NZ, PA, PE, PH, PK, PL, PT, PY, SE, SG, SV, TR, UY, VE, ZA);",
"     </li>",
"     <li>",
"      Venoferrum (KP)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F184576\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Iron sucrose is dissociated by the reticuloendothelial system into iron and sucrose. The released iron increases serum iron concentrations and is incorporated into hemoglobin.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F184592\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      dss",
"     </sub>",
"     : Healthy adults: 7.9 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Dissociated into iron and sucrose by the reticuloendothelial system",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Healthy adults: 6 hours; Nondialysis-dependent adolescents: 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Healthy adults: Urine (5%) within 24 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      al-Momen AK, al-Meshari A, al-Nuaim L, et al \"Intravenous Iron Sucrose Complex in the Treatment of Iron Deficiency Anemia During Pregnancy,\"",
"      <i>",
"       Eur J Obstet Gynecol Reprod Biol",
"      </i>",
"      , 1996, 69(2):121-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/31/41461/abstract-text/8902444/pubmed\" id=\"8902444\" target=\"_blank\">",
"        8902444",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American College of Obstetricians and Gynecologists, &ldquo;ACOG Practice Bulletin No. 95: Anemia in Pregnancy,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2008, 112(1):201-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/31/41461/abstract-text/18591330/pubmed\" id=\"18591330\" target=\"_blank\">",
"        18591330",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Blumenthal S, et al, \"Iron Sucrose in Hemodialysis Patients: Safety of Replacement and Maintenance Regimens,\"",
"      <i>",
"       Kidney Int",
"      </i>",
"      , 2004, 66(3):1193-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/31/41461/abstract-text/15327417/pubmed\" id=\"15327417\" target=\"_blank\">",
"        15327417",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Baker WF Jr, &ldquo;Iron Deficiency in Pregnancy, Obstetrics, and Gynecology,&rdquo;",
"      <i>",
"       Hematol Oncol Clin North Am",
"      </i>",
"      , 2000, 14(5):1061-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/31/41461/abstract-text/11005034/pubmed\" id=\"11005034\" target=\"_blank\">",
"        11005034",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      IOM (Institute of Medicine),",
"      <i>",
"       Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc",
"      </i>",
"      , Washington, DC: National Academy Press, 2001.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Leijn E, Monnens LA, and Cornelissen EA, &ldquo;Intravenous Iron Supplementation in Children on Hemodialysis,&rdquo;",
"      <i>",
"       J Nephrol",
"      </i>",
"      , 2004, 17(3):423-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/31/41461/abstract-text/15365964/pubmed\" id=\"15365964\" target=\"_blank\">",
"        15365964",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Practice Guidelines in Oncology&trade;: Cancer- and Chemotherapy-Induced Anemia Version 1.2013.&rdquo; Available at file://www.nccn.org/professionals/physician_gls/f_guidelines.asp",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Kidney Foundation, &ldquo;KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease,&rdquo;",
"      <i>",
"       Am J Kidney Dis",
"      </i>",
"      , 2007, 50(3):529-30. Available at file://www.kidney.org/professionals/KDOQI/guidelines_anemia/index.htm",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Van Damme-Lombaerts R and Herman J, &ldquo;Erythropoietin Treatment In Children With Renal Failure,&rdquo;",
"      <i>",
"       Prediatr Nephrol",
"      </i>",
"      , 1999, 13(2):148-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/31/41461/abstract-text/10229005/pubmed\" id=\"10229005\" target=\"_blank\">",
"        10229005",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9004 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-85249D4AE1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_31_41461=[""].join("\n");
var outline_f40_31_41461=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184604\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184605\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184620\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184607\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6010345\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184608\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16160034\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16160035\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184587\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184573\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184590\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3071704\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184589\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349644\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7897706\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184618\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184593\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184577\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299545\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184581\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184583\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184594\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184612\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6789329\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323230\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184585\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184588\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184595\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184576\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184592\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9004\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9004|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?28/41/29331?source=related_link\">",
"      Iron sucrose: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/39/21110?source=related_link\">",
"      Iron sucrose: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_31_41462="Duodenal amyloid HandE";
var content_f40_31_41462=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F81395&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F81395&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Amyloidosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 363px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic biopsy of nodular duodenal epithelium stained with hematoxylin and eosin. Note the pink amorphous deposit in the lamina propria (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael Camilleri, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_31_41462=[""].join("\n");
var outline_f40_31_41462=null;
var title_f40_31_41463="Overview of glaucoma in infants and children";
var content_f40_31_41463=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of glaucoma in infants and children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/31/41463/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/31/41463/contributors\">",
"     Scott E Olitsky, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/31/41463/contributors\">",
"     James D Reynolds, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/31/41463/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/31/41463/contributors\">",
"     Evelyn A Paysse, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/31/41463/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/31/41463/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/31/41463/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glaucoma is a group of eye diseases that are traditionally characterized by elevated intraocular pressure (IOP). Increased IOP leads to optic nerve damage and consequent visual loss. Peripheral vision loss occurs first, but if glaucoma is untreated, central vision loss and complete blindness can occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41463/abstract/1\">",
"     1",
"    </a>",
"    ]. In infants and toddlers, additional damage to the visual system, including large refractive error, astigmatism, strabismus, and amblyopia, may occur. Early diagnosis and referral are crucial to ensuring optimal visual outcome.",
"   </p>",
"   <p>",
"    An overview of the causes, presentation, and treatment of pediatric glaucoma will be presented here. Primary infantile glaucoma and glaucoma in adults are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/57/5016?source=see_link\">",
"     \"Primary infantile glaucoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/59/15289?source=see_link\">",
"     \"Open-angle glaucoma: Epidemiology, clinical presentation, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The angle of the eye is the recess formed by the irido-corneal juncture. The scleral spur, trabecular meshwork, and Schwalbe's line lie within this angle. The trabecular meshwork is a fenestrated structure that transmits aqueous fluid to Schlemm's canal, from which it drains into the venous system (",
"    <a class=\"graphic graphic_figure graphicRef71234 \" href=\"mobipreview.htm?10/60/11201\">",
"     figure 1",
"    </a>",
"    ). When the drainage of aqueous fluid from the anterior chamber is compromised, a new steady state develops with abnormally high intraocular pressure (",
"    <a class=\"graphic graphic_figure graphicRef71433 \" href=\"mobipreview.htm?14/26/14753\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pediatric glaucoma is classified into primary and secondary types to provide a framework for the evaluation and management of individual patients (",
"    <a class=\"graphic graphic_table graphicRef56982 \" href=\"mobipreview.htm?23/16/23821\">",
"     table 1",
"    </a>",
"    ). Primary glaucomas are those with isolated angle malformations (trabeculodysgenesis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41463/abstract/2\">",
"     2",
"    </a>",
"    ]. Primary glaucoma may have onset at birth, in the first few years of life, or later in life (congenital, primary infantile, and juvenile glaucoma, respectively). The age at which symptoms first appear probably is related to the severity of angle dysgenesis. Although congenital, infantile, and juvenile glaucoma appear to represent three points on the spectrum of one disease, juvenile glaucoma traditionally is treated as a separate entity because it has a different clinical presentation. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Juvenile glaucoma'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Secondary glaucoma either is acquired or related to an underlying ocular abnormality; it can occur at any age and may be present at birth.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PRIMARY INFANTILE GLAUCOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary infantile glaucoma is a rare disease, with onset in the first years of life. A distinction sometimes is made between glaucoma that is present at birth (true congenital glaucoma) and glaucoma that has onset in the first two to three years of life (infantile glaucoma) because the prognosis differs. The later the onset, the less severe the structural anomaly, and the more likely the glaucoma will respond to treatment. Primary infantile glaucoma is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/57/5016?source=see_link\">",
"     \"Primary infantile glaucoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     JUVENILE GLAUCOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary glaucoma diagnosed after four to five years of age usually is referred to as juvenile glaucoma. The pathogenesis of juvenile glaucoma is similar to that of infantile glaucoma (angle dysgenesis) and the disorder sometimes is called late-onset primary infantile glaucoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41463/abstract/3\">",
"     3",
"    </a>",
"    ]. The age at which symptoms first appear probably is related to the severity of angle dysgenesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41463/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Juvenile glaucoma overlaps with juvenile-onset open-angle glaucoma (JOAG), a form of glaucoma that presents in childhood to early adulthood without ocular enlargement. JOAG is commonly inherited in an autosomal dominant fashion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41463/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Molecular defects causing primary open-angle glaucoma have been identified on the long arm of chromosome 1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41463/abstract/7-11\">",
"     7-11",
"    </a>",
"    ]. One such molecular defect has been mapped to the trabecular meshwork-induced glucocorticoid response gene (TIGR), also known as myocilin (MYOC) on chromosome 1q23-25 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41463/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the pathogenesis of infantile and juvenile glaucoma is similar, the presenting signs and symptoms differ. The presentation of juvenile glaucoma is insidious. Patients usually are asymptomatic and optic nerve damage is occult. In contrast to infantile glaucoma patients, who present in the first few years of life when the cornea and sclera are more elastic, patients with juvenile glaucoma do not develop enlarged cornea or buphthalmos; they are much less likely to develop corneal edema with tearing and photophobia. Elevations of intraocular pressure are usually unrecognized unless optic nerve cupping (",
"    <a class=\"graphic graphic_picture graphicRef71467 \" href=\"mobipreview.htm?20/19/20799\">",
"     picture 1",
"    </a>",
"    ) is noticed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41463/abstract/13\">",
"     13",
"    </a>",
"    ]. Peripheral vision is affected first, and if left untreated, central vision loss and blindness may occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis is usually made because of coexisting ocular or systemic disease or because of a positive family history of disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41463/abstract/1\">",
"     1",
"    </a>",
"    ]. Once the diagnosis is made, children and adolescents with juvenile glaucoma can be followed with intraocular pressure measurements in the office and serial automated visual field testing. The frequency of follow-up depends upon individual case severity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with infantile glaucoma, surgical intervention is the mainstay of therapy, and medications are used as an adjunct. First-line surgical options include goniotomy and trabeculotomy. Trabeculectomy, drainage devices, and cyclodestructive procedures are considered when first-line procedures fail. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/57/5016?source=see_link&amp;anchor=H17#H17\">",
"     \"Primary infantile glaucoma\", section on 'Surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SECONDARY GLAUCOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secondary glaucoma can occur in a variety of conditions (",
"    <a class=\"graphic graphic_table graphicRef56982 \" href=\"mobipreview.htm?23/16/23821\">",
"     table 1",
"    </a>",
"    ). Some of the causes of secondary glaucoma have associated angle anomalies. In others, glaucoma may become an important complication, although it is not usually considered a primary manifestation of the disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Angle anomalies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glaucoma occurs secondarily in several disorders that have associated angle anomalies (",
"    <a class=\"graphic graphic_table graphicRef56982 \" href=\"mobipreview.htm?23/16/23821\">",
"     table 1",
"    </a>",
"    ). Detailed descriptions of many of these disorders are provided separately. (See appropriate topic reviews). Sturge-Weber syndrome, aniridia, and neural crest disorders, three of the most common disorders with secondary glaucoma, are discussed briefly below.",
"   </p>",
"   <p>",
"    The pathogenesis of angle-anomaly glaucoma is similar to that of primary infantile and juvenile glaucoma. For this reason, the treatment strategies are similar. Surgical therapy is almost always necessary to control intraocular pressure (IOP) and preserve vision. Medical therapy is adjunctive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Sturge-Weber syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classic triad of Sturge-Weber syndrome includes facial port-wine stain (",
"    <a class=\"graphic graphic_picture graphicRef59124 graphicRef73978 \" href=\"mobipreview.htm?21/27/21943\">",
"     picture 2A-B",
"    </a>",
"    ), intracranial angiomata, and glaucoma (",
"    <a class=\"graphic graphic_picture graphicRef74289 \" href=\"mobipreview.htm?39/29/40400\">",
"     picture 3",
"    </a>",
"    ). The disorder, one of the phakomatoses, also known as encephalotrigeminal angiomatosis, has several variants. Systemic manifestations include seizures, intellectual disability (mental retardation), paresis, and cerebral calcifications. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/39/4727?source=see_link\">",
"     \"Sturge-Weber syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Sturge-Weber syndrome is a sporadic disorder, with only rare familial cases. Although the syndrome is rare, it is one of the more common causes of secondary glaucoma in children. Individuals with Sturge-Weber syndrome can develop glaucoma even if they do not have the classic triad [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41463/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Glaucoma has been reported in 40 to 60 percent of patients with Sturge-Weber syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41463/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Glaucoma is most often unilateral on the same side as the port wine stain. Patients who develop glaucoma usually have port-wine stains of both the upper and lower eyelids. The risk of glaucoma is highest in the first decade of life. Approximately one-half of patients with Sturge-Weber syndrome have glaucoma at birth and present with enlargement of the globe. Occasionally, patients develop glaucoma in adulthood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41463/abstract/18\">",
"     18",
"    </a>",
"    ]. Thus, continued vigilance is needed, even in patients with initially normal intraocular pressure.",
"   </p>",
"   <p>",
"    The pathogenesis of the glaucoma is variable, depending upon the age of onset [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41463/abstract/19\">",
"     19",
"    </a>",
"    ]. Most cases that present early are due to a developmental angle anomaly that is indistinguishable from that in primary infantile glaucoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41463/abstract/20\">",
"     20",
"    </a>",
"    ]. Other possible mechanisms for later-onset glaucoma include hypersecretion from an associated angioma of the choroid, elevated venous pressure associated with an episcleral hemangioma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41463/abstract/19,21\">",
"     19,21",
"    </a>",
"    ], or a combination of these abnormalities.",
"   </p>",
"   <p>",
"    As is the case with primary pediatric glaucoma, surgery is the mainstay of treatment for glaucoma in patients with Sturge-Weber syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41463/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. However, some patients can be successfully managed medically [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41463/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Aniridia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aniridia is a rare congenital abnormality of neural crest cell migration and development. The majority of cases are sporadic, with occasional familial cases. The familial cases are autosomal dominant and involve deletion of chromosome 11p13, a deletion that increases the risk of Wilms tumor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41463/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/0/23562?source=see_link\">",
"     \"Congenital cytogenetic abnormalities\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The ocular manifestations of aniridia are not limited to the iris, although it is nearly always affected. The iris may be almost completely absent or have only minor changes. Other ocular manifestations include macular hypoplasia, nystagmus, optic nerve hypoplasia, glaucoma, and progressive corneal degenerative changes. Glaucoma often presents in infancy but can present at any time.",
"   </p>",
"   <p>",
"    The pathogenesis of the glaucoma in aniridia is variable. A minority of patients have an anomalous angle present from birth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41463/abstract/25\">",
"     25",
"    </a>",
"    ]. Others form iris adhesions within the anterior chamber angle and go on to develop classic secondary angle closure glaucoma. Thus, aniridic glaucoma can result from congenital or acquired structural angle anomalies. Patients with aniridia should be regularly monitored for the development of glaucoma. Evaluation should include assessment of corneal signs (eg, edema, enlargement), examination of the optic nerve, and measurement of IOP.",
"   </p>",
"   <p>",
"    The treatment of aniridic glaucoma is difficult. Goniotomy appears to be a reasonable option for patients with an open angle. Some authors have suggested prophylactic goniotomy for patients with aniridia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41463/abstract/26\">",
"     26",
"    </a>",
"    ]; however, this is controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41463/abstract/27\">",
"     27",
"    </a>",
"    ]. Trabeculotomy may be best suited for patients with angle closure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41463/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Anterior segment dysgenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anterior segment dysgenesis refers to developmental defects of the anterior segment and iris that result in a spectrum of ocular and systemic manifestations. These disorders were formerly known as anterior chamber cleavage syndromes or mesodermal dysgenesis, terms that should be avoided as it is now known that neural crest cells, not mesoderm, are primarily responsible for anterior segment development and that the simple concept of anterior segment \"cleavage\" may not be valid.",
"   </p>",
"   <p>",
"    Anterior segment dysgenesis represents an arrest in late gestational development that may result in retained primitive endothelium, failure of the peripheral iris to migrate posteriorly,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    failure of the corneal endothelium to fully differentiate. Individual disorders within this spectrum include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41463/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Posterior embryotoxon or anteriorly displaced Schwalbe's line",
"     </li>",
"     <li>",
"      Axenfeld-Rieger syndrome, which includes disorders formerly known as Axenfeld anomaly, Axenfeld syndrome, Rieger anomaly, Rieger syndrome, and iridogoniodysgenesis",
"     </li>",
"     <li>",
"      Posterior keratoconus",
"     </li>",
"     <li>",
"      Peters anomaly, a central defect in the corneal basement membrane with various degrees of adhesion of the iris and lens capsule to the central cornea",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Glaucoma occurs at some time in approximately 60 percent of patients with these disorders. It may occur during infancy or much later. The increased intraocular pressure appears to be related to developmental angle anomalies. Patients with anterior segment dysgenesis should be monitored regularly for the development of glaucoma. Evaluation should include assessment of corneal signs (eg, edema, enlargement), examination of the optic nerve, and measurement of IOP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Retinopathy of prematurity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retinopathy of prematurity (ROP) is a developmental vascular proliferative disorder that occurs in the incompletely vascularized retina of premature infants. It is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/32/10762?source=see_link&amp;anchor=H1#H1\">",
"     \"Retinopathy of prematurity\", section on 'Introduction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Glaucoma is a severe complication of ROP. It can occur across the spectrum of visual acuity and at any time. Between one-quarter and one-third of patients with Stage 5 ROP (complete retinal detachment) develop glaucoma as a complication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41463/abstract/32\">",
"     32",
"    </a>",
"    ]. Diminished visual acuity",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pain (particularly in blind eyes) may suggest the diagnosis of glaucoma in patients with ROP.",
"   </p>",
"   <p>",
"    The pathogenesis of glaucoma in ROP varies. Mechanisms include contraction of the retrolental membranes leading to anterior rotation of the lens-iris diaphragm and secondary angle closure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41463/abstract/33-36\">",
"     33-36",
"    </a>",
"    ], high iris convexity, anterior iris insertion, pigment clumping in the trabecular meshwork, and the appearance of a translucent matrix in the angle structures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41463/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The treatment of glaucoma in ROP varies depending upon the underlying mechanism. Lensectomy is the preferred procedure for obliteration of angle by forward displacement of the lens-iris diaphragm. Medications",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    surgery may be used in other cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Aphakia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children who have undergone cataract surgery are at risk for developing secondary open-angle or angle-closure glaucoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41463/abstract/37\">",
"     37",
"    </a>",
"    ]. Aphakic glaucoma is the second-most common cause of glaucoma in children (after primary infantile glaucoma), accounting for 20 percent of cases of glaucoma that presented to one children's hospital during a 20-year period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41463/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/14/22761?source=see_link&amp;anchor=H28#H28\">",
"     \"Cataract in children\", section on 'Post-operative complications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The prevalence of glaucoma as a complication of pediatric cataract surgery has changed as surgical techniques have evolved. Current",
"    <span class=\"nowrap\">",
"     irrigation/aspiration",
"    </span>",
"    techniques for congenital cataract surgery, coupled with mechanical anterior vitrectomy, seem to have reduced the rate of postoperative glaucoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41463/abstract/39\">",
"     39",
"    </a>",
"    ]. However, the exact prevalence is not known. In one study of 137 patients who had undergone congenital cataract surgery and were followed for a mean of 9.6 years, glaucoma developed in 12 percent of the eyes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41463/abstract/40\">",
"     40",
"    </a>",
"    ]. Higher prevalence has been reported in smaller (and earlier) series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41463/abstract/39\">",
"     39",
"    </a>",
"    ]. Risk factors for the development of glaucoma include surgery before 10 days of age and microphthalmos [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41463/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The implantation of an intraocular lens has not been shown to decrease the incidence of glaucoma after cataract surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41463/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is some evidence to suggest that surgery performed after one month of age may lower the risk of glaucoma. However, the benefits of a delay in cataract removal need to be weighed against the risk of deprivation amblyopia development [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41463/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of corneal thickness in the management of these patients is being investigated. Many patients demonstrate abnormally thick corneas, which may artificially raise IOP measurements.",
"   </p>",
"   <p>",
"    Several factors may contribute to the development of aphakic glaucoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41463/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      An underlying anterior segment defect that contributed to the development of congenital cataract",
"     </li>",
"     <li>",
"      Subclinical angle anomalies",
"     </li>",
"     <li>",
"      Predisposition from the combination of cataract and microcornea",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Regardless of the pathogenesis, children who have undergone cataract surgery should be monitored for the development of glaucoma with periodic evaluation of the optic nerve and tonometry (in cooperative patients) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41463/abstract/45\">",
"     45",
"    </a>",
"    ]. Most patients who develop aphakic glaucoma do so within four to six years of their cataract surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41463/abstract/46,47\">",
"     46,47",
"    </a>",
"    ], although it may take longer than eight years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41463/abstract/39\">",
"     39",
"    </a>",
"    ]. Excessive loss of hyperopia (farsightedness) or corneal clouding in the aphakic patient should arouse immediate suspicion of glaucoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41463/abstract/48,49\">",
"     48,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The outcome of surgery for aphakic glaucoma is less favorable than that for primary congenital glaucoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41463/abstract/3\">",
"     3",
"    </a>",
"    ]. In contrast, aphakic glaucoma may respond to medical therapy. Thus, a trial of medical therapy usually is attempted before surgical intervention is undertaken.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Intraocular inflammation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glaucoma can occur as a complication of inflammation or uveitis. The mechanism is similar regardless of age of onset: damage to and blockage of trabecular meshwork by inflammatory cells or scarring. The underlying cause of uveitis varies by age. Inflammatory glaucoma in children usually is a complication of juvenile idiopathic arthritis (formerly juvenile rheumatoid arthritis) or sarcoidosis, or is idiopathic (often of viral etiology). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/16/23817?source=see_link\">",
"     \"Uveitis: Etiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment centers on control of inflammation. Acute trabeculitis, inflammatory obstruction, and pupillary block usually respond to corticosteroids and antiglaucoma medications. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/57/5016?source=see_link&amp;anchor=H18#H18\">",
"     \"Primary infantile glaucoma\", section on 'Medical therapy'",
"    </a>",
"    .) Goniotomy has been shown to be an effective procedure in children whose intraocular pressure remains elevated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41463/abstract/50,51\">",
"     50,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Glaucoma caused by angle closure usually requires trabeculectomy or tube shunt surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glaucoma can occur as a complication of ocular tumors, including retinoblastoma, medulloepithelioma, juvenile xanthogranuloma, histiocytosis X, and leukemia. (See appropriate topic reviews). Secondary glaucoma can occur as a result of:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Tumor infiltration of the angle",
"     </li>",
"     <li>",
"      Inflammation of the angle",
"     </li>",
"     <li>",
"      Secondary hemorrhage into the angle [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/31/41463/abstract/52\">",
"       52",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Angle closure, produced by anterior displacement of the iris-lens diaphragm by a bulky tumor (typical in retinoblastoma)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glaucoma can occur as an acute or late complication of blunt or penetrating ocular trauma. The mechanisms for traumatic glaucoma include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Blockage of the trabecular meshwork with red blood cells or debris in hyphema",
"     </li>",
"     <li>",
"      Damage to the angle, leading to decreased outflow of aqueous (a late complication)",
"     </li>",
"     <li>",
"      Inflammation of the trabecular meshwork",
"     </li>",
"     <li>",
"      Damage to the lens",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In children, glaucoma associated with hyphema is of particular interest. Intraocular pressure can rise rapidly to high levels, causing damage to the optic nerve and blood-staining of the cornea. Children with hyphema should be evaluated urgently by an ophthalmologist. Surgical evacuation of the blood collection may be necessary if the intraocular pressure cannot be controlled. Modest elevation of intraocular pressure usually responds to temporary medical therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/10/38057?source=see_link\">",
"     \"Traumatic hyphema: Clinical features and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Steroid-induced",
"    </span>",
"    &nbsp;&mdash;&nbsp;Steroid-induced glaucoma is more common among adults but can occur in children. This form of glaucoma occurs most commonly in patients who use corticosteroid eye drops, although it has been observed infrequently in chronic and, to a lesser extent, acute systemic corticosteroid use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41463/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. The mechanism of steroid-induced glaucoma remains unknown. The condition usually subsides after discontinuation of steroids. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=see_link&amp;anchor=H8#H8\">",
"     \"Major side effects of systemic glucocorticoids\", section on 'Eye'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Glaucoma is a group of eye diseases that is characterized by elevated intraocular pressure (IOP). Increased IOP leads to optic nerve damage and visual loss. Early diagnosis and referral are crucial to ensuring optimal visual outcome. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pediatric glaucoma is classified into primary and secondary types to provide a framework for the evaluation and management of individual patients (",
"      <a class=\"graphic graphic_table graphicRef56982 \" href=\"mobipreview.htm?23/16/23821\">",
"       table 1",
"      </a>",
"      ). Primary glaucomas are those with isolated angle malformations (trabeculodysgenesis). They may have onset at birth, in the first few years of life, or later in life. Secondary glaucoma either is acquired or related to an underlying ocular abnormality; it can occur at any age and may be present at birth. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Primary infantile glaucoma is a rare disease, with onset in the first years of life. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/57/5016?source=see_link\">",
"       \"Primary infantile glaucoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Primary glaucoma diagnosed after four to five years of age usually is called juvenile glaucoma. Patients typically are asymptomatic, and optic nerve damage is occult. Elevations of IOP usually are unrecognized unless optic nerve cupping (",
"      <a class=\"graphic graphic_picture graphicRef71467 \" href=\"mobipreview.htm?20/19/20799\">",
"       picture 1",
"      </a>",
"      ) is noticed. The diagnosis generally is made because of coexisting ocular or systemic disease or because of a positive family history. Surgical intervention is the mainstay of therapy, and medications are used as an adjunct. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Juvenile glaucoma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Secondary glaucoma can occur in a variety of conditions (",
"      <a class=\"graphic graphic_table graphicRef56982 \" href=\"mobipreview.htm?23/16/23821\">",
"       table 1",
"      </a>",
"      ). Causes of secondary glaucoma include angle anomalies (eg, Sturge-Weber syndrome, aniridia, anterior segment dysgenesis), retinopathy of prematurity, aphakia, intraocular inflammation, ocular tumors, trauma, and glucocorticoids. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Secondary glaucoma'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41463/abstract/1\">",
"      Kipp MA. Childhood glaucoma. Pediatr Clin North Am 2003; 50:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41463/abstract/2\">",
"      Hoskins HD Jr, Shaffer RN, Hetherington J. Anatomical classification of the developmental glaucomas. Arch Ophthalmol 1984; 102:1331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41463/abstract/3\">",
"      Beck AD. Diagnosis and management of pediatric glaucoma. Ophthalmol Clin North Am 2001; 14:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41463/abstract/4\">",
"      Tawara A, Inomata H. Developmental immaturity of the trabecular meshwork in juvenile glaucoma. Am J Ophthalmol 1984; 98:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41463/abstract/5\">",
"      Goldwyn R, Waltman SR, Becker B. Primary open-angle glaucoma in adolescents and young adults. Arch Ophthalmol 1970; 84:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41463/abstract/6\">",
"      Johnson AT, Drack AV, Kwitek AE, et al. Clinical features and linkage analysis of a family with autosomal dominant juvenile glaucoma. Ophthalmology 1993; 100:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41463/abstract/7\">",
"      Alward WL, Fingert JH, Coote MA, et al. Clinical features associated with mutations in the chromosome 1 open-angle glaucoma gene (GLC1A). N Engl J Med 1998; 338:1022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41463/abstract/8\">",
"      Belmouden A, Adam MF, Dupont de Dinechin S, et al. Recombinational and physical mapping of the locus for primary open-angle glaucoma (GLC1A) on chromosome 1q23-q25. Genomics 1997; 39:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41463/abstract/9\">",
"      Graff C, Urbak SF, Jerndal T, Wadelius C. Confirmation of linkage to 1q21-31 in a Danish autosomal dominant juvenile-onset glaucoma family and evidence of genetic heterogeneity. Hum Genet 1995; 96:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41463/abstract/10\">",
"      Sheffield VC, Stone EM, Alward WL, et al. Genetic linkage of familial open angle glaucoma to chromosome 1q21-q31. Nat Genet 1993; 4:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41463/abstract/11\">",
"      Wiggs JL, Del Bono EA, Schuman JS, et al. Clinical features of five pedigrees genetically linked to the juvenile glaucoma locus on chromosome 1q21-q31. Ophthalmology 1995; 102:1782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41463/abstract/12\">",
"      Richards JE, Ritch R, Lichter PR, et al. Novel trabecular meshwork inducible glucocorticoid response mutation in an eight-generation juvenile-onset primary open-angle glaucoma pedigree. Ophthalmology 1998; 105:1698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41463/abstract/13\">",
"      Richards JE, Lichter PR, Boehnke M, et al. Mapping of a gene for autosomal dominant juvenile-onset open-angle glaucoma to chromosome Iq. Am J Hum Genet 1994; 54:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41463/abstract/14\">",
"      Enjolras O, Riche MC, Merland JJ. Facial port-wine stains and Sturge-Weber syndrome. Pediatrics 1985; 76:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41463/abstract/15\">",
"      Khaier A, Nischal KK, Espinosa M, Manoj B. Periocular port wine stain: the great ormond street hospital experience. Ophthalmology 2011; 118:2274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41463/abstract/16\">",
"      Sharan S, Swamy B, Taranath DA, et al. Port-wine vascular malformations and glaucoma risk in Sturge-Weber syndrome. J AAPOS 2009; 13:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41463/abstract/17\">",
"      Hennedige AA, Quaba AA, Al-Nakib K. Sturge-Weber syndrome and dermatomal facial port-wine stains: incidence, association with glaucoma, and pulsed tunable dye laser treatment effectiveness. Plast Reconstr Surg 2008; 121:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41463/abstract/18\">",
"      Sujansky E, Conradi S. Sturge-Weber syndrome: age of onset of seizures and glaucoma and the prognosis for affected children. J Child Neurol 1995; 10:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41463/abstract/19\">",
"      Phelps CD. The pathogenesis of glaucoma in Sturge-Weber syndrome. Ophthalmology 1978; 85:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41463/abstract/20\">",
"      Cibis GW, Tripathi RC, Tripathi BJ. Glaucoma in Sturge-Weber syndrome. Ophthalmology 1984; 91:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41463/abstract/21\">",
"      Kranemann CF, Pavlin CJ, Trope GE. Ultrasound biomicroscopy in Sturge-Weber-associated glaucoma. Am J Ophthalmol 1998; 125:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41463/abstract/22\">",
"      van Emelen C, Goethals M, Dralands L, Casteels I. Treatment of glaucoma in children with Sturge-Weber syndrome. J Pediatr Ophthalmol Strabismus 2000; 37:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41463/abstract/23\">",
"      Olsen KE, Huang AS, Wright MM. The efficacy of goniotomy/trabeculotomy in early-onset glaucoma associated with the Sturge-Weber syndrome. J AAPOS 1998; 2:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41463/abstract/24\">",
"      Awad AH, Mullaney PB, Al-Mesfer S, Zwaan JT. Glaucoma in Sturge-Weber syndrome. J AAPOS 1999; 3:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41463/abstract/25\">",
"      Margo CE. Congenital aniridia: a histopathologic study of the anterior segment in children. J Pediatr Ophthalmol Strabismus 1983; 20:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41463/abstract/26\">",
"      Chen TC, Walton DS. Goniosurgery for prevention of aniridic glaucoma. Arch Ophthalmol 1999; 117:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41463/abstract/27\">",
"      Walton DS. Aniridic glaucoma: the results of gonio-surgery to prevent and treat this problem. Trans Am Ophthalmol Soc 1986; 84:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41463/abstract/28\">",
"      Adachi M, Dickens CJ, Hetherington J Jr, et al. Clinical experience of trabeculotomy for the surgical treatment of aniridic glaucoma. Ophthalmology 1997; 104:2121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41463/abstract/29\">",
"      Waring GO 3rd, Rodrigues MM, Laibson PR. Anterior chamber cleavage syndrome. A stepladder classification. Surv Ophthalmol 1975; 20:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41463/abstract/30\">",
"      Alward WL. Axenfeld-Rieger syndrome in the age of molecular genetics. Am J Ophthalmol 2000; 130:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41463/abstract/31\">",
"      Shields MB. Axenfeld-Rieger syndrome: a theory of mechanism and distinctions from the iridocorneal endothelial syndrome. Trans Am Ophthalmol Soc 1983; 81:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41463/abstract/32\">",
"      Hartnett ME, Gilbert MM, Richardson TM, et al. Anterior segment evaluation of infants with retinopathy of prematurity. Ophthalmology 1990; 97:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41463/abstract/33\">",
"      COHEN J, ALFANO JE, BOSHES LD, PALMGREN C. CLINICAL EVALUATION OF SCHOOL-AGE CHILDREN WITH RETROLENTAL FIBROPLASIA. Am J Ophthalmol 1964; 57:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41463/abstract/34\">",
"      Merritt JC, Kraybill EN. Retrolental fibroplasia: a five-year experience in a tertiary perinatal center. Ann Ophthalmol 1986; 18:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41463/abstract/35\">",
"      Pollard ZF. Secondary angle-closure glaucoma in cicatricial retrolental fibroplasia. Am J Ophthalmol 1980; 89:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41463/abstract/36\">",
"      Trigler L, Weaver RG Jr, O'Neil JW, et al. Case series of angle-closure glaucoma after laser treatment for retinopathy of prematurity. J AAPOS 2005; 9:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41463/abstract/37\">",
"      Egbert JE, Wright MM, Dahlhauser KF, et al. A prospective study of ocular hypertension and glaucoma after pediatric cataract surgery. Ophthalmology 1995; 102:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41463/abstract/38\">",
"      Taylor RH, Ainsworth JR, Evans AR, Levin AV. The epidemiology of pediatric glaucoma: the Toronto experience. J AAPOS 1999; 3:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41463/abstract/39\">",
"      Simon JW, Mehta N, Simmons ST, et al. Glaucoma after pediatric lensectomy/vitrectomy. Ophthalmology 1991; 98:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41463/abstract/40\">",
"      Magnusson G, Abrahamsson M, Sj&ouml;strand J. Glaucoma following congenital cataract surgery: an 18-year longitudinal follow-up. Acta Ophthalmol Scand 2000; 78:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41463/abstract/41\">",
"      Trivedi RH, Wilson ME Jr, Golub RL. Incidence and risk factors for glaucoma after pediatric cataract surgery with and without intraocular lens implantation. J AAPOS 2006; 10:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41463/abstract/42\">",
"      Khan AO, Al-Dahmash S, Al-Dahmesh S. Age at the time of cataract surgery and relative risk for aphakic glaucoma in nontraumatic infantile cataract. J AAPOS 2009; 13:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41463/abstract/43\">",
"      Phelps CD, Arafat NI. Open-angle glaucoma following surgery for congenital cataracts. Arch Ophthalmol 1977; 95:1985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41463/abstract/44\">",
"      Wallace DK, Plager DA. Corneal diameter in childhood aphakic glaucoma. J Pediatr Ophthalmol Strabismus 1996; 33:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41463/abstract/45\">",
"      Keech RV, Tongue AC, Scott WE. Complications after surgery for congenital and infantile cataracts. Am J Ophthalmol 1989; 108:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41463/abstract/46\">",
"      Walton DS. Pediatric aphakic glaucoma: a study of 65 patients. Trans Am Ophthalmol Soc 1995; 93:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41463/abstract/47\">",
"      Johnson CP, Keech RV. Prevalence of glaucoma after surgery for PHPV and infantile cataracts. J Pediatr Ophthalmol Strabismus 1996; 33:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41463/abstract/48\">",
"      Egbert JE, Kushner BJ. Excessive loss of hyperopia. A presenting sign of juvenile aphakic glaucoma. Arch Ophthalmol 1990; 108:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41463/abstract/49\">",
"      Wang VM, Demer JL, Rosenbaum A, Weissman BA. Diagnosing glaucoma in pediatric aphakia. Optometry 2002; 73:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41463/abstract/50\">",
"      Ho CL, Wong EY, Walton DS. Goniosurgery for glaucoma complicating chronic childhood uveitis. Arch Ophthalmol 2004; 122:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41463/abstract/51\">",
"      Bohnsack BL, Freedman SF. Surgical outcomes in childhood uveitic glaucoma. Am J Ophthalmol 2013; 155:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41463/abstract/52\">",
"      Kwitko ML. Secondary glaucoma in infancy and childhood. A review. Can J Ophthalmol 1969; 4:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41463/abstract/53\">",
"      Long WF. A case of elevated intraocular pressure associated with systemic steroid therapy. Am J Optom Physiol Opt 1977; 54:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41463/abstract/54\">",
"      Fran&ccedil;ois J. Corticosteroid glaucoma. Ophthalmologica 1984; 188:76.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6272 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-61.234.146.186-850F4342A6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_31_41463=[""].join("\n");
var outline_f40_31_41463=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PRIMARY INFANTILE GLAUCOMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      JUVENILE GLAUCOMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SECONDARY GLAUCOMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Angle anomalies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Sturge-Weber syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Aniridia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Anterior segment dysgenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Retinopathy of prematurity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Aphakia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Intraocular inflammation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Trauma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Steroid-induced",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6272\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6272|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?10/60/11201\" title=\"figure 1\">",
"      Angle anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?14/26/14753\" title=\"figure 2\">",
"      Impaired aqueous flow",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6272|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?20/19/20799\" title=\"picture 1\">",
"      Glaucomatous optic disc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?18/32/18946\" title=\"picture 2A\">",
"      Port wine stain - V2 infant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?0/45/722\" title=\"picture 2B\">",
"      Port wine stain - V2 child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?39/29/40400\" title=\"picture 3\">",
"      Diffuse choroidal hemangioma in SWS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6272|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/16/23821\" title=\"table 1\">",
"      Classification glaucoma children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/14/22761?source=related_link\">",
"      Cataract in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/0/23562?source=related_link\">",
"      Congenital cytogenetic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/59/15289?source=related_link\">",
"      Open-angle glaucoma: Epidemiology, clinical presentation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/57/5016?source=related_link\">",
"      Primary infantile glaucoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/32/10762?source=related_link\">",
"      Retinopathy of prematurity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/39/4727?source=related_link\">",
"      Sturge-Weber syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/10/38057?source=related_link\">",
"      Traumatic hyphema: Clinical features and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/16/23817?source=related_link\">",
"      Uveitis: Etiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_31_41464="Overview of the clinical manifestations of systemic lupus erythematosus in adults";
var content_f40_31_41464=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of the clinical manifestations of systemic lupus erythematosus in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/31/41464/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/31/41464/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/31/41464/contributors\">",
"     Dafna D Gladman, MD, FRCPC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/31/41464/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/31/41464/contributors\">",
"     David S Pisetsky, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/31/41464/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/31/41464/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/31/41464/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 23, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic lupus erythematosus (SLE) is a chronic inflammatory disease of unknown cause that can affect the skin, joints, kidneys, lungs, nervous system, serous membranes,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    other organs of the body. Immunologic abnormalities, especially the production of a number of antinuclear antibodies, are another prominent feature of the disease.",
"   </p>",
"   <p>",
"    The clinical course of SLE is variable and may be characterized by periods of remissions and of chronic or acute relapses. Women, especially in their 20s and 30s, are affected more frequently than men.",
"   </p>",
"   <p>",
"    Patients with SLE are subject to myriad symptoms, complaints, and inflammatory involvement that can affect virtually every organ [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41464/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The most common pattern is a mixture of constitutional complaints with skin, musculoskeletal, mild hematologic, and serologic involvement (",
"    <a class=\"graphic graphic_table graphicRef70386 \" href=\"mobipreview.htm?29/29/30173\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41464/abstract/1\">",
"     1",
"    </a>",
"    ]. However, some patients have predominately hematologic, renal, or central nervous system manifestations. The pattern that dominates during the first few years of illness tends to prevail subsequently [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41464/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Signs and symptoms that can occur in SLE are discussed in this topic review. Both constitutional symptoms and those related to specific organ systems can occur; these are both reviewed here and are discussed in more detail separately. (See appropriate topic reviews)",
"   </p>",
"   <p>",
"    Criteria that can be used to establish the diagnosis of SLE and a discussion of differential diagnosis of this disease are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/16/3338?source=see_link\">",
"     \"Diagnosis and differential diagnosis of systemic lupus erythematosus in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment of SLE is based upon preventive measures, reversal of inflammation, prevention of organ impairment, and alleviation of symptoms, and an approach to the management of SLE is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/38/41578?source=see_link\">",
"     \"Overview of the therapy and prognosis of systemic lupus erythematosus in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CONSTITUTIONAL SYMPTOMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fatigue, fever, and weight loss are typically present at some time during the course of the disease, occurring in 50 to 100 percent of patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Fatigue",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fatigue is the most common complaint and is occasionally the most debilitating. It occurs in 80 to 100 percent of patients, and its presence is not clearly correlated with other measures of disease activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41464/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. Fatigue is strongly associated with diminished exercise tolerance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41464/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, fatigue may not be due to active SLE but to one or more of the following: increased work load, depression, unhealthful habits (smoking, fad diets, sedentary living, drug abuse), stress, anemia, hypothyroidism, use of certain medications (including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , beta-blockers), any inflammatory",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    infectious disease, coexistent fibromyalgia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41464/abstract/11-13\">",
"     11-13",
"    </a>",
"    ], sleep disturbances, deconditioning, or a perception of poor social support [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41464/abstract/8,14\">",
"     8,14",
"    </a>",
"    ]. Fatigue due to SLE may respond to glucocorticoids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41464/abstract/15\">",
"     15",
"    </a>",
"    ], to antimalarials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41464/abstract/16\">",
"     16",
"    </a>",
"    ], and, in some studies, to exercise and psychosocial interventions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41464/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Myalgia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myalgia is common in SLE. Myalgia and muscle weakness are discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/12/23753?source=see_link&amp;anchor=H13#H13\">",
"     \"Musculoskeletal manifestations of systemic lupus erythematosus\", section on 'Muscle disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Weight changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Weight changes are frequent in patients with SLE and may be related to the disease or to its treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Weight loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Weight loss often occurs prior to the diagnosis of SLE. Unintentional weight loss may be due to decreased appetite, to the side effects of medications (particularly diuretics or antimalarials), and to gastrointestinal disease (eg, gastroesophageal reflux, abdominal pain, peptic ulcer disease, or pancreatitis). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/50/5928?source=see_link\">",
"     \"Gastrointestinal manifestations of systemic lupus erythematosus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Weight gain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Weight gain in SLE is usually due to one of two factors: salt and water retention associated with hypoalbuminemia (eg, due to nephrotic syndrome or protein losing enteropathy) or increased appetite associated with the use of glucocorticoids. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/18/32041?source=see_link\">",
"     \"Overview of heavy proteinuria and the nephrotic syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/50/5928?source=see_link&amp;anchor=H15#H15\">",
"     \"Gastrointestinal manifestations of systemic lupus erythematosus\", section on 'Protein-losing enteropathy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fever that is thought to be due to active disease is seen in over 50 percent of patients with SLE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41464/abstract/2\">",
"     2",
"    </a>",
"    ]. Fever may also represent infection or a drug reaction. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A total of 83 febrile episodes in 63 patients with SLE were assessed in one study. Sixty percent of the fevers were thought to be due to SLE, 23 percent were thought to be due to infection, and 17 percent were thought to be due to other causes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/31/41464/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A retrospective study of 1949 consecutively hospitalized patients with SLE noted 487 (25 percent) had fever. Of those with fever, 265 were ascribed to infection, and 206 were ascribed to SLE (54 and 42 percent of fevers, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/31/41464/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The history may be helpful in determining the cause of the fever. As an example, fever developing while on moderate or high doses of glucocorticoids should make one strongly suspect new infection, particular if other signs of active lupus have begun to remit.",
"   </p>",
"   <p>",
"    The pattern of fever may be helpful diagnostically. Episodic fever is suggestive of active SLE or infection; in comparison, sustained fever may reflect central nervous system (CNS) involvement or an adverse effect to a drug [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41464/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serious infectious complications, especially of the skin, respiratory, and urinary systems, develop in up to 50 percent of SLE patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41464/abstract/2,19,21-23\">",
"     2,19,21-23",
"    </a>",
"    ]. A large majority (approximately 80 percent) is due to pathogenic bacteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41464/abstract/23\">",
"     23",
"    </a>",
"    ]. Opportunistic infections, including those due to fungi, related to immunosuppressive therapy are a common cause of death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41464/abstract/24-27\">",
"     24-27",
"    </a>",
"    ]. Consequently, ascribing fever to SLE in an immunocompromised patient should be done only after reasonable efforts have been made to exclude infection.",
"   </p>",
"   <p>",
"    Risk factors for infection include active (SLE) disease, long-term disease damage, neutropenia, lymphopenia, hypocomplementemia, renal involvement, neuropsychiatric manifestations, and the use of glucocorticoids and other immunosuppressive drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41464/abstract/23\">",
"     23",
"    </a>",
"    ]. Viral infections are also common, including parvovirus B19 (which can cause a lupus-like syndrome), Epstein-Barr virus, cytomegalovirus, varicella-zoster virus, and human papilloma virus. Mycobacterial infections, including non-tuberculosis, have been noted to be more frequent in patients with SLE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41464/abstract/19,23\">",
"     19,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fever that does not respond to nonsteroidal antiinflammatory drugs (NSAIDs),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    ,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    low to moderate doses of glucocorticoids further raises the suspicion of an infectious or drug-related etiology, since most fevers due to active SLE will remit with use of these agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41464/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SPECIFIC ORGAN INVOLVEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;SLE affects multiple organ systems. The course is marked by remissions and relapses and may vary from mild to severe.",
"   </p>",
"   <p>",
"    What follows is a brief review of the types of symptoms that can occur. Manifestations of the involvement of specific organ systems are discussed in detail separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Joint symptoms occur in over 90 percent of patients at some time during the illness and are often the earliest manifestation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41464/abstract/12\">",
"     12",
"    </a>",
"    ]. Arthritis, with inflammation, occurs in 65 to 70 percent of patients and tends to be migratory and symmetrical. Only a few joints are usually affected, especially those of the hands. The arthritis is moderately painful and is rarely deforming (",
"    <a class=\"graphic graphic_picture graphicRef78325 graphicRef65248 \" href=\"mobipreview.htm?0/51/819\">",
"     picture 1A-B",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/12/23753?source=see_link\">",
"     \"Musculoskeletal manifestations of systemic lupus erythematosus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Mucocutaneous",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients have skin lesions at some time during the course of the illness. The most common lesion is the butterfly rash, erythema over the cheeks and nose (but sparing the nasolabial folds), which appears after sun exposure (",
"    <a class=\"graphic graphic_picture graphicRef75781 graphicRef55875 \" href=\"mobipreview.htm?36/46/37608\">",
"     picture 2A-B",
"    </a>",
"    ). It lasts only a few days but often recurs. Some patients will develop discoid lesions, which are more inflammatory and which have a tendency to scar (",
"    <a class=\"graphic graphic_picture graphicRef75833 graphicRef64844 \" href=\"mobipreview.htm?17/32/17929\">",
"     picture 3A-B",
"    </a>",
"    ). Hair loss (alopecia) is common, but baldness is not. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/33/36378?source=see_link\">",
"     \"Mucocutaneous manifestations of systemic lupus erythematosus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many patients develop oral",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    nasal ulcers, which are usually painless, in contrast to herpetic chancre blisters. Such ulceration has been noted in 12 to 45 percent of patients. Perforation of the nasal septum occurs infrequently. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/33/36378?source=see_link&amp;anchor=H29#H29\">",
"     \"Mucocutaneous manifestations of systemic lupus erythematosus\", section on 'Mucous membranes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Raynaud phenomenon",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cold- or emotion-induced color changes of the digits of the hands",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    feet (the Raynaud phenomenon) are frequent problems and may antedate other features of the disease (",
"    <a class=\"graphic graphic_picture graphicRef66438 \" href=\"mobipreview.htm?15/41/16018\">",
"     picture 4",
"    </a>",
"    ). Self-reported skin color changes consistent with the Raynaud phenomenon occurred in 16 to 40 percent of patients in two large series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41464/abstract/2,12\">",
"     2,12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/48/6921?source=see_link\">",
"     \"Clinical manifestations and diagnosis of the Raynaud phenomenon\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Renal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal involvement becomes clinically apparent in approximately 50 percent of patients; however, most of the remaining patients have subclinical disease that can be demonstrated if renal biopsy were performed. Renal involvement usually develops in the first few years of illness and should be detected early by periodic urinalyses, by quantitation of proteinuria, and by estimation of the glomerular filtration rate (usually by monitoring the plasma creatinine concentration). Several forms of glomerulonephritis can occur, and renal biopsy is useful to define the type and extent of renal involvement. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/3/27706?source=see_link\">",
"     \"Diagnosis and classification of renal disease in systemic lupus erythematosus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Gastrointestinal tract",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gastrointestinal tract is often involved, more commonly from medication side effects than from active SLE. Examples of the former include gastritis and even peptic ulcers secondary to the use of NSAIDs alone or in combination with glucocorticoids. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/49/17177?source=see_link\">",
"     \"Nonselective NSAIDs: Overview of adverse effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On the other hand, SLE vasculitis can lead to pancreatitis, peritonitis, and colitis. Symptoms of esophageal irritation or reflux may occur. Nonspecific abdominal pain is frequent. Liver involvement from lupus is unusual, and presentation with liver abnormalities and a positive antinuclear antibody (ANA) test is more consistent with chronic active hepatitis (&ldquo;lupoid hepatitis&rdquo;). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/50/5928?source=see_link\">",
"     \"Gastrointestinal manifestations of systemic lupus erythematosus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Pulmonary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pleurisy, pleural effusion, pneumonitis, interstitial lung disease, pulmonary hypertension, and alveolar hemorrhage can all occur in SLE. The risk of thromboembolic involvement is increased in those with antiphospholipid antibodies or with lupus anticoagulant. The presence of dyspnea, of episodic pleuritic chest pain, and of a progressive decrease in lung volume in the absence of interstitial fibrosis or significant pleural disease suggests the shrinking lung syndrome. Pulmonary function tests are often significantly abnormal, with restrictive abnormalities, prior to complaints of dyspnea. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/60/11210?source=see_link\">",
"     \"Pulmonary manifestations of systemic lupus erythematosus in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Cardiovascular",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a variety of cardiovascular manifestations of SLE. Pericarditis is relatively common. Verrucous (Libman-Sacks) endocarditis is usually clinically silent, but it can produce valvular insufficiency and can serve as a source of emboli (",
"    <a class=\"graphic graphic_picture graphicRef79709 \" href=\"mobipreview.htm?37/6/37984\">",
"     picture 5",
"    </a>",
"    ). Myocarditis is uncommon but may be severe. Patients with SLE have an increased risk of coronary artery disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/59/22456?source=see_link\">",
"     \"Non-coronary cardiac manifestations of systemic lupus erythematosus in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/13/28889?source=see_link\">",
"     \"Coronary heart disease in systemic lupus erythematosus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Neonatal lupus can cause heart block of varying degrees that may be noted in utero and or that may present as congenital heart block. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/57/24474?source=see_link\">",
"     \"Neonatal lupus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Neurologic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurologic complications include cognitive defects, organic brain syndromes, delirium, psychosis, seizures, headache,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    peripheral neuropathies. Other less common problems are movement disorders, cranial neuropathies, myelitis, and meningitis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/11/33978?source=see_link\">",
"     \"Neurologic manifestations of systemic lupus erythematosus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Psychosis, which may be due to SLE or to glucocorticoid treatment, is one of several psychiatric manifestations of SLE. Others include depression, anxiety, and mania. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/46/38631?source=see_link\">",
"     \"Neuropsychiatric manifestations of systemic lupus erythematosus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thromboembolic events, often in association with antiphospholipid antibodies or with lupus anticoagulant, may occur in a substantial minority (20 percent) of patients with SLE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41464/abstract/29\">",
"     29",
"    </a>",
"    ]. Arterial thromboemboli may cause focal neurologic problems, such as stroke or seizures,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    more diffuse cognitive defects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41464/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/31/23034?source=see_link\">",
"     \"Clinical manifestations of the antiphospholipid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Ophthalmologic",
"    </span>",
"    &nbsp;&mdash;&nbsp;The eye is frequently involved in SLE, with the most common manifestation being keratoconjunctivitis sicca. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/1/11287?source=see_link\">",
"     \"Clinical manifestations of Sj&ouml;gren's syndrome: Exocrine gland disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Uncommon or rare ophthalmologic manifestations of SLE include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cotton wool exudates due to retinal vasculitis (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/49/33561?source=see_link\">",
"       \"Retinal vasculitis associated with systemic disorders and infections\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Episcleritis or scleritis (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/5/80?source=see_link\">",
"       \"Episcleritis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/32/22023?source=see_link\">",
"       \"Clinical manifestations and diagnosis of scleritis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Anterior uveitis (iritis, iridocyclitis) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/16/23817?source=see_link&amp;anchor=H5#H5\">",
"       \"Uveitis: Etiology, clinical manifestations, and diagnosis\", section on 'Systemic inflammatory diseases associated with uveitis'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Hematologic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytopenias and thrombophilia, an increased propensity to develop thromboembolic disease, may be features of SLE.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Cytopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with SLE frequently develop abnormalities in one or more of the three blood cell lines. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/49/14106?source=see_link\">",
"     \"Hematologic manifestations of systemic lupus erythematosus in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Leukopenia is common. While diagnostically useful, it is usually not symptomatic unless severe (eg,",
"      <span class=\"nowrap\">",
"       &lt;2000/mm",
"       <sup>",
"        3",
"       </sup>",
"       ).",
"      </span>",
"      White blood counts of",
"      <span class=\"nowrap\">",
"       &lt;4500/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      have been noted in 43 to 66 percent of patients.",
"     </li>",
"     <li>",
"      Many patients have a mild anemia, which is most often due to the anemia of chronic disease. Hemolytic anemia is rare but can be very severe. Others may have hemolytic anemia which is more severe and which requires immediate therapy.",
"     </li>",
"     <li>",
"      Thrombocytopenia is also frequently seen. However, bleeding usually occurs only with platelet counts below",
"      <span class=\"nowrap\">",
"       25,000/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      (",
"      <a class=\"graphic graphic_picture graphicRef73728 \" href=\"mobipreview.htm?36/63/37887\">",
"       picture 6",
"      </a>",
"      ). Acute thrombocytopenia is usually associated with active disease. However, some patients have chronic thrombocytopenia which does not require therapy unless there is evidence of bleeding.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Thrombophilia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with SLE, particularly those with antiphospholipid antibodies or with severe nephrotic syndrome, have an increased risk of thromboembolic disease which, in nephrotic syndrome, may be manifested as renal vein thrombosis. This may manifest as venous thromboembolism or as arterial disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/31/23034?source=see_link\">",
"     \"Clinical manifestations of the antiphospholipid syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/12/3273?source=see_link\">",
"     \"Renal vein thrombosis and hypercoagulable state in nephrotic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Lymphadenopathy and splenomegaly",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients have peripheral lymphadenopathy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    splenomegaly. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/49/14106?source=see_link&amp;anchor=H25#H25\">",
"     \"Hematologic manifestations of systemic lupus erythematosus in adults\", section on 'Lymphadenopathy and splenomegaly'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other hematologic features of SLE include hypocomplementemia and elevations in the erythrocyte sedimentation rate and gamma globulin levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Allergic",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no evidence that there is an increased risk of immunoglobulin E (IgE)-mediated",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    -associated allergic diseases in patients with SLE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41464/abstract/30\">",
"     30",
"    </a>",
"    ]. Exposure to sulfonamide antibiotics is associated with an increased risk of exacerbation of SLE, but this is not an &ldquo;allergic&rdquo; phenomenon.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Immunologic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autoantibody production is a hallmark of systemic lupus erythematous. A discussion of the diagnostic usefulness of testing for antinuclear and other autoantibodies is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/16/3338?source=see_link&amp;anchor=H9#H9\">",
"     \"Diagnosis and differential diagnosis of systemic lupus erythematosus in adults\", section on 'Autoantibodies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Anticardiolipin antibodies can produce a false-positive test for syphilis (eg, VDRL). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/16/35081?source=see_link&amp;anchor=H4#H4\">",
"     \"Pathogenesis of the antiphospholipid syndrome\", section on 'False positive serologic test for syphilis'",
"    </a>",
"    .) As noted earlier, antiphospholipid antibodies may also be present in the serum of patients with SLE and are associated with an increased risk of a variety of thromboembolic events and adverse pregnancy outcomes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/31/23034?source=see_link\">",
"     \"Clinical manifestations of the antiphospholipid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     PRECIPITATING FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The onset of SLE is infrequently attributed to a single event, although most clinicians have seen patients in which the disease began shortly following some memorable occurrence.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Exposure to the sun and other sources of ultraviolet light (especially UVB and, to some extent, UVA) may cause exacerbations or may even induce the first sign of lupus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/31/41464/abstract/31\">",
"       31",
"      </a>",
"      ]. The relapse is usually limited to a rash, although other symptoms can also develop. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/33/36378?source=see_link\">",
"       \"Mucocutaneous manifestations of systemic lupus erythematosus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Infections can initiate lupus or can cause a relapse [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/31/41464/abstract/32-34\">",
"       32-34",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/43/2743?source=see_link&amp;anchor=H3#H3\">",
"       \"Anti-U1 RNP antibodies in mixed connective tissue disease\", section on 'Initiation of an autoantibody response'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Stress has been implicated in causing flares, particularly of mild disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/31/41464/abstract/35\">",
"       35",
"      </a>",
"      ]. Unfortunately, stress as an entity has never been clinically defined, except as it relates to its psychosomatic effects [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/31/41464/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Surgery is another insult that can increase lupus activity. The mechanism is unclear but may be related to the release of nuclear and other antigens into the bloodstream, in which they bind to circulating antinuclear antibodies to form immune complexes.",
"     </li>",
"     <li>",
"      Pregnancy can cause an exacerbation or can even trigger the first symptoms of lupus; a relapse is more likely to develop in the immediate postpartum period (puerperium) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/31/41464/abstract/37\">",
"       37",
"      </a>",
"      ]. The hormonal adjuvants that are used during ovulation induction and during ovarian stimulation in preparation for in vitro fertilization may also cause exacerbations of SLE [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/31/41464/abstract/38\">",
"       38",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/45/39641?source=see_link\">",
"       \"Pregnancy in women with systemic lupus erythematosus\"",
"      </a>",
"      .) Therapeutic abortions can also induce a relapse, perhaps via mechanisms related to pregnancy or to the surgery itself.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although it had been suggested that use of hair dye may be associated with SLE, a very large prospective cohort study found no evidence of such a relationship [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41464/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/42/22178?source=see_link\">",
"       \"Patient information: Lupus (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/49/36626?source=see_link\">",
"       \"Patient information: Lupus and kidney disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/35/29238?source=see_link\">",
"       \"Patient information: Systemic lupus erythematosus (SLE) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H914472797\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Systemic lupus erythematosus (SLE) is a chronic inflammatory disease of unknown cause that can affect the skin, joints, kidneys, lungs, nervous system, serous membranes,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      other organs of the body. Immunologic abnormalities, especially the production of a number of antinuclear antibodies, are another prominent feature of the disease. The clinical course of SLE is variable and may be characterized by periods of remissions and chronic or acute relapses. Women, especially in their 20s and 30s, are affected more frequently than men. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common pattern is a mixture of constitutional complaints with skin, musculoskeletal, mild hematologic, and serologic involvement (",
"      <a class=\"graphic graphic_table graphicRef70386 \" href=\"mobipreview.htm?29/29/30173\">",
"       table 1",
"      </a>",
"      ). However, some patients have predominately hematologic, renal, or central nervous system manifestations. The pattern that dominates during the first few years of illness tends to prevail subsequently. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fatigue, fever, and weight loss are typically present at some time during the course of the disease, occurring in 50 to 100 percent of patients. Other symptoms may include myalgia and weight gain. Fever due to active disease is seen in over 50 percent of patients with SLE; fever may also represent infection or a drug reaction. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Constitutional symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The course is marked by remissions and relapses and may vary from mild to severe. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Specific organ involvement'",
"      </a>",
"      above.) Major manifestations include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Arthritis, with joint symptoms in &gt;90 percent of patients (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Arthritis'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Mucocutaneous lesions, including skin lesions in most patients, hair loss, and oral",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      nasal ulcers, which occur in 12 to 45 percent (see",
"      <a class=\"local\" href=\"#H11\">",
"       'Mucocutaneous'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Raynaud phenomenon, which is present in 16 to 40 percent (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Raynaud phenomenon'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Renal involvement, with histopathologic change in most patients but with clinically apparent disease in approximately 50 percent (see",
"      <a class=\"local\" href=\"#H13\">",
"       'Renal'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Gastrointestinal tract disease, which is more often due to complications of medications than to active SLE (see",
"      <a class=\"local\" href=\"#H14\">",
"       'Gastrointestinal tract'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Pulmonary disease, including pleurisy, pleural effusion, pneumonitis, interstitial lung disease, pulmonary hypertension, and alveolar hemorrhage (see",
"      <a class=\"local\" href=\"#H15\">",
"       'Pulmonary'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Cardiovascular disease, including pericarditis (which is relatively common), verrucous endocarditis, and increased risk of coronary artery disease (see",
"      <a class=\"local\" href=\"#H16\">",
"       'Cardiovascular'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Neurologic disease, including cognitive defects, organic brain syndromes, delirium, psychosis, seizures, headache, peripheral neuropathies, and thromboembolic disease (see",
"      <a class=\"local\" href=\"#H17\">",
"       'Neurologic'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Ophthalmologic manifestations, particularly keratoconjunctivitis sicca, as well as more uncommon manifestations (see",
"      <a class=\"local\" href=\"#H18\">",
"       'Ophthalmologic'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Hematologic manifestations, including cytopenias, thrombophilia, thromboembolic disease, lymphadenopathy, and splenomegaly (see",
"      <a class=\"local\" href=\"#H19\">",
"       'Hematologic'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Autoantibody production (see",
"      <a class=\"local\" href=\"#H25\">",
"       'Immunologic'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The onset of SLE is infrequently attributed to a single event, although most clinicians have seen patients in which the disease began shortly following some memorable occurrence. Precipitating factors may include exposure to ultraviolet light, infections, stress, surgery, and pregnancy. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Precipitating factors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41464/abstract/1\">",
"      Von Feldt JM. Systemic lupus erythematosus. Recognizing its various presentations. Postgrad Med 1995; 97:79, 83, 86 passim.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41464/abstract/2\">",
"      Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 2003; 82:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41464/abstract/3\">",
"      Estes D, Christian CL. The natural history of systemic lupus erythematosus by prospective analysis. Medicine (Baltimore) 1971; 50:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41464/abstract/4\">",
"      Fessler BJ, Boumpas DT. Severe major organ involvement in systemic lupus erythematosus. Diagnosis and management. Rheum Dis Clin North Am 1995; 21:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41464/abstract/5\">",
"      McKinley PS, Ouellette SC, Winkel GH. The contributions of disease activity, sleep patterns, and depression to fatigue in systemic lupus erythematosus. A proposed model. Arthritis Rheum 1995; 38:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41464/abstract/6\">",
"      Schwartz JE, Jandorf L, Krupp LB. The measurement of fatigue: a new instrument. J Psychosom Res 1993; 37:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41464/abstract/7\">",
"      Tench CM, McCurdie I, White PD, D'Cruz DP. The prevalence and associations of fatigue in systemic lupus erythematosus. Rheumatology (Oxford) 2000; 39:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41464/abstract/8\">",
"      Jump RL, Robinson ME, Armstrong AE, et al. Fatigue in systemic lupus erythematosus: contributions of disease activity, pain, depression, and perceived social support. J Rheumatol 2005; 32:1699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41464/abstract/9\">",
"      Robb-Nicholson LC, Daltroy L, Eaton H, et al. Effects of aerobic conditioning in lupus fatigue: a pilot study. Br J Rheumatol 1989; 28:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41464/abstract/10\">",
"      Keyser RE, Rus V, Cade WT, et al. Evidence for aerobic insufficiency in women with systemic Lupus erythematosus. Arthritis Rheum 2003; 49:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41464/abstract/11\">",
"      Wang B, Gladman DD, Urowitz MB. Fatigue in lupus is not correlated with disease activity. J Rheumatol 1998; 25:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41464/abstract/12\">",
"      Greco CM, Rudy TE, Manzi S. Adaptation to chronic pain in systemic lupus erythematosus: applicability of the multidimensional pain inventory. Pain Med 2003; 4:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41464/abstract/13\">",
"      Wolfe F, Petri M, Alarc&oacute;n GS, et al. Fibromyalgia, systemic lupus erythematosus (SLE), and evaluation of SLE activity. J Rheumatol 2009; 36:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41464/abstract/14\">",
"      Iaboni A, Ibanez D, Gladman DD, et al. Fatigue in systemic lupus erythematosus: contributions of disordered sleep, sleepiness, and depression. J Rheumatol 2006; 33:2453.",
"     </a>",
"    </li>",
"    <li>",
"     Wallace DJ. Principles of therapy and local measures. In: Dubois' Lupus Erythematosus, 6th edition, Wallace DJ, Hahn BH.  (Eds), Lippincott, Philadelphia 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41464/abstract/16\">",
"      Wallace DJ. Antimalarial agents and lupus. Rheum Dis Clin North Am 1994; 20:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41464/abstract/17\">",
"      Cleanthous S, Tyagi M, Isenberg DA, Newman SP. What do we know about self-reported fatigue in systemic lupus erythematosus? Lupus 2012; 21:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41464/abstract/18\">",
"      Stahl NI, Klippel JH, Decker JL. Fever in systemic lupus erythematosus. Am J Med 1979; 67:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41464/abstract/19\">",
"      Zhou WJ, Yang CD. The causes and clinical significance of fever in systemic lupus erythematosus: a retrospective study of 487 hospitalised patients. Lupus 2009; 18:807.",
"     </a>",
"    </li>",
"    <li>",
"     Rothfield N. Clinical features of systemic lupus erythematosus. In: Textbook of Rheumatology, Kelley WN, Harris ED, Ruddy S, Sledge CB (Eds), Saunders, Philadelphia 1981.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41464/abstract/21\">",
"      Nived O, Sturfelt G, Wollheim F. Systemic lupus erythematosus and infection: a controlled and prospective study including an epidemiological group. Q J Med 1985; 55:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41464/abstract/22\">",
"      Hidalgo-Tenorio C, Jim&eacute;nez-Alonso J, de Dios Luna J, et al. Urinary tract infections and lupus erythematosus. Ann Rheum Dis 2004; 63:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41464/abstract/23\">",
"      Cuchacovich R, Gedalia A. Pathophysiology and clinical spectrum of infections in systemic lupus erythematosus. Rheum Dis Clin North Am 2009; 35:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41464/abstract/24\">",
"      Hellmann DB, Petri M, Whiting-O'Keefe Q. Fatal infections in systemic lupus erythematosus: the role of opportunistic organisms. Medicine (Baltimore) 1987; 66:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41464/abstract/25\">",
"      Zandman-Goddard G, Shoenfeld Y. SLE and infections. Clin Rev Allergy Immunol 2003; 25:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41464/abstract/26\">",
"      Chen HS, Tsai WP, Leu HS, et al. Invasive fungal infection in systemic lupus erythematosus: an analysis of 15 cases and a literature review. Rheumatology (Oxford) 2007; 46:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41464/abstract/27\">",
"      Barber CE, Barnabe C. Another consequence of severe lupus: invasive fungal disease. J Rheumatol 2012; 39:1772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41464/abstract/28\">",
"      Rovin BH, Tang Y, Sun J, et al. Clinical significance of fever in the systemic lupus erythematosus patient receiving steroid therapy. Kidney Int 2005; 68:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41464/abstract/29\">",
"      Romero-D&iacute;az J, Garc&iacute;a-Sosa I, S&aacute;nchez-Guerrero J. Thrombosis in systemic lupus erythematosus and other autoimmune diseases of recent onset. J Rheumatol 2009; 36:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41464/abstract/30\">",
"      Sekigawa I, Yoshiike T, Iida N, et al. Allergic diseases in systemic lupus erythematosus: prevalence and immunological considerations. Clin Exp Rheumatol 2003; 21:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41464/abstract/31\">",
"      Nived O, Johansen PB, Sturfelt G. Standardized ultraviolet-A exposure provokes skin reaction in systemic lupus erythematosus. Lupus 1993; 2:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41464/abstract/32\">",
"      Hess EV, Farhey Y. Epidemiology, genetics, etiology, and environment relationships of systemic lupus erythematosus. Curr Opin Rheumatol 1994; 6:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41464/abstract/33\">",
"      Duffy KN, Duffy CM, Gladman DD. Infection and disease activity in systemic lupus erythematosus: a review of hospitalized patients. J Rheumatol 1991; 18:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41464/abstract/34\">",
"      Granholm NA, Cavallo T. Autoimmunity, polyclonal B-cell activation and infection. Lupus 1992; 1:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41464/abstract/35\">",
"      Pawlak CR, Witte T, Heiken H, et al. Flares in patients with systemic lupus erythematosus are associated with daily psychological stress. Psychother Psychosom 2003; 72:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41464/abstract/36\">",
"      Schur M. Comments on the metapsychology of somatization. The psychoanalytic study of the child. The Psychoanalytic Study of the Child 1955; 10:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41464/abstract/37\">",
"      Ruiz-Irastorza G, Lima F, Alves J, et al. Increased rate of lupus flare during pregnancy and the puerperium: a prospective study of 78 pregnancies. Br J Rheumatol 1996; 35:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41464/abstract/38\">",
"      Guballa N, Sammaritano L, Schwartzman S, et al. Ovulation induction and in vitro fertilization in systemic lupus erythematosus and antiphospholipid syndrome. Arthritis Rheum 2000; 43:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41464/abstract/39\">",
"      S&aacute;nchez-Guerrero J, Karlson EW, Colditz GA, et al. Hair dye use and the risk of developing systemic lupus erythematosus. Arthritis Rheum 1996; 39:657.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4674 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-D34A3220F9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_31_41464=[""].join("\n");
var outline_f40_31_41464=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H914472797\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CONSTITUTIONAL SYMPTOMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Fatigue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Myalgia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Weight changes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Weight loss",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Weight gain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SPECIFIC ORGAN INVOLVEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Arthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Mucocutaneous",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Raynaud phenomenon",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Renal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Gastrointestinal tract",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Pulmonary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Cardiovascular",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Neurologic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Ophthalmologic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Hematologic",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Cytopenia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Thrombophilia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Lymphadenopathy and splenomegaly",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Allergic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Immunologic",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      PRECIPITATING FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H914472797\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/4674\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/4674|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?9/26/9647\" title=\"picture 1A\">",
"      Lupus arthritis swan neck",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?32/59/33727\" title=\"picture 1B\">",
"      Deforming arthritis in SLE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?31/39/32371\" title=\"picture 2A\">",
"      Acute cutaneous lupus erythematosus - malar",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?3/47/3828\" title=\"picture 2B\">",
"      Acute cutaneous lupus erythematosus - malar eruption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?8/11/8372\" title=\"picture 3A\">",
"      Discoid lupus - left ear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?15/56/16261\" title=\"picture 3B\">",
"      Discoid lupus - right cheek",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?15/41/16018\" title=\"picture 4\">",
"      Acute Raynaud phenomenon",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?37/6/37984\" title=\"picture 5\">",
"      Verrucous endocarditis in SLE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?36/63/37887\" title=\"picture 6\">",
"      Purpura in SLE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/4674|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?29/29/30173\" title=\"table 1\">",
"      Symptoms of SLE",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/43/2743?source=related_link\">",
"      Anti-U1 RNP antibodies in mixed connective tissue disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/32/22023?source=related_link\">",
"      Clinical manifestations and diagnosis of scleritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/48/6921?source=related_link\">",
"      Clinical manifestations and diagnosis of the Raynaud phenomenon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/1/11287?source=related_link\">",
"      Clinical manifestations of Sj&ouml;gren's syndrome: Exocrine gland disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/31/23034?source=related_link\">",
"      Clinical manifestations of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/13/28889?source=related_link\">",
"      Coronary heart disease in systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/3/27706?source=related_link\">",
"      Diagnosis and classification of renal disease in systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/16/3338?source=related_link\">",
"      Diagnosis and differential diagnosis of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/5/80?source=related_link\">",
"      Episcleritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/50/5928?source=related_link\">",
"      Gastrointestinal manifestations of systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/49/14106?source=related_link\">",
"      Hematologic manifestations of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/33/36378?source=related_link\">",
"      Mucocutaneous manifestations of systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/12/23753?source=related_link\">",
"      Musculoskeletal manifestations of systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/57/24474?source=related_link\">",
"      Neonatal lupus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/11/33978?source=related_link\">",
"      Neurologic manifestations of systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/46/38631?source=related_link\">",
"      Neuropsychiatric manifestations of systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/59/22456?source=related_link\">",
"      Non-coronary cardiac manifestations of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/49/17177?source=related_link\">",
"      Nonselective NSAIDs: Overview of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/18/32041?source=related_link\">",
"      Overview of heavy proteinuria and the nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/38/41578?source=related_link\">",
"      Overview of the therapy and prognosis of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/16/35081?source=related_link\">",
"      Pathogenesis of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/42/22178?source=related_link\">",
"      Patient information: Lupus (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/49/36626?source=related_link\">",
"      Patient information: Lupus and kidney disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/35/29238?source=related_link\">",
"      Patient information: Systemic lupus erythematosus (SLE) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/45/39641?source=related_link\">",
"      Pregnancy in women with systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/60/11210?source=related_link\">",
"      Pulmonary manifestations of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/12/3273?source=related_link\">",
"      Renal vein thrombosis and hypercoagulable state in nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/49/33561?source=related_link\">",
"      Retinal vasculitis associated with systemic disorders and infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/16/23817?source=related_link\">",
"      Uveitis: Etiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_31_41465="Steroid responsive autoimmune chronic hepatitis - medium power";
var content_f40_31_41465=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F80142&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F80142&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 520px\">",
"   <div class=\"ttl\">",
"    Steroid responsive autoimmune chronic hepatitis (medium power, Masson trichrome)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 500px; height: 365px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An enlarged portal triad with stage II fibrosis and grade 2 inflammation and interface hepatitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marshall M. Kaplan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_31_41465=[""].join("\n");
var outline_f40_31_41465=null;
var title_f40_31_41466="Therapy for metastatic colorectal cancer in elderly patients and those with a poor performance status";
var content_f40_31_41466=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Therapy for metastatic colorectal cancer in elderly patients and those with a poor performance status",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/31/41466/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/31/41466/contributors\">",
"     Hanna K Sanoff, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/31/41466/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/31/41466/contributors\">",
"     Richard M Goldberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/31/41466/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/31/41466/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/31/41466/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 19, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colorectal cancer (CRC) is a leading cause of cancer-related death in the United States and other developed countries. Rarely diagnosed before the age of 40 except in familial CRC syndromes, the incidence of CRC steadily increases with age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/1\">",
"     1",
"    </a>",
"    ]. Approximately 70 percent of cases develop over the age of 65; 40 percent are 75 years or older. The US Census bureau projects that by the year 2030 the number of Americans over age 65 will double [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/2\">",
"     2",
"    </a>",
"    ]. As a result, the number of patients over the age of 70 presenting for CRC care is expected to rise.",
"   </p>",
"   <p>",
"    Although a few patients with metastatic CRC (mCRC) are potentially resectable for cure (particularly those with isolated liver metastases), treatment for most patients is palliative and generally consists of systemic chemotherapy. For decades, 5-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    (5-FU) was the sole active agent. This has changed markedly since the year 2000, with the approval of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    , three humanized monoclonal antibodies that target either vascular endothelial growth factor (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    ) or the epidermal growth factor receptor (EGFR,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"     panitumumab",
"    </a>",
"    ), and most recently, intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/28/37312?source=see_link\">",
"     aflibercept",
"    </a>",
"    , a recombinant fusion protein consisting of vascular endothelial growth factor (VEGF) binding portions from the human VEGF receptors 1 and 2 fused to the Fc portion of human immunoglobulin G1. The best way to combine and sequence these agents is still not established. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/1/44058?source=see_link&amp;anchor=H56909840#H56909840\">",
"     \"Systemic chemotherapy for nonoperable metastatic colorectal cancer: Treatment recommendations\", section on 'Aflibercept'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic review will cover issues related to systemic chemotherapy for nonresectable mCRC in elderly patients and those with a poor performance status. General principles of chemotherapy treatment for mCRC, clinical trials data, and specific treatment recommendations for non-elderly patients are presented elsewhere, as is adjuvant chemotherapy for elderly patients with colon cancer and the management of potentially resectable CRC liver and lung metastases. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/20/21833?source=see_link\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: General principles\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/1/44058?source=see_link\">",
"     \"Systemic chemotherapy for nonoperable metastatic colorectal cancer: Treatment recommendations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/51/11066?source=see_link\">",
"     \"Adjuvant therapy for resected colon cancer in elderly patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41850?source=see_link\">",
"     \"Management of potentially resectable colorectal cancer liver metastases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/15/13560?source=see_link\">",
"     \"Surgical resection of pulmonary metastases: Outcomes by histology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/32/13834?source=see_link\">",
"     \"Surgical resection of pulmonary metastases: Benefits; indications; preoperative evaluation and techniques\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CHALLENGES SPECIFIC TO THE ELDERLY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The essential principles of treating mCRC in the elderly are the same as in younger patients. However, in older patients, who may have age-related organ function decline and medical comorbidity, special attention must be paid to the risks of chemotherapy (both treatment-related toxicity and quality of life [QOL] issues), particularly in the context of estimated life expectancy.",
"   </p>",
"   <p>",
"    The following age-related changes should be considered when assessing the risk of systemic chemotherapy for mCRC. A broader discussion of these issues is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/42/10922?source=see_link\">",
"     \"Systemic chemotherapy for cancer in elderly persons\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Age-related organ function decline",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aging is commonly accompanied by a decline in the function of critical organ systems. This has several implications for elderly patients undergoing chemotherapy for mCRC (",
"    <a class=\"graphic graphic_table graphicRef57349 \" href=\"mobipreview.htm?21/61/22491\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/42/10922?source=see_link&amp;anchor=H3#H3\">",
"     \"Systemic chemotherapy for cancer in elderly persons\", section on 'Age-related organ function decline'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Declining liver and kidney function can alter cancer drug metabolism and elimination.",
"     </li>",
"     <li>",
"      Other organ systems may be at increased risk of organ-specific toxicity.",
"     </li>",
"     <li>",
"      Declining organ function probably underlies age-related loss of physiologic reserve. Older patients with little reserve are at risk for decompensation into a state of increased frailty upon exposure to a severe stressor such as chemotherapy toxicity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following specific organ changes are particularly relevant to assessing the risk of chemotherapy for mCRC in the elderly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Liver",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aging is associated with a decline in hepatic volume and hepatic blood flow [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/3\">",
"     3",
"    </a>",
"    ]. As a result:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Drug metabolism may be slowed, potentially exposing patients to higher drug concentrations for longer periods of time.",
"     </li>",
"     <li>",
"      Patients with a large burden of liver metastases may have a greater than expected degree of hepatic decompensation.",
"     </li>",
"     <li>",
"      In the setting of decreased volume of normal hepatic parenchyma, careful monitoring of liver function is recommended in older patients receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      , particularly prior to resection of colorectal cancer liver metastases, given the known adverse effect of oxaliplatin-associated steatohepatitis. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Liver metastases'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, comorbidities such as alcohol abuse or a history of viral hepatitis may be relevant considerations in treatment decisions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/2/44074?source=see_link&amp;anchor=H8#H8\">",
"     \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\", section on 'Impact of preexisting liver disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Kidney",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glomerular filtration rate (GFR) falls with age. Age-related loss of muscle mass makes the serum creatinine concentration alone a less reliable marker of GFR in older patients. Estimation equations have been derived to estimate GFR based upon clearance of creatinine (Cr Cl). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=see_link&amp;anchor=H20659769#H20659769\">",
"     \"Assessment of kidney function\", section on 'Estimation equations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Of the drugs used to treat mCRC,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    are predominately cleared by the kidneys:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 25 percent dose reduction is recommended for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      in patients who have an estimated Cr Cl of 30 to 50",
"      <span class=\"nowrap\">",
"       mL/min,",
"      </span>",
"      and the drug should be avoided if the estimated Cr Cl is &lt;30",
"      <span class=\"nowrap\">",
"       mL/min.",
"      </span>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41738?source=see_link&amp;anchor=H20#H20\">",
"       \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\", section on 'Capecitabine'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The FDA-approved labeling does not contain renal dosing adjustment guidelines for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      , and at least some data suggest that doses up to 130",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      every three weeks are well tolerated in patients with mild to moderate renal impairment (Cr Cl 20 to 59",
"      <span class=\"nowrap\">",
"       mL/min).",
"      </span>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41738?source=see_link&amp;anchor=H9#H9\">",
"       \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\", section on 'Oxaliplatin'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because of their diminished renal reserve, volume depletion can lead to exaggerated reductions in renal function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/3\">",
"     3",
"    </a>",
"    ]. Thus, careful attention should be paid to fluid management in patients who develop chemotherapy-associated vomiting or diarrhea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Bone marrow",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone marrow reserve diminishes as a part of normal aging, placing older patients at greater risk for severe and prolonged chemotherapy-related cytopenias. Dose reduction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    delay may be necessary; another alternative is the use of hematopoietic growth factor support during treatment.",
"   </p>",
"   <p>",
"    Guidelines from the American Society of Clinical Oncology (ASCO) support primary prophylaxis with myeloid growth factors for chemotherapy regimens that have a risk of febrile neutropenia of approximately 20 percent or more [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/5\">",
"     5",
"    </a>",
"    ]. None of the commonly used combination chemotherapy regimens used for treatment of advanced colorectal cancer (",
"    <a class=\"graphic graphic_table graphicRef64504 \" href=\"mobipreview.htm?5/20/5454\">",
"     table 2",
"    </a>",
"    ) meet this criterion. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/9/33945?source=see_link\">",
"     \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/9/33945?source=see_link&amp;anchor=H523774212#H523774212\">",
"     \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\", section on 'Primary prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Cardiovascular",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal aging is associated with an increasing risk of coronary artery disease, an increased frequency and severity of valvular heart disease, and a decrease in ventricular compliance.",
"   </p>",
"   <p>",
"    Among patients undergoing chemotherapy for mCRC, the possibility of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    induced vasospasm should be considered in patients who develop chest pain or otherwise unexplained decompensated heart failure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/12/40138?source=see_link&amp;anchor=H2#H2\">",
"     \"Cardiotoxicity of nonanthracycline cancer chemotherapy agents\", section on 'Antimetabolites'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cardiovascular toxicity associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    includes left ventricular dysfunction and heart failure, hypertension, and arterial (angina, myocardial infarction, stroke) as well as venous thromboembolic events. The risk for arterial thromboembolic events (ATEs) appears to be highest (17 percent) in patients with a prior history of an ATE and, in some reports, those over age 65 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/6\">",
"     6",
"    </a>",
"    ]. In such patients with a personal history of stroke or active coronary artery disease, the benefit of bevacizumab is likely outweighed by the risk and in most cases should be avoided. Patients over age 65 should be counseled that their risk may be greater than that of the rest of the population. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/12/40138?source=see_link&amp;anchor=H30#H30\">",
"     \"Cardiotoxicity of nonanthracycline cancer chemotherapy agents\", section on 'Bevacizumab'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/36/6730?source=see_link&amp;anchor=H18#H18\">",
"     \"Drug-induced thrombosis and vascular disease in patients with malignancy\", section on 'Bevacizumab'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Comorbid conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients over the age of 75 have an average of five other medical conditions at the time of diagnosis of CRC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. The most common conditions are anemia (often from occult blood loss related to the primary tumor), hypertension, gastrointestinal diagnoses, and heart disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/7\">",
"     7",
"    </a>",
"    ]. Liver and kidney disease place patients at greatest risk of noncancer-related death.",
"   </p>",
"   <p>",
"    For seriously ill patients with severe comorbid illness that results in a short life expectancy (particularly one year or less), the risks of chemotherapy often outweigh its benefits. Most of these patients should receive supportive care rather than chemotherapy, with attention to palliation of symptoms.",
"   </p>",
"   <p>",
"    On the other hand, palliative chemotherapy is reasonable for elderly patients with mCRC who have chronic conditions that are not imminently life threatening.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Quality of life issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Quality of life (QOL) is a crucial component of decision-making when treating older cancer patients. The available data suggest that older patients are just as willing to try chemotherapy as their younger counterparts, but less willing to endure severe treatment-related side effects.",
"   </p>",
"   <p>",
"    There are few data about how chemotherapy affects QOL in older patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. A major issue is whether the higher response rates and generally longer survival seen with modern combination regimens (as compared to a strategy of sequential single agents) are outweighed by the greater likelihood of side effects and adverse impact on QOL. In one of the only trials to address this issue, the MRC FOCUS2 trial, 459 patients who were considered unfit for full-dose chemotherapy because of advanced age alone (29 percent), frailty (32 percent), or both (38 percent) were randomly assigned, using a 2x2 factorial design, to short-term infusional 5-FU plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    with or without oxaliplatin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/10\">",
"     10",
"    </a>",
"    ]. The median age was 74, with 43 percent of patients older than 75, and 13 percent older than 80 years of age; 29 percent had a performance status of 2 (",
"    <a class=\"graphic graphic_table graphicRef72901 \" href=\"mobipreview.htm?9/15/9467\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the factorial comparison, the addition of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      to either fluoropyrimidine was associated with significantly higher response rates and a trend toward better progression-free and overall survival that was not statistically significant. However, the use of oxaliplatin had a detrimental impact on QOL, with significantly fewer patients reporting improved global QOL at week 12 to 14 (49 versus 62 percent, p=0.04).",
"     </li>",
"     <li>",
"      QOL improvement was the primary outcome measure for the comparison of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      versus short-term infusional 5-FU plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      . Rates of improved global QOL at 12 to 14 weeks were the same in both groups (56 percent), despite more treatment-related side effects with capecitabine.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This study is described in more detail below. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Oxaliplatin/5-FU combinations'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H14\">",
"     'Capecitabine'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Measures of physical function and reserve",
"    </span>",
"    &nbsp;&mdash;&nbsp;The previously described age-related changes in physical health vary widely among individuals. Chronological age is a poor marker of a patient's functional status. Several methods of functional assessment are available.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Performance status",
"      </strong>",
"      &ndash; The most common method to measure physiologic reserve and functional status in cancer patients is the clinician estimated performance status (PS). There are two widely used scales, the Eastern Cooperative Oncology Group (ECOG) scale (",
"      <a class=\"graphic graphic_table graphicRef72901 \" href=\"mobipreview.htm?9/15/9467\">",
"       table 3",
"      </a>",
"      ) and Karnofsky Performance Status (KPS) (",
"      <a class=\"graphic graphic_table graphicRef58785 \" href=\"mobipreview.htm?2/11/2236\">",
"       table 4",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      Both the ECOG PS and KPS are useful to assess a patient's ability to tolerate chemotherapy and to assess short-term prognosis. Regardless of age, patients with a poor PS (eg, ECOG PS &gt;2, KPS &lt;60) usually tolerate chemotherapy poorly and have a short median overall survival. However, PS tends to underrepresent the degree of functional impairment in the older patient. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/42/10922?source=see_link&amp;anchor=H24#H24\">",
"       \"Systemic chemotherapy for cancer in elderly persons\", section on 'Assessments of physical function and reserve'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Studies addressing management of patients with mCRC and a poor performance status (who may not necessarily be elderly) are presented below. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Management of patients with a poor performance status'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       ADL and IADL scales",
"      </strong>",
"      &ndash; A more comprehensive understanding of an older patient's functional state can be obtained by use of Activities of Daily Living (ADL) and Instrumental Activities of Daily Living (IADL) scales. ADL refers to the skills that are necessary for basic living, and include feeding, grooming, transferring, and toileting. IADL refers to the skills required to live independently in the community, including shopping, managing finances, housekeeping, preparing meals, and the ability to take medications.",
"     </li>",
"     <li>",
"      <strong>",
"       Comprehensive geriatric assessment",
"      </strong>",
"      &ndash; Assessment of functional status with the ADL and IADL scales is a component of the comprehensive geriatric assessment (CGA) that is used by geriatricians to identify frail older patients at high risk of adverse outcomes such as falls, hospitalization, and death. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/7/28792?source=see_link\">",
"       \"Frailty\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Incorporating a more thorough geriatric assessment of function using the CGA can aid treatment decision-making in older cancer patients. There is no uniform CGA measurement tool, but all include some multidisciplinary assessment of the following domains: physical function, comorbid conditions, psychological state, social support, cognitive function, nutrition, and polypharmacy (",
"      <a class=\"graphic graphic_table graphicRef68620 \" href=\"mobipreview.htm?9/13/9436\">",
"       table 5",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/56/41864?source=see_link\">",
"       \"Comprehensive geriatric assessment for patients with cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Guiding treatment decisions by assessment of physical function",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is general agreement that frail older adults, those with significant functional impairment or an ECOG PS of 3 to 4 (",
"    <a class=\"graphic graphic_table graphicRef72901 \" href=\"mobipreview.htm?9/15/9467\">",
"     table 3",
"    </a>",
"    ), should be supported with palliative measures aimed at maintaining QOL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/11\">",
"     11",
"    </a>",
"    ]. There is also general agreement that active, fit, older patients without comorbidity should be treated in the same fashion as younger patients with mCRC (",
"    <a class=\"graphic graphic_table graphicRef68620 \" href=\"mobipreview.htm?9/13/9436\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The patients who are neither frail nor fit are the patients in whom treatment decision-making is most complex. Their treatment requires excellent communication and individualized care.",
"   </p>",
"   <p>",
"    Validated models have been developed that can be useful in predicting which patients are at increased risk of developing severe or fatal toxicity from chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/12\">",
"     12",
"    </a>",
"    ]. Parameters included within this model include age, type of cancer, the proposed chemotherapy regimen, renal and hematologic function, hearing, and activity levels from the comprehensive geriatric assessment (ability to take medications, physical activity, social activity). These parameters have been combined into a model that can be useful in predicting which patients are at increased risk of developing severe or fatal toxicity from chemotherapy (",
"    <a class=\"graphic graphic_table graphicRef78775 \" href=\"mobipreview.htm?17/51/18237\">",
"     table 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef60649 \" href=\"mobipreview.htm?41/40/42636\">",
"     table 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/12\">",
"     12",
"    </a>",
"    ]. This subject is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/42/10922?source=see_link&amp;anchor=H1242770806#H1242770806\">",
"     \"Systemic chemotherapy for cancer in elderly persons\", section on 'Models predicting chemotherapy toxicity and early death'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SAFETY AND EFFICACY OF CHEMOTHERAPY IN THE ELDERLY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemotherapy for mCRC markedly improves outcomes over supportive cancer alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/13\">",
"     13",
"    </a>",
"    ]. The availability of newer agents (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"     panitumumab",
"    </a>",
"    ), and especially exposure to all active drugs during the course of treatment, has markedly improved response rates, time to progression, median overall survival, and the number of patients able to undergo potentially curative resection of liver metastases.",
"   </p>",
"   <p>",
"    Since the introduction of these newer agents, overall survival has nearly quadrupled [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/14\">",
"     14",
"    </a>",
"    ]. Phase III trials conducted in patients of all ages now commonly report median survivals of over two years (compared to six to eight months prior to the introduction of these agents), and nearly 10 percent of patients are still alive at five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/20/21833?source=see_link\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: General principles\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A similar trend has been seen in the elderly, although of a smaller magnitude than has been seen in analyses of phase III clinical trials which have been conducted primarily in a younger population. An analysis of patients over the age of 65 who received chemotherapy for metastatic colon cancer demonstrated a 6.8 month improvement in life expectancy between 1995 and 2005 that was felt attributable to the introduction of newer chemotherapeutic agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/16\">",
"     16",
"    </a>",
"    ]. However, these drugs are expensive, and the cost per life-year gained was $66,200, and the cost per quality adjusted life year gained was nearly $100,000, a cost-effectiveness ratio that is below commonly cited estimates of \"willingness to pay\" for a life-year gained. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/30/26087?source=see_link&amp;anchor=H9#H9\">",
"     \"A short primer on cost-effectiveness analysis\", section on 'Cost-effectiveness ratio'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/20/21833?source=see_link&amp;anchor=H183911606#H183911606\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: General principles\", section on 'Chemotherapy versus supportive care'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite the demonstrated benefits of these new agents, the available evidence suggests that fewer elderly patients receive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    as a component of initial therapy as compared to younger individuals, presumably because of toxicity concerns [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/17\">",
"     17",
"    </a>",
"    ]. In some trials, elderly patients receiving chemotherapy for mCRC have been more susceptible to toxicity, particularly diarrhea and neutropenia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/18-21\">",
"     18-21",
"    </a>",
"    ], although this is not a universal finding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/22-25\">",
"     22-25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of the small number of older patients enrolled in clinical trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/26,27\">",
"     26,27",
"    </a>",
"    ], good quality evidence about safety and efficacy of chemotherapy in older patients with CRC has come mainly from subgroup analyses of pooled data from large phase III clinical trials performed both in the adjuvant and metastatic disease settings. These pooled analyses and other trials of various chemotherapy regimens in combined populations suggest that older patients have similar efficacy from chemotherapy for CRC as do younger patients, usually with only minor differences in rates of severe toxicity (",
"    <a class=\"graphic graphic_table graphicRef76722 \" href=\"mobipreview.htm?13/1/13341\">",
"     table 8",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/11,28-32\">",
"     11,28-32",
"    </a>",
"    ]. However, in general, patients in these trials have been fit and uniformly of good performance status.",
"   </p>",
"   <p>",
"    Phase II and III trials of chemotherapy for mCRC are beginning to be conducted in elderly patients, but the patients enrolled in these trials are usually fit and have a good performance status. It is unclear that any of these data can be extrapolated to less fit older patients. Nevertheless, these are the best data that are available.",
"   </p>",
"   <p>",
"    The following sections will review the available data from both pooled analyses and clinical trials that specifically address the benefits and side effects of different options for chemotherapy of mCRC in elderly patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Single agent fluorouracil",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"     Fluorouracil",
"    </a>",
"    (5-FU) alone or when given with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    modulation is consistently tolerable in older patients, and efficacy is similar to that in younger patients.",
"   </p>",
"   <p>",
"    Efficacy was addressed in a retrospective analysis of 629 patients over the age of 70 who were treated on 22 phase II or III trials of 5-FU with or without modulators (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    , interferon, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/28\">",
"     28",
"    </a>",
"    ]. There were 484 patients aged 70 and 75, 125 aged 75 to 80, and 20 older than 80. Response rates and survival durations among elderly patients were similar to those of younger individuals, with infusional 5-FU regimens having a higher response rate than bolus regimens.",
"   </p>",
"   <p>",
"    The results of this pooled analysis have been replicated by a number of other investigators in population-based studies, other pooled analyses, and a few phase II studies conducted exclusively in the elderly with mCRC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/19,33-35\">",
"     19,33-35",
"    </a>",
"    ]. In general, older patients derive as much benefit as younger individuals, the incidence of severe neutropenia is only slightly higher in older patients, and there is no increase in other severe complications with age.",
"   </p>",
"   <p>",
"    The schedule of administration impacts on toxicity:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A subgroup analysis of one study that used 5-FU and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      administered by bolus dose daily for five days once per month (the so-called Mayo regimen) found that patients over age 70 were significantly more likely to experience severe treatment-related toxicity including diarrhea (24 versus 14 percent), leukopenia (24 versus 10 percent), and treatment-related death (9 versus 2 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast, short-term infusional 5-FU with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      (the de Gramont schedule) is particularly well tolerated in the elderly, and is preferred over bolus administration, where feasible [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/36\">",
"       36",
"      </a>",
"      ]. The need for central venous access and an ambulatory infusion pump may be a limiting factor. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link&amp;anchor=H11#H11\">",
"       \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'Optimizing the schedule and dose'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Capecitabine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Largely based upon the convenience of oral dosing,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    is routinely used for treatment of advanced CRC in older patients; however, it appears to be associated with more treatment-related side effects than is short-term infusional 5-FU plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    . A number of small elderly-specific trials in mCRC have found capecitabine monotherapy to be fairly well tolerated in fit elderly patients with a similar or slightly better efficacy than expected with 5-FU given in bolus regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/37-41\">",
"     37-41",
"    </a>",
"    ]. As an example, a Spanish trial of 51 patients aged 70 or older with mCRC who were considered ineligible for combination chemotherapy used capecitabine 1250",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    twice daily for 14 of every 21 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/41\">",
"     41",
"    </a>",
"    ]. The overall response rate was 24 percent, and grade 3 or 4 adverse events were noted only in six patients (12 percent).",
"   </p>",
"   <p>",
"    Treatment-related toxicity may be more prominent in the oldest old, and in less fit elderly patients, as illustrated by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a combined analysis of data from phase III trials, a higher incidence of grade 3 or 4 adverse effects (largely diarrhea, but also hand-foot syndrome) was seen in patients &ge;80 compared to the overall population (60 versus 40 percent), particularly diarrhea (31 versus 13 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/42\">",
"       42",
"      </a>",
"      ]. The specific dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      was not given.",
"     </li>",
"     <li>",
"      In the MRC FOCUS2 trial described above, 459 patients who were considered unfit for full-dose chemotherapy because of age, frailty, or both were randomly assigned, using a 2x2 factorial design, to short-term infusional 5-FU plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      with or without oxaliplatin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/10\">",
"       10",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Quality of life issues'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Starting doses were reduced by 20 percent in all groups, with dose escalation to 100 percent of standard dose allowed at six weeks provided no grade 2 or worse toxic effects. The patients in the capecitabine alone arm began treatment at 1000",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      twice daily on days 1 to 15 every 21 days.",
"      <br/>",
"      <br/>",
"      The following findings were noted in the factorial comparison of capecitabine versus short-term infusional 5-FU plus leucovorin:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      QOL improvement was the primary outcome measure for the comparison of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      versus short-term infusional 5-FU plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      . Rates of improved global QOL at 12 to 14 weeks were the same in both groups (56 percent).",
"     </li>",
"     <li>",
"      There was no evidence that substitution of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"       fluorouracil",
"      </a>",
"      with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      had an effect on response rates (23 versus 24 percent with capecitabine and 5-FU-based regimens, respectively), response duration, or overall survival.",
"     </li>",
"     <li>",
"      Compared with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"       fluorouracil",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      significantly increased the risk of a grade 3 or worse toxicity, and was specifically associated with higher rates of nausea, vomiting, diarrhea, anorexia, and hand-foot syndrome. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    monotherapy appears to be an equally effective, albeit more toxic substitute for 5-FU in fit elderly patients with mCRC, at least for those under the age of 80.",
"   </p>",
"   <p>",
"    The appropriate dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    is not well defined, at least for American patients. As in the MRC FOCUS2 trial described above, many clinicians start with 1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    rather than 1250",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    twice daily, and dose-escalate to tolerance. Additional data on the use of capecitabine as a substitute for short-term infusional 5-FU in combination regimens in the elderly are discussed below. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Substituting capecitabine for 5-FU in combinations'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Oral cytotoxics such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    require patients to make decisions regarding the safety of taking a dose in light of ongoing adverse effects such as diarrhea and hand-foot syndrome. This shifts the burden of treatment decisions from provider to the patient, which may be difficult for some older patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Oxaliplatin/5-FU combinations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The results of pooled and subgroup analyses of phase III trials and phase II trials conducted exclusively in older patients suggest that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    plus short-term infusional 5-FU and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    (FOLFOX, (",
"    <a class=\"graphic graphic_table graphicRef64504 \" href=\"mobipreview.htm?5/20/5454\">",
"     table 2",
"    </a>",
"    )) is just as effective and well tolerated in fit older patients who are enrolled on clinical trials as in younger individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/11,30,31,44,45\">",
"     11,30,31,44,45",
"    </a>",
"    ], although rates of side effects may be slightly higher in older patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. One analysis of elderly patients with CRC who were treated in the community concluded that individuals age 70 and older had higher rates of nausea, neutropenia, and neuropathy with an oxaliplatin-containing regimen as compared to those treated with a fluoropyrimidine alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The benefit of an",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    as compared to a non-oxaliplatin-containing regimen in less fit patients was directly addressed in the MRC FOCUS2 trial, described above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Quality of life issues'",
"    </a>",
"    above.) Briefly, 459 patients who were considered unfit for full-dose chemotherapy because of age, frailty, or both were randomly assigned, using a 2x2 factorial design, to short-term infusional 5-FU plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    with or without oxaliplatin, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    with or without oxaliplatin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/10\">",
"     10",
"    </a>",
"    ]. Starting doses were reduced by 20 percent in all groups, with dose escalation to 100 percent of standard dose allowed at six weeks provided no grade 2 or worse toxic effects. In the comparison of FOLFOX versus short-term infusional 5-FU and leucovorin alone (the de Gramont regimen), the following were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      FOLFOX was associated with a significantly higher objective response rate (38 versus 11 percent) and disease control rate (objective response plus stable disease, 71 versus 467 percent).",
"     </li>",
"     <li>",
"      There was a trend toward longer median progression-free (5.8 versus 3.5 months) and overall survival (10.7 versus 10.1 months) with FOLFOX, which was not statistically significant.",
"     </li>",
"     <li>",
"      The overall risk of having a grade 3 or worse toxic effect during the first 12 weeks of treatment was slightly higher for FOLFOX (33 versus 27 percent). In the factorial comparison of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      -containing versus non-oxaliplatin-containing chemotherapy, use of oxaliplatin was associated with significantly higher rates of grade 3 or worse diarrhea, neurosensory toxicity, nausea, vomiting, and neutropenia compared with no use of oxaliplatin. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, the available data suggest that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    combination regimens with short-term 5-FU and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    are as effective in older as compared to younger individuals and relatively well tolerated in the fit elderly. The benefits of an oxaliplatin-containing regimen may not outweigh the risks in less fit elderly patients who are considered poor candidates for full-dose chemotherapy. Additional data on combination regimens substituting",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    for short-term infusional 5-FU are discussed below. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Substituting capecitabine for 5-FU in combinations'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/45/10963?source=see_link\">",
"     \"Treatment protocols for colorectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Irinotecan/5-FU combinations",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/25,47-50\">",
"     25,47-50",
"    </a>",
"    ] but not all [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/51\">",
"     51",
"    </a>",
"    ] studies, combinations of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    with infusional FU and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    (eg, FOLFIRI, (",
"    <a class=\"graphic graphic_table graphicRef76300 \" href=\"mobipreview.htm?19/2/19502\">",
"     table 9",
"    </a>",
"    )) have been well tolerated in older patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The safety and efficacy in elderly as compared to younger patients was addressed in a pooled analysis of 1259 (19 percent &ge;70) patients treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      with either bolus FU (IFL) or short-term infusional 5-FU (FOLFIRI) for mCRC [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/47\">",
"       47",
"      </a>",
"      ]. There were no age-related differences in response rate, time to progression, or survival (median 17 versus 18 months for older and younger patients, respectively). There were no age-related increases in diarrhea, infection, or other severe adverse events.",
"     </li>",
"     <li>",
"      The benefit and toxicity of adding",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      to",
"      <span class=\"nowrap\">",
"       5-FU/",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"        leucovorin",
"       </a>",
"      </span>",
"      in the elderly was directly addressed in a trial in which 166 patients &ge;75 years of age were randomly assigned to short-term infusional 5-FU and leucovorin with or without irinotecan (150",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      for cycles 1 and 2, with the dose increased to 180",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      thereafter if tolerated) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/50\">",
"       50",
"      </a>",
"      ]. In a preliminary report of an interim analysis, overall response rate were higher with FOLFIRI (31 versus 18 percent), but so was grade 3 or 4 toxicity (neutropenia in 28 versus 1 percent with",
"      <span class=\"nowrap\">",
"       5-FU/leucovorin,",
"      </span>",
"      diarrhea in 16 versus 0 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Regimens combining",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    with bolus 5-FU and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    (eg, IFL) are even more toxic. An investigation into early deaths in patients treated on North Central Cancer Treatment Group (NCCTG) N9741 and Cancer and Leukemia Group B (CALGB) 89803 trials suggested that age was a potential risk factor for early treatment-related death in patients receiving IFL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Results from the randomized phase III BICC-C study also support the use of infusional as compared to bolus",
"    <span class=\"nowrap\">",
"     5-FU/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"      leucovorin",
"     </a>",
"    </span>",
"    in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    . In period 2 of that trial, 117 patients with mCRC received either FOLFIRI or a modified IFL bolus regimen, both with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    . In a subset analysis of older (&ge; age 70) versus younger patients, median PFS and overall survival were both longer in the FOLFIRI group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/32\">",
"     32",
"    </a>",
"    ]. Rates of grade 3 or higher toxicity did not differ significantly by age group. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link&amp;anchor=H24#H24\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'Irinotecan plus capecitabine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Taken together, these studies suggest that",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"      irinotecan",
"     </a>",
"     /FU",
"    </span>",
"    regimens are relatively safe for the elderly, but administration with infusional rather than bolus 5-FU is preferred. Combinations of irinotecan with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    are discussed below. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'XELIRI'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Single agent irinotecan",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     Irinotecan",
"    </a>",
"    is active as monotherapy. In some trials, older age is a risk factor for severe (grade 3 or 4) diarrhea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/53-55\">",
"     53-55",
"    </a>",
"    ]. As an example, in a phase III comparison of weekly (125",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    versus every three week (300",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    for those over the age of 70, otherwise 350",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    dosing of single agent irinotecan, patients over age 70 had 1.8 times the odds of severe diarrhea than younger patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/55\">",
"     55",
"    </a>",
"    ]. They were also twice as likely to have severe neutropenia. The authors did not comment on rates of infection or hospitalization by age, or what proportion of the patients with grade 5 (fatal) chemotherapy toxicity were elderly.",
"   </p>",
"   <p>",
"    The manufacturer's FDA-approved package insert recommends reducing the initial dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    in patients aged &gt;70 (300",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    rather than 350",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every three weeks). However, this practice is not uniformly supported by more recent data. Excessive toxicity was not seen in a trial of second-line irinotecan (350",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    once every three weeks) in 339 patients with mCRC (72 age 70 or older) who were progressing on a fluoropyrimidine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/56\">",
"     56",
"    </a>",
"    ]. Older patients had comparable efficacy, and toxicity (including diarrhea) was not worse as compared to younger individuals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Substituting capecitabine for 5-FU in combinations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple trials that substitute the oral fluoropyrimidine",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    for IV 5-FU in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    <span class=\"nowrap\">",
"     (XELOX/CAPOX)",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef64504 \" href=\"mobipreview.htm?5/20/5454\">",
"     table 2",
"    </a>",
"    ) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    <span class=\"nowrap\">",
"     (XELIRI/CAPIRI)",
"    </span>",
"    have reported efficacy and safety in fit elderly patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/30,57-62\">",
"     30,57-62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     XELOX",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy and safety of XELOX in fit elderly patients has been addressed in several trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two phase II trials enrolled exclusively elderly patients:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A Spanish trial administered",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      (130",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on day 1) followed by",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      (1000",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      twice daily for 14 of every 21 days) for first-line therapy of mCRC in 50 patients age 70 or older [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/59\">",
"       59",
"      </a>",
"      ]. The response rate was 36 percent, and median time to tumor progression (TTP) and overall survival were 6 and 13 months, respectively. Treatment was relatively well tolerated. Grade 3 or 4 adverse events included diarrhea (22 percent), asthenia (16 percent), nausea and vomiting (14 percent), neutropenia or thrombocytopenia (6 percent), and hand-foot syndrome (4 percent). There was one treatment-related death. Comparable results were reported in an Italian study of a similar regimen in 76 patients &ge;age 70 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/58\">",
"       58",
"      </a>",
"      ]. The starting dose of capecitabine was 1000",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      twice daily with dose escalation permitted to 1250",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      twice daily in the absence of toxicity; the initial oxaliplatin dose was 85",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       ,",
"      </span>",
"      with escalation to 110",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       ,",
"      </span>",
"      or even 130",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      if tolerated.",
"      <br/>",
"      <br/>",
"      The overall response rate was 41 percent, and median progression-free survival (PFS) and overall survival were 9 and 14 months, respectively. Only 5 percent of patients developed grade 3 or 4 hematologic toxicity during treatment, 8 percent developed grade 3 neuropathy, and 13 percent had severe hand foot syndrome.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The previously described randomized phase III trial of first-line",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      plus either short term weekly infusional 5-FU or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      included 109 patients 70 years of age or older and 233 younger individuals [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/30\">",
"       30",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Oxaliplatin/5-FU combinations'",
"      </a>",
"      above.) The objective response rates for XELOX in older and younger patients were 35 and 45 percent, respectively, and median overall survival was 17 versus 21 months; neither difference was statistically significant. Within the XELOX group, the only statistically significant toxicity difference between older and younger patients was a higher rate of grade 3 or 4 diarrhea (25 versus 8 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The efficacy and risks of XELOX in less fit elderly patients were addressed in the previously described MRC FOCUS2 trial, described above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Quality of life issues'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Briefly, 459 patients who were considered unfit for full-dose chemotherapy because of age, frailty, or both were randomly assigned, using a 2x2 factorial design, to short-term infusional 5-FU plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    with or without oxaliplatin. Starting doses were reduced by 20 percent in all groups, with dose escalation to 100 percent of standard dose allowed at six weeks provided no grade 2 or worse toxic effects. The patients randomly assigned to XELOX started with capecitabine 800",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    twice daily on days 1 to 15, and oxaliplatin 104",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on day 1, with cycles repeated every 21 days.",
"   </p>",
"   <p>",
"    The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Compared to FOLFOX, the use of XELOX was associated with a slightly lower objective response rate (32 versus 38 percent) and overall disease control rate (objective response plus stable disease, 65 versus 71 percent), identical progression-free survival (5.8 months in each group), and a trend toward longer median overall survival that was not statistically significant (12.4 versus 10.7 months).",
"     </li>",
"     <li>",
"      From the standpoint of toxicity, the overall risk of having a grade 3 or worse event was higher with XELOX than FOLFOX (43 versus 33 percent). In the factorial comparison of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      versus 5-FU-contioning chemotherapy, capecitabine was specifically associated with higher rates of nausea, vomiting, diarrhea, anorexia, and hand-foot syndrome. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Taken together, these data suggest that for fit elderly patients, XELOX is an effective alternative, albeit with somewhat higher rates of grade 3 or 4 toxicities, as compared to regimens that combine",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    with short-term infusional 5-FU. For less fit individuals, it is unclear whether the risks of substituting",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    for short-term infusional 5-FU in combination with oxaliplatin outweigh the benefits.",
"   </p>",
"   <p>",
"    The appropriate dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    to use in the XELOX regimen is not established. While the two European trials described above used 1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    twice daily for 14 days, this dose is higher than most American patients can tolerate. We generally start with 850",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    twice daily in fit elderly patients and start with 800",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    twice daily in less fit or very old patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/45/10963?source=see_link\">",
"     \"Treatment protocols for colorectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     XELIRI",
"    </span>",
"    &nbsp;&mdash;&nbsp;XELIRI (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    ) produced inferior outcomes compared to FOLFIRI (",
"    <a class=\"graphic graphic_table graphicRef64504 \" href=\"mobipreview.htm?5/20/5454\">",
"     table 2",
"    </a>",
"    ) as first-line therapy in the randomized BICC-C trial. In the original report, compared to FOLFIRI alone,",
"    <span class=\"nowrap\">",
"     capecitabine/irinotecan",
"    </span>",
"    was associated with significantly higher rates of nausea, vomiting, diarrhea, febrile neutropenia, and dehydration as well as significantly worse PFS and a trend towards inferior median survival. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link&amp;anchor=H24#H24\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'Irinotecan plus capecitabine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a later subanalysis of elderly (&gt;70 years of age) versus nonelderly patients enrolled in the trial, elderly patients had significantly higher rates of asthenia and dehydration with XELIRI compared to their younger counterparts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/32\">",
"     32",
"    </a>",
"    ]. Similar high rates of toxicity with XELIRI have been seen by others despite the use of lower starting doses of both drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/61,63\">",
"     61,63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, because of concerns as to efficacy and safety, XELIRI should probably not be used as a substitute for FOLFIRI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;XELOX is a reasonable substitute for FOLFOX in the fit elderly. However, XELOX is not necessarily less toxic, more convenient, or less expensive than FOLFOX for the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The appropriate dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      is not well defined, at least for American patients.",
"     </li>",
"     <li>",
"      A central venous access line is often needed for reasons other than infusional 5-FU in patients with mCRC. Because a significant number of patients report local pain when",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      is infused via peripheral vein, many centers routinely infuse the drug centrally.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These issues are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/1/44058?source=see_link&amp;anchor=H13#H13\">",
"     \"Systemic chemotherapy for nonoperable metastatic colorectal cancer: Treatment recommendations\", section on 'XELOX'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of both efficacy and toxicity concerns, the combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    should NOT be used as a substitute for FOLFIRI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Targeted therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to the growing evidence about the safety and efficacy of combination chemotherapy in fit older patients, few data are available in such patients concerning the use of the currently approved biologic agents:",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/28/37312?source=see_link\">",
"     aflibercept",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"     panitumumab",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/16/32006?source=see_link\">",
"     regorafenib",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Bevacizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     Bevacizumab",
"    </a>",
"    is a humanized monoclonal antibody targeting VEGF. Adding bevacizumab to regimens containing a fluoropyrimidine,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    improves response rates, PFS, and survival. However, these advances have come with a cost of treatment-related side effects, including bleeding, hypertension, proteinuria, bowel perforation, arterial thromboembolic events, and wound healing complications. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link&amp;anchor=H44#H44\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'Agents targeting VEGF'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43882?source=see_link\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36538?source=see_link\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The arterial thromboembolic events (ATEs) have been of greatest concern for treatment of the elderly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/6,64-72\">",
"     6,64-72",
"    </a>",
"    ]. The following studies address issues of toxicity and efficacy of adding",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    to chemotherapy for elderly patients with mCRC:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An analysis of 2526 patients over age 65 with stage IV colorectal cancer derived from the linked",
"      <span class=\"nowrap\">",
"       SEER/Medicate",
"      </span>",
"      database found a modest improvement in outcomes when",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      was added to chemotherapy (hazard ratio [HR] for death 0.85, 95% CI 0.78-0.93), although subset analysis demonstrated little to no benefit among patients receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      -based regimens (HR 0.96, 95% CI 0.86-1.07) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/72\">",
"       72",
"      </a>",
"      ]. The addition of bevacizumab significantly increased the risk of stroke (4.9 versus 2.5 percent with chemotherapy alone) but not venous thrombotic events.",
"      <br/>",
"      <br/>",
"      A later analysis of a larger data set from the linked",
"      <span class=\"nowrap\">",
"       SEER/Medicare",
"      </span>",
"      database found a lower three-year incidence of ATEs in elderly patients treated with bevacizumab (165 cases out of 6370 mCRC patients with no history of a prior ATE, 2.6 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/73\">",
"       73",
"      </a>",
"      ]. Although use of bevacizumab was associated with a significantly higher risk of an ATE compared to no bevacizumab use (HR 1.82, 95% CI 1.20-2.76), the absolute incidence rates of ATE were 15.9 versus 12.4 per 1000 person-years followup, thus reflecting an excess risk of only 3.5 additional cases per 1000 person-years.",
"     </li>",
"     <li>",
"      In a report from the BRiTE registry that included 896 patients &ge;65 years of age, the incidence of ATE was higher among elderly as compared to nonelderly patients receiving first-line",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      -containing chemotherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/74\">",
"       74",
"      </a>",
"      ]. Unadjusted rates of ATEs per 100 patient-years were 4.8, 4.0, 1.4 and 1.4 in patients &ge;80, 75 to &lt;80, 65 to &lt;75, and &lt;65 years of age, respectively. However, ECOG performance status, anticoagulation therapy, a history of hypertension requiring medication, and arterial disease history were stronger prognostic factors for ATE than was older age.",
"     </li>",
"     <li>",
"      In a randomized phase II trial of 5-FU with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      in 209 patients with mCRC who were not considered candidates for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      (168 of whom were &ge;65 years of age), the use of bevacizumab significantly improved outcomes (response rates and PFS) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/66\">",
"       66",
"      </a>",
"      ]. Grade 3 hypertension (which could be controlled with medication) was more common with bevacizumab (16 versus 3 percent), and ATEs developed in twice as many patients treated with bevacizumab, although the incidence was low overall (10 versus 5 cases).",
"     </li>",
"     <li>",
"      Two separate randomized trials examining the benefit of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      with and without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      have both concluded that the addition of bevacizumab improved efficacy and was safe in elderly patients:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The Australasian Gastrointestinal Trials Group MAX trial noted a significant 3.2 month longer PFS and a trend toward longer overall survival (15.7 versus 13.4 months, p=0.16) among a subgroup of patients &gt;75 years of age who were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      in combination with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      versus capecitabine alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/75\">",
"       75",
"      </a>",
"      ]. There was no indication of increased toxicity from bevacizumab in older individuals when compared to those &lt;75 years of age, including thromboembolic events.",
"     </li>",
"     <li>",
"      In the multi-center AVEX trial, 280 patients age 70 or older with previously untreated mCRC were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/76\">",
"       76",
"      </a>",
"      ]. In a preliminary report presented at the 2013 ASCO GI Cancers Symposium, combined therapy was associated with significantly longer median PFS (the primary endpoint, 9.1 versus 5.1 months) and a non-significant trend toward longer overall survival (median 21 versus 17 months). However, there were significantly more events leading to treatment discontinuation in the bevacizumab arm (25 versus 14 percent), and higher rates of all-grade hemorrhage (25 versus 7 percent), hypertension (19 versus 5 percent), and venous thromboembolic events (12 versus 4 percent, grade 3 or higher, 8 versus 4 percent). Although rates of grade 5 (fatal) toxicities were not higher with bevacizumab (8.2 versus 11.8 percent with capecitabine alone), they were higher than expected in both groups. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hypertension is also of concern; older age is considered a risk factor for adverse consequences of elevated blood pressure in patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/77\">",
"     77",
"    </a>",
"    ]. Guidelines for pretreatment risk assessment, surveillance, and treatment of hypertension in patients receiving VEGF pathway signaling inhibitors are available (",
"    <a class=\"graphic graphic_table graphicRef73373 \" href=\"mobipreview.htm?22/7/22652\">",
"     table 10",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef63338 \" href=\"mobipreview.htm?32/36/33356\">",
"     table 11",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36538?source=see_link&amp;anchor=H21639449#H21639449\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects\", section on 'Hypertension'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Caution (and informed consent) is warranted when prescribing the drug in combination with chemotherapy for elderly patients, particularly those with a history of atherosclerotic cardiovascular disease. The risks probably outweigh the benefits in patients with a history of stroke or myocardial infarction within the preceding 6 to 12 months, or a history of thromboembolic disease, and the drug is contraindicated in patients with severe uncontrolled hypertension. The supportive data are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36538?source=see_link&amp;anchor=H291526440#H291526440\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects\", section on 'Arterial thromboembolic events'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36538?source=see_link&amp;anchor=H21639449#H21639449\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects\", section on 'Hypertension'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26272734\">",
"    <span class=\"h3\">",
"     Aflibercept",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/28/37312?source=see_link\">",
"     Aflibercept",
"    </a>",
"    (VEGF Trap, Zaltrap&reg;) is a recombinant fusion protein consisting of VEGF binding portions from key domains of human VEGF receptors 1 and 2 fused to the Fc portion of human immunoglobulin G1. It acts as a soluble &ldquo;decoy&rdquo; receptor that binds to human VEGF-A, VEGF-B, and placental growth factor (PIGF), thereby inhibiting the binding of these ligands and activation of their respective receptors.",
"    <br/>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/28/37312?source=see_link\">",
"     Aflibercept",
"    </a>",
"    is approved in the United States for use in combination with FOLFIRI for the treatment of patients with mCRC that is resistant to or has progressed following an",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    -containing regimen. Approval was based on the placebo-controlled VELOUR trial, in which 1226 patients with oxaliplatin-refractory mCRC were randomly assigned to aflibercept (4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV) or placebo, plus FOLFIRI, every two weeks until progression. In a preliminary report presented at the 2011 meeting of the European Society of Medical Oncology (ESMO), median overall survival was significantly longer in patients treated with aflibercept (13.5 versus 12.1 months) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/78\">",
"     78",
"    </a>",
"    ]. Benefit and safety were similar regardless of prior",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    exposure. While the side effect profile of aflibercept was consistent with other agents targeting VEGF (bleeding, hypertension, proteinuria, wound infection, arterial thromboembolic events), rates of diarrhea, mucositis, complicated neutropenia, infection, and fatigue associated with aflibercept in this trial were higher than usually seen with bevacizumab, as were rates of treatment discontinuation for toxicity or refusal (30 versus 12 percent). The VELOUR trial enrolled patients over the age of 65, and in a preliminary subgroup analysis presented at the 2011 meeting of ESMO, the survival benefit was similar in older as compared to younger individuals; a breakdown of toxicities according to age was not provided [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/79\">",
"     79",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link&amp;anchor=H23212877#H23212877\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'Aflibercept'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The optimal way to integrate",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/28/37312?source=see_link\">",
"     aflibercept",
"    </a>",
"    into treatment of elderly patients with mCRC is unclear. Particularly given the data on benefit from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    after progression on a first-line bevacizumab-containing regimen, whether aflibercept plus second-line FOLFORI is the preferred approach after progression on first-line FOLFOX plus bevacizumab is unclear. In our view, FOLFORI plus aflibercept is an alternative to FOLFIRI alone or FOLFIRI with bevacizumab in this setting. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/1/44058?source=see_link&amp;anchor=H29#H29\">",
"     \"Systemic chemotherapy for nonoperable metastatic colorectal cancer: Treatment recommendations\", section on 'Continuation of bevacizumab beyond progression'",
"    </a>",
"    .) &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    As with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    , because of the risk of impaired wound healing, bowel perforation, and fistula formation, at least 28 days should elapse between major surgery and administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/28/37312?source=see_link\">",
"     aflibercept",
"    </a>",
"    , except in emergency situations. This recommendation does not apply to minor procedures such as implantation of a venous access device. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43882?source=see_link&amp;anchor=H1651227429#H1651227429\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\", section on 'Delayed wound healing'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43882?source=see_link&amp;anchor=H1651227451#H1651227451\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\", section on 'Intestinal perforation/fistula formation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Cetuximab and panitumumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two monoclonal antibodies targeting the EGFR are active in the treatment of mCRC,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"     panitumumab",
"    </a>",
"    . Few clinical trials have addressed the safety and efficacy of these drugs in older patients; however, there are no readily apparent safety concerns about their use:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective series of 56 patients over the age of 70 (median age 76) who received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"       cetuximab",
"      </a>",
"      with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      for heavily pretreated mCRC found no unexpected toxicities [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/80\">",
"       80",
"      </a>",
"      ]. Skin rash occurred in 75 percent of treated patients (11 percent grade 3), and diarrhea in 80 percent (20 percent grade 3 or 4). The authors concluded that efficacy was similar to that expected in younger individuals and that tolerability of cetuximab was acceptable in elderly patients.",
"     </li>",
"     <li>",
"      Similar conclusions were reached in an analysis of 657 patients (305 &ge;65 years old) receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"       cetuximab",
"      </a>",
"      plus chemotherapy for treatment of metastatic colorectal cancer and were registered into an observational database in Germany [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/81\">",
"       81",
"      </a>",
"      ]. Efficacy was comparable in older as compared to younger individuals, and the prevalence of side effects was similar, although there was a trend toward higher grade and duration of both dermatologic and non-dermatologic toxicity in older individuals.",
"     </li>",
"     <li>",
"      In contrast, a higher rate of acneiform rash was noted in a phase II trial of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"       cetuximab",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      in 66 elderly patients with previously untreated mCRC (30 percent grade 3 or 4) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/82\">",
"       82",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/6/9322?source=see_link\">",
"       \"Acneiform eruption secondary to epidermal growth factor (EGFR) inhibitors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In the registration trial of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"       panitumumab",
"      </a>",
"      compared with best supportive care, a stratified analysis by age found those over 65 received a similar degree of PFS benefit as did those younger than 65 (HR &gt;65, 0.60; HR &lt;65, 0.51) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/83\">",
"       83",
"      </a>",
"      ]. Toxicity information was not reported.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The benefit of adding an anti-EGFR agent to first-line chemotherapy of mCRC is addressed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/1/44058?source=see_link&amp;anchor=H32#H32\">",
"     \"Systemic chemotherapy for nonoperable metastatic colorectal cancer: Treatment recommendations\", section on 'Cetuximab or panitumumab as a component of initial therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All patients being considered for anti-EGFR therapy should undergo K-ras mutation testing of their tumors; treatment with these agents should be restricted to those with wild-type K-ras [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/84\">",
"     84",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/1/44058?source=see_link&amp;anchor=H31#H31\">",
"     \"Systemic chemotherapy for nonoperable metastatic colorectal cancer: Treatment recommendations\", section on 'Predictive markers for response'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8633571\">",
"    <span class=\"h3\">",
"     Regorafenib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/16/32006?source=see_link\">",
"     Regorafenib",
"    </a>",
"    is an orally active inhibitor of angiogenic (including the VEGF receptors 1 to 3) receptor tyrosine kinases and other kinases that is approved in the United States for the treatment of patients with mCRC who have been previously treated with fluoropyrimidine-,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    -, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    -based chemotherapy, an anti-VEGF agent, and, if K-ras wild type, an anti-EGFR therapy. Approval was based upon the results of the CORRECT trial, which compared best supportive care plus regorafenib (160 mg orally once daily for three of every four weeks) or placebo in 760 patients with chemotherapy refractory disease, and demonstrated a significant survival benefit for regorafenib (median 6.4 versus 5 months), albeit with little objective antitumor response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/16/32006?source=see_link\">",
"     regorafenib",
"    </a>",
"    shares many of the same side effects as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/28/37312?source=see_link\">",
"     aflibercept",
"    </a>",
"    , including hemorrhage, bowel perforation, and hypertension, it is not yet clear whether there is an increased incidence of blood clots with this agent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36538?source=see_link\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43882?source=see_link\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other reported side effects in the CORRECT trial were fatigue, diarrhea, hand-foot skin reaction, and liver failure. There are no published data on the safety or efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/16/32006?source=see_link\">",
"     regorafenib",
"    </a>",
"    in the elderly; however, a preliminary report of a preplanned subgroup analysis of the CORRECT trial presented at the 2012 annual meeting of the American Society of Clinical Oncology suggested similar efficacy in patients 65 and under and those who are older [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/86\">",
"     86",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Summary: Therapy selection in healthy elderly patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The FOLFOX and FOLFIRI regimens are among the most effective for treatment of mCRC, and both are appropriate choices for first-line therapy in fit, elderly patients. The available evidence suggests that the benefits of these regimens are similar to those in younger patients, with some variations in toxicity patterns that may affect the choice of therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sensory neuropathy is the most important dose-limiting toxicity of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      ; it tends to occur once cumulative drug doses &ge;700",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      are reached. Initiation of FOLFIRI rather than FOLFOX may be prudent in patients with a preexisting neuropathy.",
"     </li>",
"     <li>",
"      Grade 3 or 4 neutropenia and thrombocytopenia are more common with FOLFOX than with FOLFIRI (",
"      <a class=\"graphic graphic_table graphicRef66108 \" href=\"mobipreview.htm?12/38/12909\">",
"       table 12",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/87\">",
"       87",
"      </a>",
"      ]. Given the small increased risk of neutropenia, we often omit the 5-FU bolus from both FOLFOX (eg, modified FOLFOX7) (",
"      <a class=\"graphic graphic_table graphicRef55829 \" href=\"mobipreview.htm?10/19/10558\">",
"       table 13",
"      </a>",
"      ) and FOLFIRI in order to diminish treatment-related cytopenias.",
"     </li>",
"     <li>",
"      Nausea (13 versus 3 percent), vomiting (10 versus 3 percent), stomatitis (10 versus 1 percent), and alopecia (24 versus 9 percent) tend to be more common with FOLFIRI than with FOLFOX [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/87\">",
"       87",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     Bevacizumab",
"    </a>",
"    can be considered for first-line chemotherapy in older patients unless the risk of a serious adverse event (particularly arterial thromboemboli) supersedes potential benefit. For selected patients with wild-type K-ras tumors and a contraindication to bevacizumab, adding",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    to a first-line",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    -based therapy is reasonable. However, acneiform skin rash and diarrhea may be prominent.",
"   </p>",
"   <p>",
"    <span class=\"nowrap\">",
"     5-FU/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"      leucovorin",
"     </a>",
"    </span>",
"    alone or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    can be considered for elderly patients who are not suitable for an",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    -based regimen. Short-term infusional",
"    <span class=\"nowrap\">",
"     5-FU/leucovorin",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef65525 \" href=\"mobipreview.htm?36/17/37149\">",
"     table 14",
"    </a>",
"    ) is well tolerated but requires central venous access and an ambulatory infusion pump. While potentially more convenient than infusional",
"    <span class=\"nowrap\">",
"     5-FU/leucovorin,",
"    </span>",
"    capecitabine monotherapy is probably more toxic than the de Gramont regimen. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Capecitabine'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Recommendations from the NCCN for the treatment of mCRC, which include recommendations for patients who are not candidates for intensive therapy, are outlined in the table (",
"    <a class=\"graphic graphic_table graphicRef80572 \" href=\"mobipreview.htm?3/8/3213\">",
"     table 15",
"    </a>",
"    ). A compilation of commonly used chemotherapy regimens for colorectal cancer is available. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/45/10963?source=see_link\">",
"     \"Treatment protocols for colorectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     ROLE OF METASTASECTOMY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Liver metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite advances in chemotherapy for mCRC, resection offers the only chance of long-term survival for patients with metastatic disease. The likelihood of cure is greatest in patients with liver-isolated mCRC. In surgical case series including both younger and older patients, five-year survival rates after resection range from 24 to 58 percent, averaging 40 percent (",
"    <a class=\"graphic graphic_table graphicRef50132 \" href=\"mobipreview.htm?16/53/17246\">",
"     table 16",
"    </a>",
"    ), and perioperative mortality rates are generally less than 5 percent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41850?source=see_link&amp;anchor=H3#H3\">",
"     \"Management of potentially resectable colorectal cancer liver metastases\", section on 'Surgical resection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similar findings were noted in a report from the LiverMetSurvey registry of 999 well-selected elderly patients 70 or older [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/88\">",
"     88",
"    </a>",
"    ]. The three-year survival rate after hepatic metastasectomy was 57 percent (similar to that of younger patients), and the 60-day perioperative mortality rate was 4 percent.",
"   </p>",
"   <p>",
"    Preoperative chemotherapy may facilitate the downstaging of liver metastases and render initially unresectable disease potentially resectable. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41850?source=see_link&amp;anchor=H9#H9\">",
"     \"Management of potentially resectable colorectal cancer liver metastases\", section on 'Conversion therapy for initially unresectable metastases'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, few elderly patients have been included in trials of neoadjuvant chemotherapy. The safety and efficacy of liver resection and preoperative chemotherapy in elderly patients has been addressed in two series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/89,90\">",
"     89,90",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective review included 181 liver resections that were performed in 178 consecutive patients over age 70, 19 percent of whom received neoadjuvant FOLFOX [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/89\">",
"       89",
"      </a>",
"      ]. Resection involved more than two liver segments (",
"      <a class=\"graphic graphic_figure graphicRef81897 \" href=\"mobipreview.htm?13/35/13878\">",
"       figure 1",
"      </a>",
"      ) in 58 percent of patients and was complete in 92 percent. Perioperative mortality was 5 percent. At a median follow-up of 18 months, the actuarial rates of three-year overall and disease-free survival were 43 and 32 percent, respectively.",
"     </li>",
"     <li>",
"      The second series included 70 patients aged 70 or older who underwent hepatic metastasectomy; 41 percent received neoadjuvant chemotherapy with XELOX (n = 19) or bolus",
"      <span class=\"nowrap\">",
"       5-FU/",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"        leucovorin",
"       </a>",
"      </span>",
"      (n = 10) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/90\">",
"       90",
"      </a>",
"      ]. In the elderly, use of XELOX was associated with a significantly higher response rate than bolus",
"      <span class=\"nowrap\">",
"       5-FU/leucovorin",
"      </span>",
"      (68 versus 0 percent), and responding patients had significantly better overall and recurrence-free survival (RFS). Five-year overall survival in elderly patients was comparable to that of younger individuals treated at the same institution over the same time period (38 versus 43 percent, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon these observations, the principles of management of potentially resectable liver metastases in fit elderly patients are the same as in younger patients. However, treatment choices for neoadjuvant chemotherapy, if needed to downstage liver metastases to the point of resectability, are likely to be more critical for older patients. As noted above, whether the decreased volume of normal hepatic parenchyma seen as a consequence of normal aging predisposes older patients to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    -associated steatohepatitis is unknown. Clinicians should exercise caution when giving oxaliplatin to an older patient pre-resection. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Age-related organ function decline'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41850?source=see_link&amp;anchor=H5842613#H5842613\">",
"     \"Management of potentially resectable colorectal cancer liver metastases\", section on 'Chemotherapy-related liver toxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     Bevacizumab",
"    </a>",
"    inhibits wound healing. In view of this fact, and the long half life of this agent (20 days), at least 28 days (and preferably six to eight weeks) should elapse between the last dose of bevacizumab and major surgery, including hepatectomy, if bevacizumab is included in the preoperative regimen. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43882?source=see_link&amp;anchor=H1651227437#H1651227437\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\", section on 'Bevacizumab'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Pulmonary metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metastasectomy may also be considered for fit older patients with isolated pulmonary metastases. There are no large series that examine the feasibility and outcomes in the elderly. However, older age has not been an independent predictor of adverse outcomes in series in which it has been examined in multivariate analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/91-95\">",
"     91-95",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/15/13560?source=see_link&amp;anchor=H3#H3\">",
"     \"Surgical resection of pulmonary metastases: Outcomes by histology\", section on 'Colorectal cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF PATIENTS WITH A POOR PERFORMANCE STATUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with the elderly, physicians may be reluctant to administer aggressive combination chemotherapy to patients with a poor performance status (PS) for fear that they will derive more toxicity and less benefit than those with a better PS. Regardless of age, individuals with a poor PS (eg, ECOG PS&ge;2 [(",
"    <a class=\"graphic graphic_table graphicRef72901 \" href=\"mobipreview.htm?9/15/9467\">",
"     table 3",
"    </a>",
"    )], Karnofsky PS &lt;60 [(",
"    <a class=\"graphic graphic_table graphicRef62939 \" href=\"mobipreview.htm?30/6/30830\">",
"     table 17",
"    </a>",
"    )]) usually tolerate chemotherapy poorly and have a poor short-term prognosis.",
"   </p>",
"   <p>",
"    However, patients with mCRC who have a PS of 2 should be considered for chemotherapy, particularly if their PS decline is cancer related. Although such patients have a median survival that is approximately half that seen for patients with a PS of 0 or 1, they benefit to an equal extent from combination chemotherapy.",
"   </p>",
"   <p>",
"    The influence of PS on the efficacy and toxicity of first-line chemotherapy was addressed in a pooled analysis of nine trials with over 6200 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/96\">",
"     96",
"    </a>",
"    ]. Patients with PS of 2 derived similar advantages with regard to efficacy from superior (ie, combination versus single agent) chemotherapy as did those with a PS of 0 to 1, but with a significantly higher risk of &ge;grade 3 nausea and vomiting. The median survival for patients with a PS of 2 was less than nine months, and 12 percent died within 60 days of the start of treatment.",
"   </p>",
"   <p>",
"    The choice of regimen is unclear. In the MRC trial of 5-FU or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    in elderly and frail patients discussed above (in which 29 percent of the 460 enrollees had a PS of 2), the addition of oxaliplatin to a fluoropyrimidine significantly improved outcomes without worsening toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/97\">",
"     97",
"    </a>",
"    ]. In contrast, the substitution of capecitabine for infusional",
"    <span class=\"nowrap\">",
"     5-FU/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"      leucovorin",
"     </a>",
"    </span>",
"    did not improve outcomes and significantly worsened toxicity. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'XELOX'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    FOLFOX or FOLFIRI with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    are reasonable options in elderly patients who thought to be able to tolerate them. For patients who are not considered appropriate candidates for intensive first-line therapy with an",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    -based regimen,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    (LV)-modulated 5-FU is an appropriate option [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/6\">",
"     6",
"    </a>",
"    ]. Short-term infusional",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef66108 \" href=\"mobipreview.htm?12/38/12909\">",
"     table 12",
"    </a>",
"    ) is preferred, because of its more favorable toxicity profile compared to other schedules. The addition of bevacizumab is reasonable, but the modest survival benefit from adding bevacizumab to first-line therapy must be balanced against the potential for serious treatment-related toxicity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link&amp;anchor=H10#H10\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'Leucovorin plus 5-FU'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/45/10963?source=see_link\">",
"     \"Treatment protocols for colorectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An equally effective but potentially more toxic alternative first-line regimen, when fluoropyrimidines alone are indicated, is",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    At the time of progression, patients initially treated with a fluoropyrimidine alone whose PS has improved could be treated either with an",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    -based or an",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    -based regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/31/41466/abstract/98\">",
"     98",
"    </a>",
"    ]. In contrast, supportive care alone is an option for those whose performance status declines or does not improve.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/27/19890?source=see_link\">",
"       \"Patient information: Colon and rectal cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?6/0/6148?source=see_link\">",
"       \"Patient information: Colon and rectal cancer (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/22/40293?source=see_link\">",
"       \"Patient information: Colorectal cancer treatment; metastatic cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Elderly patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principles of treating metastatic colorectal cancer (mCRC) in the elderly are similar to those that guide treatment of younger patients. However, in older patients, who may have age-related organ function decline and medical comorbidity, special attention must be paid to the risks of chemotherapy (treatment-related toxicity and quality of life [QOL] issues), particularly in the context of estimated life expectancy. Serious comorbidity negatively impacts survival and increases the complexity of cancer management in this population. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Challenges specific to the elderly'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Treatment decisions should not be based upon age alone, but upon functional status, the presence of comorbidities, and consideration of drug-specific toxicities that can be worse in older individuals because of their diminished reserve:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In general, fit elderly patients with mCRC derive as much benefit from chemotherapy as do younger patients, with only a minor increase in expected toxicity. We recommend that these patients be offered combination chemotherapy, including a biologic agent, if appropriate.",
"     </li>",
"     <li>",
"      Combination chemotherapy should be used cautiously, given in attenuated doses initially, or be avoided altogether in frail older patients (particularly those with severe comorbidity, poor physical function). In this population, sequential single agent therapy is a probably preferable.",
"      <br/>",
"      <br/>",
"      However, if the decline in physical function is entirely related to cancer, treatment should be considered, as patients with ECOG PS2 (",
"      <a class=\"graphic graphic_table graphicRef72901 \" href=\"mobipreview.htm?9/15/9467\">",
"       table 3",
"      </a>",
"      ) appear to benefit from chemotherapy. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Management of patients with a poor performance status'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The majority of elderly patients are neither fit nor frail. Individualized treatment decision-making is paramount in this group as presently there is no evidence to support or refute the benefit and safety of therapy. However, we strongly encourage physicians to at least discuss treatment with these patients and to tailor it by starting with attenuated doses in combination regimens or single agents, escalating intensity as tolerated. The default of simply omitting chemotherapy is no longer acceptable.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Choice of regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following represents our general approach to initial treatment for fit elderly patients with mCRC, which mirrors our approach to nonelderly patients (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/1/44058?source=see_link\">",
"     \"Systemic chemotherapy for nonoperable metastatic colorectal cancer: Treatment recommendations\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For fit relatively healthy elderly patients, we suggest a chemotherapy doublet (FOLFOX, XELOX, or FOLFIRI) (",
"      <a class=\"graphic graphic_table graphicRef64504 \" href=\"mobipreview.htm?5/20/5454\">",
"       table 2",
"      </a>",
"      ) rather than a fluoropyrimidine alone (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). The choice among these regimens may be driven by toxicity concerns. Our preferred FOLFOX regimen is modified FOLFOX6 (mFOLFOX6) (",
"      <a class=\"graphic graphic_table graphicRef50132 \" href=\"mobipreview.htm?16/53/17246\">",
"       table 16",
"      </a>",
"      ). Given the small increased risk of neutropenia, we often omit the 5-FU bolus from both FOLFOX (eg, modified FOLFOX7) (",
"      <a class=\"graphic graphic_table graphicRef63338 \" href=\"mobipreview.htm?32/36/33356\">",
"       table 11",
"      </a>",
"      ) and FOLFIRI in order to diminish treatment-related cytopenias. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Summary: Therapy selection in healthy elderly patients'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/45/10963?source=see_link\">",
"       \"Treatment protocols for colorectal cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Regardless of whether an",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      -based or an",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      -based chemotherapy regimen is selected, we suggest adding",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      to first-line chemotherapy (",
"      <a class=\"graphic graphic_table graphicRef62939 \" href=\"mobipreview.htm?30/6/30830\">",
"       table 17",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef75802 \" href=\"mobipreview.htm?23/8/23694\">",
"       table 18",
"      </a>",
"      )&nbsp;(",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). However, the potential for improved outcomes from the addition of bevacizumab to first-line therapy must be balanced against the potential for serious treatment-related toxicity. Because patients over age 65 may be at increased risk of a bevacizumab-induced arterial thromboembolic event, bevacizumab should only be used with informed consent regarding these risks. In patients with a personal history of stroke or active coronary heart disease, the benefit offered by bevacizumab is likely outweighed by the risk of an arterial thrombotic event. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Bevacizumab'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/45/10963?source=see_link\">",
"       \"Treatment protocols for colorectal cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients who are not considered appropriate candidates for intensive first-line therapy with an",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      -based regimen, we suggest LV-modulated 5-FU (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We prefer short-term infusional",
"      <span class=\"nowrap\">",
"       5-FU/LV",
"      </span>",
"      (",
"      <a class=\"graphic graphic_table graphicRef66108 \" href=\"mobipreview.htm?12/38/12909\">",
"       table 12",
"      </a>",
"      ), because of its more favorable toxicity profile compared to other schedules. The survival benefit of adding",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      to first-line 5-FU plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      must be balanced against the potential for serious treatment-related toxicity. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Single agent fluorouracil'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H23\">",
"       'Bevacizumab'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/45/10963?source=see_link\">",
"       \"Treatment protocols for colorectal cancer\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      An equally effective but potentially more toxic alternative first-line regimen, when fluoropyrimidines alone are indicated, is",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      with or without bevacizumab. However, the appropriate capecitabine dose is unclear. Capecitabine also requires dose reduction in patients with renal function impairment. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Capecitabine'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      As noted above, the potential for improved outcomes from the addition of bevacizumab to first-line therapy must be balanced against the potential for serious treatment-related toxicity. Because patients over age 65 may be at increased risk of a bevacizumab-induced arterial thromboembolic event, bevacizumab should only be used with informed consent regarding these risks. In patients with a personal history of stroke or active coronary heart disease, the benefit offered by bevacizumab is likely outweighed by the risk of an arterial thrombotic event. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Bevacizumab'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      As with younger patients, for selected older individuals (eg, those with wild-type K-ras tumors and a contraindication to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      ), adding",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"       cetuximab",
"      </a>",
"      to first-line",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      -based chemotherapy, or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"       panitumumab",
"      </a>",
"      to an",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      -based regimen is a reasonable option. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Cetuximab and panitumumab'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/1/44058?source=see_link&amp;anchor=H32#H32\">",
"       \"Systemic chemotherapy for nonoperable metastatic colorectal cancer: Treatment recommendations\", section on 'Cetuximab or panitumumab as a component of initial therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We routinely incorporate drug holidays into the treatment plan for many patients with mCRC, regardless of age. This allows recovery from cumulative toxicity that will often permit later resumption of chemotherapy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/1/44058?source=see_link&amp;anchor=H17#H17\">",
"       \"Systemic chemotherapy for nonoperable metastatic colorectal cancer: Treatment recommendations\", section on 'Reducing drug toxicity with chemotherapy holidays'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Poor performance status",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with mCRC who have an ECOG PS of 2 (",
"    <a class=\"graphic graphic_table graphicRef72901 \" href=\"mobipreview.htm?9/15/9467\">",
"     table 3",
"    </a>",
"    ), we suggest chemotherapy rather than supportive care alone, particularly if their PS decline is cancer related (",
"    <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"     Grade 2B",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H29\">",
"     'Management of patients with a poor performance status'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who are not considered appropriate candidates for intensive first-line therapy with an",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      -based regimen based on their performance status, LV-modulated 5-FU (eg, with the de Gramont regimen, (",
"      <a class=\"graphic graphic_table graphicRef65525 \" href=\"mobipreview.htm?36/17/37149\">",
"       table 14",
"      </a>",
"      )) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      monotherapy is an appropriate option. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/45/10963?source=see_link\">",
"       \"Treatment protocols for colorectal cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      As with elderly patients, the survival benefit from adding",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      to first-line therapy must be balanced against the potential for serious treatment-related toxicity. At the time of progression, patients whose performance status has improved could be treated either with an",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      -based or an",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      -based regimen. For those whose performance status declines or does not improve, supportive care alone is an option.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Ries L, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2006, National Cancer Institute. Bethesda, MD. file://seer.cancer.gov/csr/1975_2006/ (Accessed on March 14, 2011).",
"    </li>",
"    <li>",
"     file://www.census.gov/population/www/projections/usinterimproj/ (Accessed on March 14, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/3\">",
"      Sawhney R, Sehl M, Naeim A. Physiologic aspects of aging: impact on cancer management and decision making, part I. Cancer J 2005; 11:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/4\">",
"      Sehl M, Sawhney R, Naeim A. Physiologic aspects of aging: impact on cancer management and decision making, part II. Cancer J 2005; 11:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/5\">",
"      Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006; 24:3187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/6\">",
"      Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007; 99:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/7\">",
"      Yancik R, Wesley MN, Ries LA, et al. Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients: a population-based study. Cancer 1998; 82:2123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/8\">",
"      Yancik R, Ries LA. Cancer in older persons. Magnitude of the problem--how do we apply what we know? Cancer 1994; 74:1995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/9\">",
"      Sanoff HK, Goldberg RM, Pignone MP. A systematic review of the use of quality of life measures in colorectal cancer research with attention to outcomes in elderly patients. Clin Colorectal Cancer 2007; 6:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/10\">",
"      Seymour MT, Thompson LC, Wasan HS, et al. Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. Lancet 2011; 377:1749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/11\">",
"      Goldberg RM, Tabah-Fisch I, Bleiberg H, et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 2006; 24:4085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/12\">",
"      Hurria A, Togawa K, Mohile SG, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol 2011; 29:3457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/13\">",
"      Simmonds PC. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group. BMJ 2000; 321:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/14\">",
"      Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004; 22:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/15\">",
"      Sanoff HK, Sargent DJ, Campbell ME, et al. Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J Clin Oncol 2008; 26:5721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/16\">",
"      Howard DH, Kauh J, Lipscomb J. The value of new chemotherapeutic agents for metastatic colorectal cancer. Arch Intern Med 2010; 170:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/17\">",
"      McKibbin T, Frei CR, Greene RE, et al. Disparities in the use of chemotherapy and monoclonal antibody therapy for elderly advanced colorectal cancer patients in the community oncology setting. Oncologist 2008; 13:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/18\">",
"      Stein BN, Petrelli NJ, Douglass HO, et al. Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial. Cancer 1995; 75:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/19\">",
"      D'Andre S, Sargent DJ, Cha SS, et al. 5-Fluorouracil-based chemotherapy for advanced colorectal cancer in elderly patients: a north central cancer treatment group study. Clin Colorectal Cancer 2005; 4:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/20\">",
"      Rothenberg ML, Cox JV, DeVore RF, et al. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer 1999; 85:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/21\">",
"      Hochster HS, Luo W, Popa EC, et al. Phase II study of uracil-tegafur with leucovorin in elderly (&gt; or = 75 years old) patients with colorectal cancer: ECOG 1299. J Clin Oncol 2007; 25:5397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/22\">",
"      Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/23\">",
"      Folprecht G, Seymour MT, Saltz L, et al. Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials. J Clin Oncol 2008; 26:1443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/24\">",
"      Aparicio T, Desram&eacute; J, Lecomte T, et al. Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly. Br J Cancer 2003; 89:1439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/25\">",
"      Sastre J, Marcuello E, Masutti B, et al. Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors study. J Clin Oncol 2005; 23:3545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/26\">",
"      Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999; 341:2061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/27\">",
"      Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA 2004; 291:2720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/28\">",
"      Folprecht G, Cunningham D, Ross P, et al. Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann Oncol 2004; 15:1330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/29\">",
"      Sargent DJ, Goldberg RM, Jacobson SD, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001; 345:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/30\">",
"      Sastre J, Aranda E, Massut&iacute; B, et al. Elderly patients with advanced colorectal cancer derive similar benefit without excessive toxicity after first-line chemotherapy with oxaliplatin-based combinations: comparative outcomes from the 03-TTD-01 phase III study. Crit Rev Oncol Hematol 2009; 70:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/31\">",
"      Arkenau HT, Graeven U, Kubicka S, et al. Oxaliplatin in combination with 5-fluorouracil/leucovorin or capecitabine in elderly patients with metastatic colorectal cancer. Clin Colorectal Cancer 2008; 7:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/32\">",
"      Jackson NA, Barrueco J, Soufi-Mahjoubi R, et al. Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study. Cancer 2009; 115:2617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/33\">",
"      Popescu RA, Norman A, Ross PJ, et al. Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol 1999; 17:2412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/34\">",
"      Daniele B, Rosati G, Tambaro R, et al. First-line chemotherapy with fluorouracil and folinic acid for advanced colorectal cancer in elderly patients: a phase II study. J Clin Gastroenterol 2003; 36:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/35\">",
"      Magn&eacute; N, Fran&ccedil;ois E, Broisin L, et al. Palliative 5-fluorouracil-based chemotherapy for advanced colorectal cancer in the elderly: results of a 10-year experience. Am J Clin Oncol 2002; 25:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/36\">",
"      de Gramont A, Bosset JF, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997; 15:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/37\">",
"      Ho C, Ng K, O'Reilly S, Gill S. Outcomes in elderly patients with advanced colorectal cancer treated with capecitabine: a population-based analysis. Clin Colorectal Cancer 2005; 5:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/38\">",
"      Ershler WB. Capecitabine use in geriatric oncology: an analysis of current safety, efficacy, and quality of life data. Crit Rev Oncol Hematol 2006; 58:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/39\">",
"      Petrioli R, Pascucci A, Francini E, et al. Continuous oral capecitabine at fixed dose in patients older than 75 years with metastatic colorectal and gastric cancer: a study of the Multidisciplinary Oncology Group on Gastrointestinal Tumors. Anticancer Drugs 2008; 19:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/40\">",
"      Pasetto LM, Monfardini S. The role of capecitabine in the treatment of colorectal cancer in the elderly. Anticancer Res 2006; 26:2381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/41\">",
"      Feliu J, Escudero P, Llosa F, et al. Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an oncopaz cooperative group study. J Clin Oncol 2005; 23:3104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/42\">",
"      Cassidy J, Twelves C, Van Cutsem E, et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 2002; 13:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/43\">",
"      Weingart SN, Brown E, Bach PB, et al. NCCN Task Force Report: Oral chemotherapy. J Natl Compr Canc Netw 2008; 6 Suppl 3:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/44\">",
"      Figer A, Perez-Staub N, Carola E, et al. FOLFOX in patients aged between 76 and 80 years with metastatic colorectal cancer: an exploratory cohort of the OPTIMOX1 study. Cancer 2007; 110:2666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/45\">",
"      Mattioli R, Massacesi C, Recchia F, et al. High activity and reduced neurotoxicity of bi-fractionated oxaliplatin plus 5-fluorouracil/leucovorin for elderly patients with advanced colorectal cancer. Ann Oncol 2005; 16:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/46\">",
"      Cen P, Liu C, Du XL. Comparison of toxicity profiles of fluorouracil versus oxaliplatin regimens in a large population-based cohort of elderly patients with colorectal cancer. Ann Oncol 2012; 23:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/47\">",
"      Folprecht G, Rougier P, Saltz L, et al. Irinotecan in first line therapy of elderly and non-elderly patients wtih metastatic colorectal cancer: Meta-analysis of four trials investigating 5-FU and irinotecan (abstract #3578). J Clin Oncol 2006; 24:165s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/48\">",
"      Souglakos J, Pallis A, Kakolyris S, et al. Combination of irinotecan (CPT-11) plus 5-fluorouracil and leucovorin (FOLFIRI regimen) as first line treatment for elderly patients with metastatic colorectal cancer: a phase II trial. Oncology 2005; 69:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/49\">",
"      Fran&ccedil;ois E, Berdah JF, Chamorey E, et al. Use of the folinic acid/5-fluorouracil/irinotecan (FOLFIRI 1) regimen in elderly patients as a first-line treatment for metastatic colorectal cancer: a Phase II study. Cancer Chemother Pharmacol 2008; 62:931.",
"     </a>",
"    </li>",
"    <li>",
"     Mitry E, et al. Phase III trial of chemotherapy with or without irinotecan in the front-line treatment of metastatic colorectal cancer in elderly patients (FFCD 2001-02 trial): Results of a planned interim analysis (abstract). Data presented at the 2008 ASCO Gastrointestinal Cancers symposium, Orlando, Fl, January 25-27, 2008.",
"    </li>",
"    <li>",
"     Kuboki Y, Mizunuma N, Chin K, et al. Grade 3/4 neutropenia and febrile neutropenia in elderly patients with mCRC receiving second-line FOLFIRI4 after first-line FOLFOX4: a single institution experience qwith 35 patients (abstract #429). Data presented at the 2009 ASCO Gastrointestinal Cancers Symposium, January 15-17, San Francisco, CA, USA.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/52\">",
"      Rothenberg ML, Meropol NJ, Poplin EA, et al. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 2001; 19:3801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/53\">",
"      Cunningham D, Pyrh&ouml;nen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/54\">",
"      Rougier P, Van Cutsem E, Bajetta E, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352:1407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/55\">",
"      Fuchs CS, Moore MR, Harker G, et al. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol 2003; 21:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/56\">",
"      Chau I, Norman AR, Cunningham D, et al. Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy. Br J Cancer 2004; 91:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/57\">",
"      Sanoff HK, Bleiberg H, Goldberg RM. Managing older patients with colorectal cancer. J Clin Oncol 2007; 25:1891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/58\">",
"      Comella P, Natale D, Farris A, et al. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108. Cancer 2005; 104:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/59\">",
"      Feliu J, Salud A, Escudero P, et al. XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer. Br J Cancer 2006; 94:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/60\">",
"      Comondone P, Pochettino P, Bergnolo A, et al. Capecitabine and oxaliplatin: A phase II study with a new schedule of adminstration in elderly patients with advanced colorectal cancer (abstract # 3681). J Clin Oncol 2005; 23:291s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/61\">",
"      Fiorentini G, Dentico P, Cantore M, et al. Capecitabine (XE) plus irinotecan (IRI) as second-line treatment (XELIRI) for metastatic colorectal cancer in elderly patients: feasibility and safety results from a phase II study (abstract # 3676). J Clin Oncol 2005; 23:289s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/62\">",
"      Twelves CJ, Butts CA, Cassidy J, et al. Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II study. Clin Colorectal Cancer 2005; 5:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/63\">",
"      Rosati G, Cordio S, Bordonaro R, et al. Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomized phase II study. Ann Oncol 2010; 21:781.",
"     </a>",
"    </li>",
"    <li>",
"     Avastin full prescribing information file://www.gene.com/gene/products/information/oncology/avastin/insert.jsp (Accessed on March 14, 2011).",
"    </li>",
"    <li>",
"     Sugrue MM, Yi J, Purdie D, et al. Serious arterial thromboembolic events (SATE) in patients with metastatic colorectal cancer (mCRC) treated with bevcizumab: results from the BRiTE registry (abstract). J Clin Oncol 2007; 25:197s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/66\">",
"      Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005; 23:3697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/67\">",
"      Giantonio BJ, Levy DE, O'dwyer PJ, et al. A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200. Ann Oncol 2006; 17:1399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/68\">",
"      Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335.",
"     </a>",
"    </li>",
"    <li>",
"     Kozloff MF, Sugrue MM, Purdie DM, et al. Safety and effectiveness of bevacizumab and chemotherapy in elderly patients with metastatic colorectal cancer: Results from the BRiTE observational cohort study (abstract). J Clin Oncol 2008; 26:184s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/70\">",
"      Feliu J, Safont MJ, Salud A, et al. Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer. Br J Cancer 2010; 102:1468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/71\">",
"      Puthillath A, Mashtare T Jr, Wilding G, et al. A phase II study of first-line biweekly capecitabine and bevacizumab in elderly patients with metastatic colorectal cancer. Crit Rev Oncol Hematol 2009; 71:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/72\">",
"      Meyerhardt JA, Li L, Sanoff HK, et al. Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancer. J Clin Oncol 2012; 30:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/73\">",
"      Tsai HT, Marshall JL, Weiss SR, et al. Bevacizumab use and risk of cardiovascular adverse events among elderly patients with colorectal cancer receiving chemotherapy: a population-based study. Ann Oncol 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/74\">",
"      Kozloff MF, Berlin J, Flynn PJ, et al. Clinical outcomes in elderly patients with metastatic colorectal cancer receiving bevacizumab and chemotherapy: results from the BRiTE observational cohort study. Oncology 2010; 78:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/75\">",
"      Price TJ, Zannino D, Wilson K, et al. Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C. Ann Oncol 2012; 23:1531.",
"     </a>",
"    </li>",
"    <li>",
"     Cunningham D, Lng I, Lorusso V, et al. Bevacizumab in combination with capecitabine for the first-line treatment of elderly patents with metastatic colorectal cancer: Results of the randomized phase III trial (AVEX). (abstract 337) Data presented at the 2013 ASCO Gastrointestinal Cancers Symposium, San Francisco, CA, January 22-24, 2013. Abstract available online at https://meetinglibrary.asco.org/content/106233-133 (Accessed on March 19, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/77\">",
"      Maitland ML, Bakris GL, Black HR, et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 2010; 102:596.",
"     </a>",
"    </li>",
"    <li>",
"     Van Cutsem E, Tabernero J, Lakomy R, et al. Intravenous aflibercept versus placebo in combination with irinotecan/5-FU (FOLFIRI) for second-line treatment of metastatic colorectal cancer (MCRC): results of a multinational Phase III trial (EFC10262-VELOUR) (ESMO abstract O-0024). Ann Oncol 2011; 22(suppl).",
"    </li>",
"    <li>",
"     Tabernero J, et al. Data presented at the 2011 ECCO/ESMO meetig, Stockjholm,. Sweden, September 26, 2011 (LBA6). file://futurecast.tv/mediapool/BOPA-ECCO-ESMO-2011.pdf (Accessed on August 16, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/80\">",
"      Bouchahda M, Macarulla T, Spano JP, et al. Cetuximab efficacy and safety in a retrospective cohort of elderly patients with heavily pretreated metastatic colorectal cancer. Crit Rev Oncol Hematol 2008; 67:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/81\">",
"      Jehn CF, B&ouml;ning L, Kr&ouml;ning H, et al. Cetuximab-based therapy in elderly comorbid patients with metastatic colorectal cancer. Br J Cancer 2012; 106:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/82\">",
"      Sastre J, Gr&aacute;valos C, Rivera F, et al. First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD Group Study. Oncologist 2012; 17:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/83\">",
"      Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25:1658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/84\">",
"      Allegra CJ, Jessup JM, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009; 27:2091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/85\">",
"      Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381:303.",
"     </a>",
"    </li>",
"    <li>",
"     Van Cutsem E, Sobrero AF, Siena S, et al. Phase III CORRECT trial of regorafenib in metastatic colorectal cancer (mCRC) (abstract). J Clin Oncol 30, 2012 (Suppl Abstr 3502). file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=114&amp;abstractID=94460 (Accessed on February 04, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/87\">",
"      Tournigand C, Andr&eacute; T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/88\">",
"      Adam R, Frilling A, Elias D, et al. Liver resection of colorectal metastases in elderly patients. Br J Surg 2010; 97:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/89\">",
"      de Liguori Carino N, van Leeuwen BL, Ghaneh P, et al. Liver resection for colorectal liver metastases in older patients. Crit Rev Oncol Hematol 2008; 67:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/90\">",
"      Tamandl D, Gruenberger B, Herberger B, et al. Surgery after neoadjuvant chemotherapy for colorectal liver metastases is safe and feasible in elderly patients. J Surg Oncol 2009; 100:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/91\">",
"      Onaitis MW, Petersen RP, Haney JC, et al. Prognostic factors for recurrence after pulmonary resection of colorectal cancer metastases. Ann Thorac Surg 2009; 87:1684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/92\">",
"      Lee WS, Yun SH, Chun HK, et al. Pulmonary resection for metastases from colorectal cancer: prognostic factors and survival. Int J Colorectal Dis 2007; 22:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/93\">",
"      Yedibela S, Klein P, Feuchter K, et al. Surgical management of pulmonary metastases from colorectal cancer in 153 patients. Ann Surg Oncol 2006; 13:1538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/94\">",
"      Iizasa T, Suzuki M, Yoshida S, et al. Prediction of prognosis and surgical indications for pulmonary metastasectomy from colorectal cancer. Ann Thorac Surg 2006; 82:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/95\">",
"      Kanemitsu Y, Kato T, Hirai T, Yasui K. Preoperative probability model for predicting overall survival after resection of pulmonary metastases from colorectal cancer. Br J Surg 2004; 91:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/96\">",
"      Sargent DJ, K&ouml;hne CH, Sanoff HK, et al. Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer. J Clin Oncol 2009; 27:1948.",
"     </a>",
"    </li>",
"    <li>",
"     Seymour MT, Maughan TS, Wasan HS, et al. Capecitabine and oxaliplatin in elderly and/or frail patrients with metastatic colorectal cancer: the FOCUS2 trial (abstract #9030). J Clin Oncol 2007; 25:500s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/31/41466/abstract/98\">",
"      Kim GP, Sargent DJ, Mahoney MR, et al. Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841. J Clin Oncol 2009; 27:2848.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2512 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-194.187.108.93-5353394DC6-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_31_41466=[""].join("\n");
var outline_f40_31_41466=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CHALLENGES SPECIFIC TO THE ELDERLY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Age-related organ function decline",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Liver",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Kidney",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Bone marrow",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Cardiovascular",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Comorbid conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Quality of life issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Measures of physical function and reserve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Guiding treatment decisions by assessment of physical function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SAFETY AND EFFICACY OF CHEMOTHERAPY IN THE ELDERLY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Single agent fluorouracil",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Capecitabine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Oxaliplatin/5-FU combinations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Irinotecan/5-FU combinations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Single agent irinotecan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Substituting capecitabine for 5-FU in combinations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - XELOX",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - XELIRI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Targeted therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Bevacizumab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26272734\">",
"      - Aflibercept",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Cetuximab and panitumumab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8633571\">",
"      - Regorafenib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Summary: Therapy selection in healthy elderly patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      ROLE OF METASTASECTOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Liver metastases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Pulmonary metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      MANAGEMENT OF PATIENTS WITH A POOR PERFORMANCE STATUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Elderly patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Choice of regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Poor performance status",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2512\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2512|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?13/35/13878\" title=\"figure 1\">",
"      Segmental anatomy of liver",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2512|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/61/22491\" title=\"table 1\">",
"      Organ function change age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?5/20/5454\" title=\"table 2\">",
"      Chemo regimens met CRC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/15/9467\" title=\"table 3\">",
"      ECOG performance scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/11/2236\" title=\"table 4\">",
"      Karnofsky performance status scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/13/9436\" title=\"table 5\">",
"      Elements comp geri assess",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/51/18237\" title=\"table 6\">",
"      Model for predicting chemotherapy toxicity in older adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/40/42636\" title=\"table 7\">",
"      Risk score versus physician-rated KPS chemo toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/1/13341\" title=\"table 8\">",
"      mCRC severe chemo tox",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/2/19502\" title=\"table 9\">",
"      FOLFIRI regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/7/22652\" title=\"table 10\">",
"      HTN with VEGF inhib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?32/36/33356\" title=\"table 11\">",
"      Risk factors BP VSP rx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/38/12909\" title=\"table 12\">",
"      Gr3 chemo tox elderly pts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/19/10558\" title=\"table 13\">",
"      Modified FOLFOX7 regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?36/17/37149\" title=\"table 14\">",
"      Modified de Gramont schedule for gastrointestinal cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/8/3213\" title=\"table 15\">",
"      NCCN chemotherapy guidelines for metastatic colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/53/17246\" title=\"table 16\">",
"      Modified FOLFOX6",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?30/6/30830\" title=\"table 17\">",
"      Modified FOLFOX6 plus bevacizumab chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/8/23694\" title=\"table 18\">",
"      Modified FOLFOX7 plus bevacizumab chemotherapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/30/26087?source=related_link\">",
"      A short primer on cost-effectiveness analysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/6/9322?source=related_link\">",
"      Acneiform eruption secondary to epidermal growth factor (EGFR) inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/51/11066?source=related_link\">",
"      Adjuvant therapy for resected colon cancer in elderly patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=related_link\">",
"      Assessment of kidney function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/12/40138?source=related_link\">",
"      Cardiotoxicity of nonanthracycline cancer chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/2/44074?source=related_link\">",
"      Chemotherapy hepatotoxicity and dose modification in patients with liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41738?source=related_link\">",
"      Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/56/41864?source=related_link\">",
"      Comprehensive geriatric assessment for patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/36/6730?source=related_link\">",
"      Drug-induced thrombosis and vascular disease in patients with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/7/28792?source=related_link\">",
"      Frailty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41850?source=related_link\">",
"      Management of potentially resectable colorectal cancer liver metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?6/0/6148?source=related_link\">",
"      Patient information: Colon and rectal cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/27/19890?source=related_link\">",
"      Patient information: Colon and rectal cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/22/40293?source=related_link\">",
"      Patient information: Colorectal cancer treatment; metastatic cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/32/13834?source=related_link\">",
"      Surgical resection of pulmonary metastases: Benefits; indications; preoperative evaluation and techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/15/13560?source=related_link\">",
"      Surgical resection of pulmonary metastases: Outcomes by histology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/42/10922?source=related_link\">",
"      Systemic chemotherapy for cancer in elderly persons",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=related_link\">",
"      Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/20/21833?source=related_link\">",
"      Systemic chemotherapy for metastatic colorectal cancer: General principles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/1/44058?source=related_link\">",
"      Systemic chemotherapy for nonoperable metastatic colorectal cancer: Treatment recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36538?source=related_link\">",
"      Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43882?source=related_link\">",
"      Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/45/10963?source=related_link\">",
"      Treatment protocols for colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/9/33945?source=related_link\">",
"      Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_31_41467="Causes of delayed passage of meconium";
var content_f40_31_41467=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F82181&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F82181&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diagnoses to consider in infants and children with delayed passage of meconium",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Condition",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hirschsprung disease",
"       </td>",
"       <td>",
"        Abdominal distension and vomiting are common. On digital examination, the rectal vault may be empty. On contrast enema, a transition zone may be seen, but often is not visible in newborns.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intestinal obstruction",
"       </td>",
"       <td>",
"        Consider atresia, webs or volvulus. Obstruction may be present even in infants who pass meconium.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Meconium ileus",
"       </td>",
"       <td>",
"        Symptoms often begin on second day of life. Most patients with meconium ileus have cystic fibrosis.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Functional ileus",
"       </td>",
"       <td>",
"        Occurs in setting of prematurity, sepsis, respiratory distress, pneumonia, or electrolyte disturbances.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Small left colon*",
"       </td>",
"       <td>",
"        Barium enema shows small-caliber left colon. Increased incidence with maternal diabetes.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Drugs administered to mother before delivery",
"       </td>",
"       <td>",
"        Magnesium sulfate (MgSO4), opiates, or ganglionic blocking agents.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypothyroidism",
"       </td>",
"       <td>",
"        Infants with hypothyroidism also may have prolonged jaundice, lethargy, and low body temperature.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Similar findings may occur in infants with Hirschsprung disease (HD), so affected infants should be observed closely and evaluated for HD if appropriate.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Tunnessen WJ. Constipation and fecal retention. In: Signs and Symptoms in Pediatrics, 3rd ed, Lippincott, Williams &amp; Wilkins, Philadelphia 1999. p.518.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_31_41467=[""].join("\n");
var outline_f40_31_41467=null;
var title_f40_31_41468="House-Brackmann scale";
var content_f40_31_41468=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F70562&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F70562&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    House-Brackmann classification of facial nerve dysfunction",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Grade",
"       </td>",
"       <td class=\"subtitle1\">",
"        Characteristics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        I. Normal",
"       </td>",
"       <td>",
"        Normal function in all areas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"8\">",
"        II. Mild dysfunction",
"       </td>",
"       <td class=\"sublist1_start\">",
"        Gross",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Slight weakness noticeable on close inspection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        May have slight synkinesis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Normal symmetry and tone at rest",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Motion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Forehead: Moderate to good function",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Eye: Complete closure with minimal effort",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Mouth: Slight asymmetry",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"8\">",
"        III. Moderate dysfunction",
"       </td>",
"       <td class=\"sublist1_start\">",
"        Gross",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Obvious but not disfiguring difference between the two sides",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Noticeable but not severe synkinesis, contracture, or hemifacial spasm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Normal symmetry and tone at rest",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Motion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Forehead: Slight to moderate movement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Eye: Complete closure with effort",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Mouth: Slightly weak with maximum effort",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"7\">",
"        IV. Moderately severe dysfunction",
"       </td>",
"       <td class=\"sublist1_start\">",
"        Gross",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Obvious weakness and/or disfiguring asymmetry",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Normal symmetry and tone at rest",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Motion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Forehead: None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Eye: Incomplete closure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Mouth: Asymmetric with maximum effort",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"7\">",
"        V. Severe dysfunction",
"       </td>",
"       <td class=\"sublist1_start\">",
"        Gross",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Only barely perceptible motion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Asymmetry at rest",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Motion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Forehead: None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Eye: Incomplete closure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Mouth: Slight movement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        VI. Total paralysis",
"       </td>",
"       <td>",
"        No movement",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_31_41468=[""].join("\n");
var outline_f40_31_41468=null;
var title_f40_31_41469="CVA in sickle cell disease";
var content_f40_31_41469=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F61397&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F61397&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 520px\">",
"   <div class=\"ttl\">",
"    Cerebrovascular accidents in sickle cell disease and its variants",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 500px; height: 323px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Age at first cerebrovascular accident (CVA) and cumulative incidence of CVA in 2436 patients with sickle cell anemia (Hb SS), 839 with Hb SC disease, 188 with Hb S-beta (0) thalassemia, and 184 with Hb S-beta (+) thalassemia. Cerebrovascular accidents occurred earlier and more frequently with age in patients with Hb SS.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Ohene-Frempong, K, Weiner, SJ, Sleeper, LA, et al, Blood 1998; 91:288.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_31_41469=[""].join("\n");
var outline_f40_31_41469=null;
var title_f40_31_41470="Radiopharmaceuticals A";
var content_f40_31_41470=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F71325%7EOBGYN%2F82177&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F71325%7EOBGYN%2F82177&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Activities of radiopharmaceuticals that require instructions and records when administered to patients who are breast-feeding an infant or child",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Radionuculide",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Column 1: Activity above which instructions are required",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Column 2: Activity above which a record is required",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Column 3: Examples of recommended duration of interruption of breast-feeding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        (MBq)",
"       </td>",
"       <td class=\"subtitle2\">",
"        (mCi)",
"       </td>",
"       <td class=\"subtitle2\">",
"        (MBq)",
"       </td>",
"       <td class=\"subtitle2\">",
"        (mCi)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        I-131 NaI",
"       </td>",
"       <td>",
"        0.01",
"       </td>",
"       <td>",
"        0.0004",
"       </td>",
"       <td>",
"        0.07",
"       </td>",
"       <td>",
"        0.002",
"       </td>",
"       <td>",
"        Complete cessation (for this infant or child)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        I-123 NaI&bull;",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        I-123 OIH&bull;",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        700",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        I-123 MIBG&bull;",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        70",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        2",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        400",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        10",
"       </td>",
"       <td>",
"        24 hours for 370 MBq (10 mCi)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        12 hours for 150 MBq (4 mCi)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        I-125 OIH",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        0.08",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        0.4",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        I-131 OIH",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        0.3",
"       </td>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        1.5",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tc-99m DTPA",
"       </td>",
"       <td>",
"        1000",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        6000",
"       </td>",
"       <td>",
"        150",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tc-99m MAA",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        1.3",
"       </td>",
"       <td>",
"        200",
"       </td>",
"       <td>",
"        6.5",
"       </td>",
"       <td>",
"        12.6 hours for 150 MBq (4 mCi)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Tc-99m pertechnetate",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        100",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        3",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        600",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        15",
"       </td>",
"       <td>",
"        24 hours for 1,100 MBq (30 mCi)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        12 hours for 440 MBq (12 mCi)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tc-99m DISIDA",
"       </td>",
"       <td>",
"        1000",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        6000",
"       </td>",
"       <td>",
"        150",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tc-99m glucoheptonate",
"       </td>",
"       <td>",
"        1000",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        6000",
"       </td>",
"       <td>",
"        170",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tc-99m MIBI",
"       </td>",
"       <td>",
"        1000",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        6000",
"       </td>",
"       <td>",
"        150",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tc-99m MDP",
"       </td>",
"       <td>",
"        1000",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        6000",
"       </td>",
"       <td>",
"        150",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tc-99m PYP",
"       </td>",
"       <td>",
"        900",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        4000",
"       </td>",
"       <td>",
"        120",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Activities are rounded to one significant figure, except when it was considered appropriate to use two significant figures. Details of the calculations are shown in NUREG-1492, \"Regulatory Analysis on Criteria for the Release of Patients Administered Radioactive Material.\" If there is no recommendation in Column 3 of this table, the maximum activity normally administered is below the activities that require instructions on interruption or discontinuation of breast-feeding. Although non-byproduct materials are not regulated by NRC, information on non-byproduct material is included for the convenience of the licensee. Agreement State regulations may vary. Agreement State licensees should check with their state regulations before using these values.",
"     <br>",
"      * The duration of interruption of breast-feeding is selected to reduce the maximum dose to a newborn infant to less than 1 millisievert (0.1 rem), although the regulatory limit is 5 millisieverts (0.5 rem). The actual doses that would be received by most infants would be far below 1 millisievert (0.1 rem). Of course, the physician may use discretion in the recommendation, increasing or decreasing the duration of interruption.",
"      <br>",
"       &bull; These radionuclides are not byproduct material and are not regulated by the NRC. Information is presented for the convenience of readers of this guide, who should be alert to differences that might exist between regulations of the NRC and state requirements for non-NRC regulated material.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Source: U.S. Nuclear Regulatory Commission: file://www.nrc.gove/reading-rm/doc- collections/nuregs/staff/sr1556/v9/nureg-1556-9.pdf#page=310",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Activities of radiopharmaceuticals that require instructions and records when administered to patients who are breast-feeding an infant or child, continued",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Radionuculide",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Column 1: Activity above which instructions are required",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Column 2: Activity above which a record is required",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Column 3: Examples of recommended duration of interruption of breast-feeding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        (MBq)",
"       </td>",
"       <td class=\"subtitle2\">",
"        (mCi)",
"       </td>",
"       <td class=\"subtitle2\">",
"        (MBq)",
"       </td>",
"       <td class=\"subtitle2\">",
"        (mCi)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tc-99m red blood cell in vivo labeling",
"       </td>",
"       <td>",
"        400",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        2000",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        6 hours for 740 MBq (20 mCi)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tc-99m red blood cell in vitro labeling",
"       </td>",
"       <td>",
"        1000",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        6000",
"       </td>",
"       <td>",
"        150",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tc-99m sulphur colloid",
"       </td>",
"       <td>",
"        300",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        1000",
"       </td>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        6 hours for 440 MBq (12 mCi)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tc-99m DTPA aerosol",
"       </td>",
"       <td>",
"        1000",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        6000",
"       </td>",
"       <td>",
"        150",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tc-99m MAG3",
"       </td>",
"       <td>",
"        1000",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        6000",
"       </td>",
"       <td>",
"        150",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Tc-99m white blood cells",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        100",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        4",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        600",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        15",
"       </td>",
"       <td>",
"        24 hours for 1,100 MBq (30 mCi)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        12 hours for 440 MBq (12 mCi)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Ga-67 citrate&bull;",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        1",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        0.04",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        7",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        0.2",
"       </td>",
"       <td>",
"        1 month for 150 MBq (4 mCi)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2 weeks for 50 MBq (1.3 mCi)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1 week for 7 MBq (0.2 mCi)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cr-51 EDTA",
"       </td>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        1.6",
"       </td>",
"       <td>",
"        300",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        In-111 white blood cells&bull;",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        0.2",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1 week for 20 MBq (0.5 mCi)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tl-201 chloride&bull;",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        200",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        2 weeks for 110 MBq (3 mCi)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Activities are rounded to one significant figure, except when it was considered appropriate to use two significant figures. Details of the calculations are shown in NUREG-1492, \"Regulatory Analysis on Criteria for the Release of Patients Administered Radioactive Material.\" If there is no recommendation in Column 3 of this table, the maximum activity normally administered is below the activities that require instructions on interruption or discontinuation of breast-feeding. Although non-byproduct materials are not regulated by NRC, information on non-byproduct material is included for the convenience of the licensee. Agreement State regulations may vary. Agreement State licensees should check with their state regulations before using these values.",
"     <br>",
"      * The duration of interruption of breast-feeding is selected to reduce the maximum dose to a newborn infant to less than 1 millisievert (0.1 rem), although the regulatory limit is 5 millisieverts (0.5 rem). The actual doses that would be received by most infants would be far below 1 millisievert (0.1 rem). Of course, the physician may use discretion in the recommendation, increasing or decreasing the duration of interruption.",
"      <br>",
"       &bull; These radionuclides are not byproduct material and are not regulated by the NRC. Information is presented for the convenience of readers of this guide, who should be alert to differences that might exist between regulations of the NRC and state requirements for non-NRC regulated material.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Source: U.S. Nuclear Regulatory Commission: file://www.nrc.gove/reading-rm/doc- collections/nuregs/staff/sr1556/v9/nureg-1556-9.pdf#page=310",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_31_41470=[""].join("\n");
var outline_f40_31_41470=null;
var title_f40_31_41471="Oronasal mask";
var content_f40_31_41471=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F76935&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F76935&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Oronasal mask",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 249px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Oronasal mask (Spectrum, Respironics, Inc) adapted for use with noninvasive positive pressure ventilation. To prevent rebreathing in the case of ventilator failure, the mask incorporates an \"anti-asphyxia\" valve and a quick-release strap.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_31_41471=[""].join("\n");
var outline_f40_31_41471=null;
